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ABSTRACT 
 
Global analysis of hepatitis B virus-mediated changes to the hepatocyte 
transcriptome and metabolome 
 
Richard Jason Lamontagne 
Michael J. Bouchard, Ph.D. 
 
 
 
 Chronic infection with hepatitis B virus (HBV) remains a significant health 
concern, with between 350-500 million people chronically infected worldwide. 
Approximately 25% of chronically infected individuals will go on to develop HBV-
associated hepatocellular carcinoma (HCC), making chronic infection with HBV 
the leading risk factor for developing HCC. With the high incidence and mortality 
of HCC, it is important to fully understand the mechanisms that lead to the 
development of HBV-associated HCC. HBV requires a complex network of host-
virus interactions to meet its requirements for successful replication. Each of 
these host-virus interactions, over a decades-long chronic infection, could 
significantly alter the physiology of an infected hepatocyte, the target of HBV 
infection, and ultimately contribute to the oncogenic potential of HBV. Typically, 
studies of these host-virus interactions have focused on a single factor or 
pathway to characterize contributions to HBV replication or HBV-associated 
disease, but these studies have generally not considered hepatocyte physiology 
as a whole. We hypothesized that using broad, transcriptomic- and metabolomic 
-based technologies would allow us to establish a better understanding of the 
xii	  
complexity of the host-virus interaction mediated by HBV and how an HBV 
infection affects overall hepatocyte physiology. To achieve this, we utilized an ex 
vivo primary rat hepatocyte model and defined transcriptome-wide, HBV-
mediated changes to gene expression. We also utilized metabolomic profiling to 
assess the impact of HBV, and the HBV X protein (HBx), on overall hepatocyte 
metabolism and correlated these changes to HBV-mediated changes in gene 
expression. Using this approach, we identified significant alterations of many 
genes and pathways central to hepatocyte physiology, including cell cycle 
regulation, lipid metabolism, and energy metabolism. Our results simultaneously 
identified multiple HBV-mediated changes to hepatocyte physiology, increasing 
our understanding of the complex relationship between HBV and an infected 
hepatocyte. Additionally, the identification of HBV-regulated genes will serve as 
the basis for future studies in understanding the physiological impact of an HBV 
infection. Together, these findings will allow a better understanding of HBV-
mediated affects on hepatocyte physiology that could ultimately contribute to the 
development of HBV-associated disease, potentially guiding the generation of 
novel therapeutics and strategies to prevent HBV-associated HCC.	  

1 
Chapter 1. Introduction: HBV 
(Parts of this section have been published in [1] or submitted for publication in 
[2]) 
2 
Introduction 
The discovery by Baruch Blumberg and colleagues of the Australia 
antigen, which would later be identified as the hepaitits B virus (HBV) surface 
antigen, was a major breakthrough towards improving global health [3, 4]. For 
decades prior, an unknown virus in blood and plasma samples had been the 
suspected cause of post-transfusion hepatitis [5]. Recognition of the Australia 
antigen as a cause of viral hepatitis led to a blood screening protocol that 
dropped the rate of post-transfusion hepatitis two to three fold [6] (with the 
remaining cases likely being due to hepatitis C virus, which would not be 
identified for another 23 years [7]). Retrospective studies also associated the 
Australia antigen with chronic liver diseases such as cirrhosis and hepatocellular 
carcinoma (HCC) [8, 9], and the development of a vaccine greatly reduced the 
global burden of HBV [10-12]. For his work, Baruch Blumberg was awarded the 
1976 Nobel Prize in Medicine.  
Despite the decades of work between the discovery of HBV and our 
current understanding of the virus, many aspects of the viral life cycle and viral 
pathogenesis remain unclear. The fact that it is estimated that as much as a third 
of the world's population has been infected with HBV at some point, that roughly 
5% of the population (350-500 million people) are chronically infected with the 
virus, and that ~800,000 people die annually from acute or chronic HBV-related 
consequences underscore the importance of a more complete understanding of 
HBV (reviewed in [13, 14]). 
3 
Hepadnaviridae 
While the discovery of the human hepatitis B virus occurred in the 1960s, 
recent research has shown that hepatitis B viruses have actually been present 
since the time of the dinosaurs. The earliest known hepatitis B virus is, in fact, 
approximately 82 million years old and was identified from the DNA of infected 
birds from the Mesozoic period [15]. Although multiple theories of the origins of 
human HBV exist, it appears the infection of mammals is a much more recent 
event. The jump into humans, in particular, may have been only ~40,000 years 
ago [16]. Despite the evolutionary timeline, modern HBV is remarkably similar to 
these ancient hepatitis B viruses [15] (and reviewed in [17]).  
The present day Hepadnaviridae family is a group of small, hepatotropic, 
DNA viruses divided into two distinct genera based on their divergent genomic 
sequences and narrow host range of infection. The avihepadnaviruses, such as 
the duck hepatitis virus (DHBV) and heron hepatitis virus (HHBV), infect birds. 
The orthohepadnaviruses, on the other hand, infect mammals, and include the 
human hepatitis B virus (HBV), and woodchuck hepatitis virus (WHV), among 
others. Each member of the Hepadnaviridae family is primarily species specific. 
For example, the only non-human hosts of human HBV are chimpanzee and 
treeshrew, each of which can be experimentally infected [18, 19]. Additionally, a 
primate virus similar to HBV, called woolly monkey hepatitis B virus (WMHV), has 
been identified in woolly monkeys and has been designated as the prototype of a 
new species of hepatitis B-like viruses. A maximum of 40% sequence divergence 
exists between orthohepadnaviruses, while only 20% sequence divergence 
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exists among avihepadnaviruses, however little to no homology exists between 
the two genera. Additionally, all mammalian hepatitis B viruses encode an X 
protein, which has been shown to be required for viral replication and has 
oncogenic properties (discussed below). This X protein is either lacking or highly 
divergent in avian viruses, and the acquisition of this X protein represents a 
potential cause for the evolution from avian into mammalian hosts [15]. Genomic 
diversity between species of hepatitis B viruses is reviewed in detail in [13] and 
[17]. 
 While significant genomic diversity exists between viral species, 
particularly between the two hepadnaviridae genera, the hepadnaviruses share a 
large number of features between all species. Among these, all members have 
an extremely small (3.0 - 3.3kb) and compact DNA genome that encodes 
overlapping open reading frames (ORFs). Additionally, each species follows a 
specific replication strategy in which the virus replicates its DNA genome using 
an RNA intermediate through the reverse transcriptase activity of the viral 
polymerase. Hepadnaviruses are distinguished from nearly all other viruses 
utilizing reverse transcription for viral replication by a number of unique features, 
including envelopment of a DNA genome, rather than RNA, and the fact that 
integration of viral DNA is not required for viral replication. These features, 
common to each member of the viral family, contributed to the designation of 
Hepadnaviridae as a distinct family of viruses [13].  
 
 
5 
Human Hepatitis B Virus 
Studies have identified a minimum of eight HBV genotypes, A-H, with 
genetic differences greater than 8%, but less than 17% between each genotype 
[13, 17, 20]. Two additional potential genotypes have been described. Genotype I 
has genetic divergence around 8% with a strong homology to genotype C [21], 
making its classification as a distinct genotype more controversial than that of the 
more well-accepted genotypes [22]. A potential 10th genotype, genotype J, has 
also been described recently and is likely the result of recombination of genotype 
C and gibbon HBV [20].  
There is a distinct distribution of HBV genotypes within specific 
populations and geographic locations (Fig. 1). Similarly, there is an association 
between genotype and disease severity and outcome. In the United States, 
where chronic HBV is relatively low, each genotype is present, though not at 
equal levels. Within the United States population, genotypes A and D are most 
prevalent, but this distribution can be further divided based on ethnicity [23, 24]. 
Specifically, genotype C is most common in Asian Americans, which correlates 
with the prevalence of this genotype in much of Asia. This is significant as 
genotype C has been associated with a more severe disease and a lower 
response rate to interferon therapy [25, 26].  
6 
Figure 1. Geographic distribution of HBV genotypes. Figure used with 
permission from [24]. 
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HBV genome organization 
HBV has a small, 3.2kb partially double stranded relaxed-circular DNA 
genome that encodes four overlapping open reading frames (ORFs). The largest 
ORF encodes the viral polymerase, which also has reverse transcriptase activity 
to replicate the first strand of the genome from an RNA intermediate. The second 
largest ORF encodes the three viral envelope proteins: large (L-), middle (M-), 
and small (S-) surface antigen (HBsAg). The next ORF encodes precore, or HBV 
E antigen (HBeAg), and the core protein, which makes up the viral capsid. The 
smallest ORF encodes the non-structural X protein (HBx), a small regulatory 
protein which has been shown to be required for viral replication both in vitro and 
in vivo [27-31]. The four viral ORFs encode distinct capped and polyadenylated 
RNAs that can be divided into genomic and subgenomic transcripts. The 
subgenomic transcripts act only as templates for viral proteins and consist of the 
0.7kb transcript, which encodes HBx, and the 2.1kb and 2.4kb HBsAg transcripts 
encoding M- and S-HBsAg, and L-HBsAg, respectively. The genomic transcripts 
act as mRNAs for precore, core, and polymerase. Additionally, the genomic 
transcript encoding core and polymerase (also referred to as pregenomic [pg] 
RNA) is multifunctional, with this 3.5kb transcript also acting as the template for 
viral replication (Fig. 2). As the viral genome is only 3.2kb, this pgRNA represents 
a greater than unit length, terminally redundant copy of the viral genome. 
Additionally, because all transcripts share the same polyadenylation site, each of 
the smaller transcripts makes up the 3' end of each of the larger transcripts. This 
means that the sequence of the HBx transcript is contained at the 3' end of all 
8 
transcripts, while the largest transcript is the only viral transcript to contain 
sequence that is not shared with the other transcripts (reviewed in [13, 32, 33]).  
Transcription of viral transcripts is driven from specific promoter 
sequences within the viral genome (Fig. 3). Much of the hepatotrophic restriction 
of the virus can be attributed to the transcriptional activation by hepatocyte-
specific transcription factors. For example, activation of the Enhancer I/HBx 
promoter is a required first step in viral transcription, as this is believed to 
enhance transcription from downstream promoters. A number of the transcription 
factors mapped to the EN1/HBx promoter are liver specific, including hepatocyte 
nuclear factor (HNF) 1, HNF3, and HNF4. Many of the transcription factor binding 
sites that have been identified within the 4 promoter regions of HBV are for 
transcription factors that are activated by HBV proteins, oftentimes HBx, implying 
a specific cascade of transcription [34]. Transcription factor-mediated regulation 
of viral transcription is reviewed in detail in [35] and [13]. 
9 
Figure 2. Genome structure of HBV. The partially double-stranded DNA 
genome of HBV is depicted at the center, surrounded by the overlapping open-
reading frames (ORFs) (thick colored arrows). The outer, black arrows represent 
the viral mRNA transcripts. HBV polymerase (pol), bound to the 5' end of (-)-
strand is depicted as a red circle. DR1/DR2 represent the direct repeat 
sequences, and EN1 and EN2 represent the location of the two HBV enhancer 
sites. Beneath the genome, the ORFs are depicted linearly, with the HBV 
transcripts below to show the overlapping nature of the ORFs and transcripts. 
Figure used with permission from [36]. 
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Figure 3. Cellular transcription factors involved in regulation of HBV 
transcription. HBV genome structure highlighting the promoter/enhancer 
regions of HBV. Inset regions represent transcription factor binding sites within 
the indicated promoter region. 
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HBV proteins 
The HBV genome encodes seven viral proteins: HBx, core, polymerase, 
L-, M-, and S-HBsAg, and precore/HBeAg. Of these proteins, HBx is a non-
structural regulatory protein, HBeAg is not incorporated into virions and is 
independently secreted from the cells, the polymerase is responsible for genome 
replication, and the core and HBsAg proteins form the structural aspects of the 
virion [13]. Each of these will be discussed in further detail below. 
E antigen 
HBeAg is the final product of post-translational processing of the 
translated precore ORF. As one of the proteins encoded by a genomic transcript, 
the genomic promoter drives its expression. HBeAg contains an endoplasmic 
reticulum targeting sequence that results in trafficking to the ER, where the 
translated protein is processed to the final 15kD protein that is secreted from 
infected cells [37]. 
The viral function of HBeAg remains unknown, as the protein is not 
incorporated in the virion and is independently secreted from the cell. Multiple 
groups have hypothesized that production of HBeAg is an immune evasion 
mechanism, and studies in transgenic mice specifically suggest that a function of 
HBeAg is to suppress the immune response to core protein [38, 39]. The 
secretion of a viral marker unrelated to the actual virus may help to dampen the 
neutralizing immune response by diverting the immune response away from 
infectious viral particles (reviewed in [13]).  
12 
From a diagnostic perspective, HBeAg is an important marker of viral 
replication as the levels of serum HBeAg are generally considered to correlate 
with viral titer. In fact, HBeAg seroconversion is considered an important aspect 
of the transition to the inactive carrier state of infection [40].  
S antigen 
HBV encodes three envelope proteins, or surface antigens, that make up 
the viral envelope: large (L), middle (M), and small (S) surface antigen. The 
smallest envelope protein, or S (24kD), is 226aa and makes up a shared C-
terminal region for the two longer envelope proteins. The M protein (31kD) 
contains the S sequence with a 55aa N-terminal extension known as preS2. 
Expression of these two proteins is driven by the S promoter, with translation 
initiating from an upstream (M) or downstream (S) AUG. The L protein (39kD), 
the largest of the envelope proteins, contains both S and preS2 in addition to 
another 108aa or 119aa (depending on genotype) N-terminal extension known 
as preS1. L-HBsAg is encoded by its own transcript driven by the preS1 
promoter.  
13 
Figure 4. Structure of L-HBsAg. L-HBsAg is depicted containing the S, preS1, 
and preS2 domains. Important regions are highlighted, consisting of the 
myristoylation signal (green), the putatitive receptor binding domains including 
essential (red) and accessory (yellow) domains, and the domain important for 
capsid packaging (blue). Figure adapted from [41]. 
14 
The envelope proteins are synthesized at the endoplasmic reticulum (ER), 
where they gain their transmembrane configuration. Because all three proteins 
contain identical C-terminal sequence, the transmembrane topology is the same 
across all three proteins in this region. Specifically, an N-terminal signal 
sequence initiates insertion of S into the ER membrane, followed by another 
signal that pushes the downstream peptide sequence into the ER lumen. The 
sequence upstream of this signal remains in the cytosol, with the signal domain 
itself acting as a transmembrane anchor domain (Fig. 4). This orientation forms 
two loops; one loop, between aa 23-79, remains on the cytosolic side, while the 
other loop, between aa 99-169, is on the luminal side [42]. Importantly, the 
luminal loop contains the major conformational epitope of HBsAg, and is 
glycosylated in nearly half of all S protein moieties [43]. Once budding of the 
membrane occurs, these epitopes are on the outer surface of the viral particles. 
The topology of M is identical to that of S, except for the presence of preS2 within 
the ER lumen [44]. 
Because of the significant N-terminal extension, the topology of L is more 
complicated than that of the smaller envelope proteins. In addition, the 
contradictory requirements for the location of preS1 during different stages of the 
life cycle makes determining the topology of L even more difficult. First, the 
glycine at position 2 of preS1 is myristylated [45], and both the preS1 and preS2 
domains remain cytosolic during translation. Co-translationally, approximately 
half of the L-HBsAg undergoes a translocation during which the preS domains 
move from the cytosolic side into the ER luman. This is an important feature of L-
15 
	  
HBsAg, as the preS1 domain contains the receptor binding region for HBV [46, 
47], meaning it needs to be exposed to the outside of the cell. A myristylated 
peptide containing a portion of the N-terminal preS1 region is sufficient to inhibit 
infection [47], and is currently being developed as a therapeutic [48]. 
 The main function of the surface antigen proteins is to form the viral 
envelope.  Three different forms of viral particles are secreted from an HBV-
infected cell as a result of the unequal expression of each of the three surface 
antigens. S-HBsAg is, by far, the highest expressed of the three envelope 
proteins and makes up the majority of the viral envelope. Intact infectious virions, 
called Dane particles, also include M-HBsAg and L-HBsAg. In addition, an 
infected cell produces non-infectious subviral particles (SVP) made primarily of 
S-HBsAg with varying (but much lower) amounts of M-HBsAg and little to no L-
HBsAg. These SVP particles can reach a concentration 10,000-fold higher than 
infectious particles in the serum of an infected individual [49, 50]. SVP are 
produced in two forms: ~25nm spheres, which are almost exclusively made up of 
S-HBsAg, and ~ 22nm filaments which are made up primarily of S-HBsAg, with 
some M-HBsAg and potentially small amounts of L-HBsAg. It is currently 
unknown why the virus produces SVP in such excess compared to the level of 
infectious virions, but multiple hypotheses have been proposed. Two of the more 
common hypotheses suggest that the excess SVP act to divert neutralizing 
antibodies away from infectious particles and that SVP play a role in inducing the 
immune tolerance required to sustain a long-term chronic infection. Also, a study 
of SVP in DHBV showed that the SVP to infectious particle ratio plays a role in 
16 
determining the efficiency of hepatocyte infection, with SVP acting to either 
enhance or inhibit infection based on the ratio of SVP to infectious particles [51].  
Core protein 
The 21kD HBV core protein, or HBcAg, is the organizing framework for the 
virion. It mainly exists as soluble dimers, or in T=3 or T=4 icosahedral capsids. 
About 95% of mature nucleocapsids isolated from fully infectious Dane particles 
contain T=4 capsids made up of 120 core dimers, with the remaining 5% being 
the smaller T=3 with 90 dimers [52]. Core is translated from the pgRNA using the 
second AUG (HBeAg utilizes the first AUG), and is always isolated as a dimer 
within a 4 helix bundle. The first 149aa of core form the assembly domain, which 
is sufficient for in vitro formation of capsids indistinguishable from capsids 
isolated from Dane particles [53]. The remaining 34-36aa make up the arginine-
rich C-terminal domain (CTD), which has been shown to be important for 
regulation of multiple stages of the HBV life cycle through is multiple regulatory 
phosphorylation sites [54-57]. 
While the best described role for core protein is assembling the 
nucleocapsid, recent evidence has suggested that it does more than simply act 
as an inert container for the viral genome. In fact, core protein has been shown to 
be bound to covalently closed circular DNA (cccDNA), potentially to regulate 
spacing of nucleosomes on the minichromosome [58]. In addition, the CTD is 
required for pgRNA packaging [59], and core protein also plays an active role 
initiating reverse transcription [60-62] and in mature nucleocapsid envelopment 
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[63]. The many potential roles of core protein in the HBV life cycle were recently 
reviewed, along with a detailed description of the mechanism of capsid assembly 
in [64]. 
Polymerase/Reverse Transcriptase 
Not long after the identification of an HBV-like virus in ducks [65], the 
DHBV model was used to demonstrate viral genome replication utilizing an RNA 
intermediate, implying that HBV replicated via a reverse transcriptase [66]. While 
reverse transcription is a mechanism employed by many viruses, 
hepadnaviruses approach genome replication with a number of unique 
differences, prompting them to be classified as pararetroviruses. The 90kD, 
838aa polymerase protein of HBV (reverse transcriptase/RT/Pol/P) is made up of 
3 functional domains and a variable spacer region. At the N-terminus is the 
terminal protein (TP) domain, which is important for multiple facets of the 
initiation of genome replication. This region, despite its important role in P binding 
to the pgRNA, RNA packaging, and protein-priming [67-69], is a unique domain 
that is not shared by any non-hepadnavirus reverse transcriptases. A variable 
spacer separates the TP domain from the RT domain, and studies have shown 
that nearly all bases within this region can be mutated without altering P function 
[70]. In fact, only 3 cysteine residues within the C-terminal end of the spacer 
region, along with a fourth in the N-terminal side of the RT domain, are thought to 
be important for pgRNA packaging [71].  
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The reverse transcriptase (RT) domain is responsible for the function of 
genome replication by reverse transcribing the pgRNA to form the (-)-strand of 
the DNA genome, and using the (-)-strand as a template for the (+)-strand of the 
DNA. This domain shares significant homology to the RT of other retroviruses, 
including HIV [72]. The RT is the only current viral target of therapeutic 
intervention [14], which is based on the efficacy of nucleoside analogs to inhibit 
the HIV RT (reviewed in [73]). In fact, portions of HBV RT can be replaced by 
homologous portions of HIV RT and result in production of mature virions [74]. 
The final P domain is the RNase H domain. This domain is responsible for 
degrading the pgRNA template during synthesis of the (-)-strand of the DNA 
genome. Coordination of metal ion binding, which is important for RNase H 
activity, is achieved through 4 conserved carboxylates [75]. Studies of the RNase 
H domain have also shown that purified recombinant RNase H domain is 
functional in vitro and that the RNase H domain of P is important for pgRNA 
packaging [76]. For further information on P, including a detailed description of 
the RT domain active sites and binding motifs, see [73, 77]. 
X Protein 
The HBV X protein (HBx) is the only non-structural, regulatory protein 
encoded by HBV. It is a 154aa, 17kD protein that is encoded by the smallest 
HBV ORF. Various studies have provided considerable evidence that HBx plays 
an essential role during HBV replication [27, 28, 31, 78]. Specifically, studies 
have shown that HBx is bound to cccDNA [79], that HBx is required for 
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transcription from cccDNA [80, 81], and that downstream HBx-mediated effects 
are required for HBV replication [29, 30, 82]. 
The lack of a single accepted model for studies of HBV and HBx has 
created confusion in the literature about the role and overall consequences of 
HBx expression. These studies are often performed in transformed or 
immortalized cell lines and with different levels of HBx expression, leaving the 
impact of HBx on a normal hepatocyte incompletely understood (reviewed in 
[36]). While HBx is generally considered to have oncogenic potential, it is yet to 
be determined if it is directly oncogenic or simply acts as a co-factor in HCC 
development, as both effects have been demonstrated in different HBx-tg mice 
[83-86]. Peripheral evidence for the oncogenic potential of HBx, however, comes 
from the fact that hepadnavirus-associated HCC seems to be restricted to 
mammalian viruses, which each express a form of the X protein. Avian viruses, 
which do develop a chronic infection, but do not lead to development of HCC, 
either do not express an X protein or express a highly divergent form [87, 88].  
HBx is a multifunctional protein that can modulate hepatocyte calcium, 
apoptosis, and proliferation signals, among other pathways, and can activate 
multiple transcription factors, including activator proteins 1 and 2 (AP-1 and AP-
2), nuclear factor of activated T cells (NFAT), and nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) [29, 30, 87-96]. HBx can also 
regulate cellular signaling factors, such as Wnt/β-catenin, p53, and Akt, that have 
been implicated in HCC [90, 95-100]. Recently, modulation of miRNA expression 
has been included in the functions of HBx, as studies have begun to look at 
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miRNA expression in response to HBV and HBx (reviewed below). HBx has been 
shown to function as a transcriptional transactivator, activating multiple signal 
transduction pathways. It is possible, however, that the many functions attributed 
to HBx could actually be the result of a few fundamental upstream HBx functions 
that can affect multiple downstream cellular signal-transduction pathways in a 
context-dependent manner.  
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Figure 5. Schematic representation of the multifunctional nature of HBx. 
Figure used with permission from [101]. 
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HBV life cycle 
Studies have shown that the species specificity and hepatotropic nature of 
HBV are due to at least two different layers of cellular factors. The first is the 
hepatocyte-specific expression of the recently described HBV receptor, sodium 
taurocholate cotransporting peptide (NTCP/SLC10A1). In addition to the fact that 
NTCP is only expressed on hepatocytes, studies have also shown that while 
human NTCP can be bound by HBV, NTCP from mouse, which cannot be 
infected directly with human HBV, cannot be bound by HBV [46]. Second, cellular 
factors, potentially transcription factors such as HNF1α and HNF4α, seem to 
control the downstream stages of the life cycle post-entry. Evidence for this 
comes from the observation that humanized mouse NTCP, in which the binding 
residues from mouse NTCP are replaced by human NTCP, allows binding to the 
receptor but does not result in a productive infection with viral replication when 
expressed in mouse cells [102]. Studies using hepatitis D virus (HDV), which is a 
satellite virus requiring HBV envelope proteins for entry into a cell, demonstrated 
that the 75aa at the N-terminal portion of the PreS1 domain of L-HBsAg are 
required residues responsible for binding to the viral receptor [103]. In addition, it 
was shown that N-myristylation of the PreS1 domain was required for infectivity, 
but not virion assembly [104]. In fact, a myristylated peptide consisting of only the 
first 47aa of the preS1 domain is able to bind to the cellular receptor and 
effectively inhibit the binding of HBV [47]. Additional studies have suggested
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Figure 6. HBV life cycle. Simplified schematic of the HBV life cycle. See text for 
detailed description of stages of the viral life cycle. 
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a role for heparin sulfate proteoglycans in the initial stages of the binding [105]. 
Although information about the binding determinants for HBV is known, 
due to the lack of an effective model system that mimics a robust natural 
infection, much of the viral life cycle immediately following receptor binding 
remains incompletely understood (Fig. 6). The observation that preS1 binds to 
clathrin heavy chain and the adapter protein AP-2 in immortalized primary human 
hepatocytes, and that knockdown of these proteins inhibits infection, suggests 
that the HBV-NTCP complex may enter the cell through clathrin-mediated 
endocytosis [106]. Once in the cell, the HBV DNA is delivered into the nucleus by 
mechanisms that remain unclear. One potential mechanism is the active 
transport of nucleocapsid through nuclear pores [107]. Another potential 
mechanism involves C-terminal domain phosphorylation of the core protein, 
exposing nuclear localization signals [54] leading to nucleocapsid disintegration 
at the nuclear pore and transfer of the polymerase-bound rcDNA into the nucleus 
[108, 109]. The single-stranded gaps are repaired, either through (+)-strand 
extension by the viral polymerase or through repair activity of host proteins, and 
cccDNA is formed as a nucleosome-bound minichromosome in the nucleus. The 
observations that some HBV-transgenic mice do not produce cccDNA [110], and 
that nucleoside analogues that inhibit the RT function of polymerase do not 
prevent cccDNA formation [111] suggest that the production of cccDNA likely 
involves specific host factors. In addition to studies suggesting a role for cellular 
histones in cccDNA formation, evidence also exists showing that cccDNA is 
bound to both core protein [58] and HBx [79], influencing the arrangement and 
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epigenetic regulation of cccDNA. Although multiple studies have suggested that 
HBx is not required for cccDNA formation, transcription of viral RNA from 
cccDNA is lost in the absence of HBx [80, 112], and HBx has been suggested to 
regulate levels of cccDNA histone acetylation and methylation [113]. cccDNA 
serves as the template for all viral transcripts, utilizing host RNA polymerase II 
and cell-specific transcription factors (Fig. 3) to produce 5'-capped and 3'-
polyadenylated transcripts. Translation of the viral transcripts occurs in the 
cytoplasm following nuclear export. 
 While a portion of the pgRNA is translated, forming the pool of core and 
polymerase proteins, pgRNA also serves as the template for reverse 
transcription. This requires encapsidation of pgRNA by 120 dimers of core 
protein, forming the nucleocapsid. This occurs through a complex cascade of 
events involving multiple viral and host proteins. Specifically, the 5' end of the 
pgRNA contains an encapsidation signal, termed ε, which is recognized and 
bound by polymerase. Studies have also shown that the 5' cap structure is 
required for packaging of the pgRNA [114]; however, polyadenylation is not 
required [115]. In addition, interaction of pgRNA-bound polymerase with the 5' 
cap and host eIF4E leads to encapsidation of this entire RNP complex [116], 
resulting in cellular eIF4E within the viral nucleocapsid. Cellular heat shock 
proteins have been suggested to play a similar role in stabilizing the binding of 
polymerase to ε [117].  
 Once packaged, reverse transcription is initiated through priming by the 
polymerase from a specific tyrosine residue within the N-terminal domain of the 
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polymerase, called the terminal protein [68, 69]. A bulge region within ε supplies 
the template for the first 3-4nt of the (-)-DNA strand before translocation to a 
matching acceptor motif in the 3' direct repeat 1* (DR1*) [118]. This strand is then 
extended 3' to 5' until completion, resulting in a unit length (-)-DNA strand copy of 
the pgRNA that contains an additional 10nt terminal redundancy (r). The majority 
of pgRNA is degraded during DNA synthesis by the RNase H activity of 
polymerase, with the remaining bases serving as the 5' primer for synthesis of 
the (+)-strand [119]. Direct extension of this primer from its 5' position results in a 
double-stranded linear form of the genome [120] that lacks the core 
promoter/enhancer, making it unable to be packaged. This double-stranded 
linear form does, however, seem to play a role as the main form of HBV DNA 
that gets integrated into the host genome [121]. Instead of direct extension of the 
RNA primer from its 5' location, successful rcDNA formation can occur only after 
the RNA primer is translocated to the 3' DR2 sequence. Once on DR2, the RNA 
primer is extended towards the 5' end of the (-)-DNA strand. Because r on the 
other end has the same sequence, exchange of the two ends allows (+)-strand 
synthesis to continue. As with the previous translocations, additional cis-acting 
elements are likely playing a role in long range base-pairing, which allows the 
close juxtaposition of these donor and acceptor sites which can otherwise be 
separated by kilobases of sequence [122, 123]. In addition, recent evidence has 
suggested a role for core protein in regulating DNA synthesis, as mutations in 
core protein inhibit the synthesis of the (+)-strand of DNA [124]. The complex 
process of reverse transcription is reviewed in more detail in [32, 33, 73]. 
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The final product of DNA synthesis is the encapsidated, partially double 
stranded rcDNA in the cytosol of the infected cell with the polymerase still bound 
to the 5' end of the (-)-DNA strand. This nucleocapsid can then proceed in one of 
two directions. The first is shuttling of the nucleocapsid back to the nucleus to 
amplify and maintain the stable pool of cccDNA [125, 126]. This recycling is 
influenced by the levels of envelope proteins, with decreased amounts of HBsAg 
promoting shuttling of the nucleocapsid to the nucleus [127]. In particular, levels 
of L-HBsAg directly influence shuttling back to the nucleus [128], and these 
findings correlate well with the early establishment of a cccDNA pool, followed by 
identification of infectious virus in the supernatant [125]. The result is a pool of 
cccDNA that contains a fluctuating number of copies (typically less than 10) of 
cccDNA per cell [129-131], which can be maintained in the cell for years. 
Additionally it has been suggested the half-life of a single cccDNA molecule is 
between 33 and 57 days [130, 132], underscoring the role of cccDNA in 
maintaining HBV persistence.  
The second potential nucleocapsid outcome is envelopment by the 
envelope glycoproteins residing in the ER membrane. Interestingly, mechanisms 
exist that may limit envelopment of capsids containing immature HBV genome, 
however these mechanisms remain incompletely understood. For example, it has 
been suggested that only mature rcDNA-containing nucleocapsids are 
enveloped, while ssDNA or RNA containing nucleocapsids are not secreted from 
the cell [133]. Other studies utilizing an RNase H-deficient polymerase, rendering 
the virus unable to initiate (+)-DNA strand synthesis, have suggested that only 
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completion of the (-)-DNA strand is required for envelopment [134], and specific 
mutations in core protein can allow envelopment of immature nucleocapsids 
[135]. The mechanisms associated with this selectivity are unknown, although 
the phosphorylation state of core protein, likely influenced by the nucleic acid 
species inside the capsid, could be playing a role. Specifically, studies have 
shown that core protein isolated from DNA-containing capsids has been 
dephosphorylated (after the prior phosphorylation required for pgRNA packaging 
and reverse transcription) in a specific C-terminal region, while immature 
nucleocapsids remain phosphorylated at least 6 different sites [55]. The overall 
secretion of infectious viral particles (Dane particles) has been hypothesized to 
be as little as 1-10 virions per cell per day [136], which, because of the large 
number of cells in the liver can account for the high viral titers in vivo, but can 
hinder in vitro research requiring isolation of large amounts of infectious virus. 
Actual secretion of the virus was originally thought to follow the same secretory 
pathway as the much more abundant subviral particles, with the envelope 
proteins residing within the ER-golgi intermediate compartment from where they 
could bind DNA-containing capsid, enter the lumen, and be secreted from the 
cell. Recent evidence has suggested that mature virions are, in fact, secreted 
from the cell using a pathway dependent on proteins involved in the endosomal 
sorting complex required for transport (ESCRT) pathway forming multivesicular 
bodies [137]. One characteristic that needs to be considered regardless of the 
pathway of viral secretion is the seemingly contradictory conformations of L-
HBsAg, with the domains required for both interaction with the nucleocapsid and 
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NTCP being needed on opposite sides of the membrane. This is addressed by 
the fact that nearly half of L-HBsAg changes transmembrane conformation after 
translation, to expose the preS domains within the ER lumen (reviewed in [138]).  
HBV natural history 
HBV infection can lead to incredibly high viral titers in the blood of infected 
individuals, with levels of HBV virions reaching as high as 1010 particles/ml [139]. 
Because of these high titers, the main mechanism for the transmission of the 
virus is through the blood. In particular, exposure during childbirth from an HBV-
infected mother is the leading global cause of HBV infections, with the potential 
of vertical transmission being as high as 90% in some parts of Asia. Additional 
routes of exposure to bodily fluids from infected individuals, such as sexual 
contact or sharing of needles, are also common routes of transmission [13]. 
The natural history of HBV has been divided into two types of infection 
(Fig. 7). For about 90-95% of infections, the result is "acute hepatitis" where the 
infected individual resolves infection to the point of undetectable viral DNA and 
the presence of antibodies against HBsAg. Symptomatic patients present with 
inflammation of the liver, which is known as hepatitis and results in nausea, 
jaundice, abdominal pain, and vomiting; however, for many cases of HBV, 
patients are asymptomatic and acute infections are generally cleared within 6 
months. In models of acute infection in woodchucks and HBV-infected 
chimpanzees, the first several weeks of infection are typically characterized by 
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Figure 7. Natural history of HBV infection. A. Flow between phases of HBV 
infection. Thickness of lines indicates likelihood of respective outcome. Perinatal 
infection typically leads to high replicative, low inflammatory/immune tolerant 
infection. Childhood transmission typically leads to chronic infection and adult 
infection commonly results in resolution, though some cases lead to chronic 
infection. B. Description of phases of chronicity, with associated DNA and liver 
enzyme levels. Figures used with permission from [140]. 
A.#
B.#
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minimal innate [141, 142] or adaptive [143] immune activation, with viral spread 
throughout the entire hepatocyte population [143, 144].  Ultimately, the eventual 
activation of an effective antiviral response, including activation of cytotoxic T 
lymphocytes (CTLs), results in inflammation and killing of the majority of 
hepatocytes over the length of a few weeks. Interestingly, studies of integrated 
WHV DNA in woodchucks treated with clevudine, a viral polymerase inhibitor, 
demonstrated that repopulation of the liver seems to occur from the population of 
infected cells, not from a smaller population of uninfected cells [145]. Clearance 
appears to be mediated by antiviral cytokines, with CTLs directly killing infected 
hepatocytes once the viral load has dropped below specific levels [146, 147]. 
The remaining 5-10% of cases of HBV infection, with percentages being 
much higher in small children, result in a persistent, chronic infection [148]. While 
this understanding is still generally accepted, the application of more sensitive 
detection techniques, such as PCR that can detect <250 virions/ml, has shown 
that many patients who were believed to be virus-free actually have low levels of 
detectable serum and liver HBV DNA. In fact, low levels of HBV DNA can be 
detected in up to 30% of patients with liver disease of previously unknown 
etiology [148-150]. This result has led to the recognition of occult HBV infections, 
in which the level of virus is persistently low, below the level of detection by 
traditional detection techniques. Because of the relatively recent identification of 
this group of infected individuals, the risk factors associated with an occult HBV 
infection remain incompletely understood, although some evidence does suggest 
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that occult infections retain much of the same risk factors as chronic HBV 
infection [151].  
 Clinically, a chronic HBV infection can be divided into multiple phases 
(reviewed in [13, 139, 140, 148]), though not all patients progress through each 
stage (Fig. 7). The "immune tolerant" phase is characterized by high titers of 
HBV DNA (>100,000 copies/ml), the presence of HBeAg, and little liver disease. 
This phase can last decades, especially in perinatally infected patients, but is 
typically short or absent in childhood- and adult-acquired HBV.  
 The "immune clearance" phase also has high levels of virus (though 
usually less than the immune tolerant phase) and HBeAg present, but has more 
advanced liver disease with increased inflammation and progression of fibrosis. 
In addition, this phase is associated with spikes in levels of aminotransferases, 
which are believed to be a result of an HBV-specific cytotoxic T-cell-mediated 
immune response [152]. This is important, as a longer duration of this phase and 
higher frequency/severity of the HBV flares are associated with the development 
of cirrhosis and HCC [153]. Typically this phase can last from several weeks to 
years, and likely represents immunological attempts to control viral titers. 
Seroconversion from HBeAg to anti-HBe is considered an important clinical 
outcome of the immune clearance phase, with immune control of the virus 
leading to very low or undetectable levels of serum HBV along with normal 
aminotransferase levels. Importantly, HBeAg seroconversion is associated with a 
favorable long-term outcome, with decreased risk of developing cirrhosis or HCC 
[40].  
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The "inactive HBsAg carrier" phase is characterized by multiple changes 
to the disease state. Specifically, there is a loss of HBeAg expression 
corresponding to an increased presence of anti-HBe. Also, a spontaneous 
seroconversion from HBsAg to anti-HBs and low to undetectable levels of serum 
HBV DNA are hallmarks of this phase. Additionally, aminotransferase levels 
remain consistently normal. Low to mild hepatitis and fibrosis may be observed 
based on the length of the immune clearance phase. This inactive carrier phase 
could potentially be maintained indefinitely, and is associated with a very 
favorable clinical outcome [140, 148].  
All patients, however, do not maintain this inactive carrier phase, and 
instead some patients enter a "reactivation/HBeAg-negative chronic hepatitits B" 
phase during which viral replication rebounds either spontaneously or as a result 
of immunesuppression. These patients are HBeAg negative/anti-HBe postive, 
and have elevated liver enzymes with increased necroinflammation. Serum HBV 
DNA levels are high, and can reach as high as 108-109 copies/ml, though levels 
are typically lower than in HBeAg-positive patients [49, 139, 140, 148].  
Ultimately, for many patients the end result of a chronic HBV infection is 
the development of HBV-associated HCC. While seven therapeutics are currently 
approved for the treatment of chronic HBV, none has proven successful at 
achieving an "absolute cure", or complete loss of HBV DNA and lifetime risk of 
development of HCC equal to natural clearing of the infection. Five of these 
therapeutics are nucleoside analogs, designed to directly inhibit the reverse 
transcriptase. The other two, standard and pegylated interferon-α, function as 
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antiviral cytokines, signaling through the interferon receptor resulting in activation 
of the JAK-STAT pathway (reviewed in [13, 140]). While generally effective at 
lowering viral load, the fact that none of these is curative means they are life-long 
treatments, which has resulted in the development of viral escape mutants. 
Because of this, specific guidelines have been developed for when to use 
antiviral therapy, and which therapeutic to use (reviewed in [140]). 
 
HBV and HCC 
 Hepatocellular carcinoma, which accounts for 80 to 90% of all liver 
cancers, is one of the most common, and most deadly cancers worldwide. 
Globally, liver cancer is the sixth most common and second deadliest cancer, 
with an incidence to mortality rate near 1 [154]. Epidemiological studies have 
identified chronic HBV infection of the liver as the leading risk factor for HCC 
development [155, 156]. Despite the availability of a vaccine, 350-500 million 
people worldwide are chronically infected with HBV and, depending on age and 
route of infection, as many as 25% of these individuals could go on to develop 
HBV-associated HCC [156, 157]. Unfortunately, the number of cases of HCC 
attributed to HBV will likely increase as occult infections become both better 
reported and better understood.  
 The molecular mechanisms that link a chronic HBV infection to HCC 
development are incompletely understood but are likely subtle considering that 
HBV-associated HCC usually occurs in the context of a decades-long chronic 
HBV infection. Studies have focused on three main factors that may be involved 
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in the development of HBV-associated HCC: chronic inflammation accompanied 
by destruction and regeneration of hepatocytes, consequences of HBV DNA 
integration into host genome, and the potential effects of HBV proteins such as 
HBx [83, 87, 157-159].  
 One particularly important intermediate aspect of a decades-long chronic 
HBV infection includes the development of HBV-associated cirrhosis prior to 
HCC development [140].  It is generally accepted that the majority, potentially as 
much as 70-90%, of all HCC occurs in the context of decompensated cirrhosis 
[156], and a strong relationship exists between chronic HBV infection and 
cirrhosis.  In fact, a recent cohort study demonstrated that the cumulative lifetime 
risk of developing HBV-associated cirrhosis is 41.5% for chronically infected 
patients, with a cumulative risk of developing HCC of 21.7% [139]. Therefore, 
establishing a clearer understanding of the cellular mechanisms associated with 
the intermediate stages of chronic disease, particularly development of cirrhosis, 
could enhance the overall understanding of causes of HBV-associated HCC. 
 
Model systems used in the study of HBV 
Cell culture models of HBV  
 The narrow host range and cellular tropism of HBV have made it difficult to 
find a tractable model system able to faithfully reproduce all aspects of a human 
HBV infection. Consequently, most HBV studies have relied on imperfect cell 
culture and animal models, each with its own advantages and disadvantages 
(Table 1). For instance, the hepatoblastoma-derived cell line HepG2 [160] and 
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the hepatoma-derived cell line Huh7 [161] are often used in studies of HBV 
biology. Similar to the majority of available human liver cell lines, HepG2 and 
Huh7 cells cannot be directly infected by HBV, in part due to lost expression of 
the HBV receptor [46]. These cells do, however, support HBV replication when 
the HBV genome is introduced by transfection of a plasmid or infection with a 
virus-based delivery vehicle, such as adenovirus, that encodes a greater-than-
unit-length copy of the HBV genome. Alternatively, HepG2.2.15 cells, derived 
from HepG2 cells and containing two integrated copies of a head-to-tail dimer of 
the HBV genome [162], have been used in tandem with HepG2 cells as a means 
to study cells with and without replicating HBV. A disadvantage of this approach, 
however, is that continuous passage over the decades since their development 
may have contributed to differences between HepG2.2.15 cells and the parental 
HepG2 cells that are not solely due to the presence of replicating HBV. Other cell 
systems that have been used in HBV-related studies are described in Table 1. 
One such cell line, HepAD38 cells, is a HepG2-derived cell line in which 
transcription of the HBV pgRNA, and therefore HBV replication, is regulated by 
an inducible, tetracycline-responsive element [163]. Additional cell lines include 
Hep3B [160] and PLC/PRF/5 [164] cells, which are derived from HBV-positive 
tumors and contain integrated HBV DNA. Both Hep3B and PLC/PRF/5 cells 
produce some HBV proteins, but neither produces infectious virus. Direct 
infection of one cell line, HepaRG, has been reported, and these cells are often 
used in HBV-related studies, however they require an extensive protocol to 
establish infectivity and maintain differentiation [165]. 
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 The main disadvantage of nearly all hepatocyte cell lines used in HBV-
related studies is that they are tumor-derived, so their cellular physiology will 
likely be more similar to that seen in a tumor than a normal hepatocyte. Multiple 
studies have confirmed this through the use of transcriptome-wide analyses. For 
example, analysis of the relationship between the gene expression profile for in 
vivo liver samples and two different hepatocyte cell lines gave an R2 value of 
~0.1. A similar comparison between in vivo liver and cultured primary 
hepatocytes gave a R2 of ~0.7, suggesting that gene expression in immortalized 
cell lines is significantly different than in primary hepatocytes and the liver. The 
recent results of another study, which used RNA-seq (discussed below) to 
establish the expression profile of HepG2 cells compared to liver samples, 
showed such a drastic difference between these cell types that the authors were 
compelled to warn against the future use of HepG2 cells as a model of 
hepatocyte gene expression [166]. 
 Additional in vitro systems that have been utilized to study the cellular 
impact of HBV replication and HBV protein expression include primary 
hepatocytes. Specifically, primary human hepatocytes have been used in 
multiple studies; however, cultured primary human hepatocytes quickly lose their 
ability to be infected by HBV, likely due to the loss of receptor expression over 
only a few days in culture [46]. In addition, primary human hepatocytes are often 
not readily available, limiting their use. On the other hand, primary hepatocytes 
from other systems, namely mouse and rat, have also been used to study the 
impact of HBV replication on regulation of gene expression. Although these cells 
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cannot be directly infected by HBV, delivery of the HBV genome by transfection 
or viral delivery system has shown that they can support HBV replication and are 
an effective surrogate model for studying the cellular impact of HBV replication 
[82, 167]. 
The recent discovery that NTCP serves as a receptor for HBV [46, 168] is 
an important step forward in the development of improved cell culture models for 
studies on the effects of natural HBV infection. Multiple studies have begun to 
exploit the relationship between NTCP and HBV to develop potential therapeutics 
or better understand the HBV life cycle [102, 169-173] (and reviewed in [174]). A 
number of these studies have utilized HepG2 cells stably expressing NTCP; 
however, the use of HepG2 cells as the backbone for this system still represents 
a significantly altered baseline from a normal hepatocyte, so results will require 
careful interpretation. 
In vivo models of HBV 
Due to the limited host range of HBV, few suitable animal models exist for 
studying an in vivo infection with human HBV. Closely related viruses, such as 
DHBV [65] and WHBV [175] have been used in their respective host animals as 
surrogate models for understanding overall hepadnavirus biology. These have 
been instrumental in establishing our understanding of the viral life cycle, 
including the identification of DNA replication through an RNA intermediate [66], 
the establishment of a pool of cccDNA as a mechanism for maintaining chronic 
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infection [176, 177], and the course of both acute [144, 178, 179] and chronic 
[180-182] infection. 
 The treeshrew, Tupaia belangeri, is a small animal model and is one of 
the very few animals which can be experimentally infected with human HBV 
[183]. Genomic analysis has placed the treeshrew phylogenetically between 
humans and rodents (reviewed in [184] and [185]), and this similarity to primates 
has spurred its use as a model for a broad range of studies, including as a model 
for viral hepatitis [19, 186]. Specifically, Tupaia belangeri has been used as a 
model to study the immediate effects of HBV infection on gene expression in the 
liver [19] and to identify genes potentially contributing to the development of 
HBV-associated HCC [187]. In fact, freshly isolated primary treeshrew 
hepatocytes were recently used in multiple studies contributing to the 
identification of NTCP as the HBV receptor [46, 188]. Recent studies also 
suggest that neonatal exposure of treeshews to HBV can lead to a disease 
progression similar to what is seen in humans, with development of a chronic 
infection leading to the eventual development of HCC [189]. Unfortunately, a 
relatively low HBV infection efficiency and lack of genetically uniform tree shrew 
strains has limited their use [190]. 
 The chimpanzee is the only non-human primate model for HBV infection 
and, along with the tree shrew, represents one of the only animal models that 
can be directly infected with human HBV. HBV can establish both acute [191] 
and chronic infections [192] in infected chimpanzees, and this model has been 
used most often for modeling the immune response to HBV and the interaction 
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between the virus and host [141, 193-196]. These studies have helped to 
establish the relationship between the innate and adaptive immune response to 
HBV infection, demonstrating minimal early activation of innate immune 
mediators [141] and a reliance on CD8+ T cells for viral clearance through 
interferon γ and tumor necrosis factor α [193], in agreement with previous work in 
HBV-tg mice [197, 198]. Another important use of the chimpanzee model has 
been as a surrogate model for preclinical drug and vaccine testing [199-202]. The 
ethical issues and high costs associated with non-human primate use, however, 
have limited the use of this model, and the recent reevaluation in the United 
States (one of only two countries to allow chimpanzee research) of the need for 
chimpanzees in preclinical research [203] could diminish their future use even 
further. 
A number of mouse models exist for the study of HBV (reviewed in [204] 
and [190]). Typically these models can be broken down into two categories: 
HBV-/HBx-transgenic(tg) mice which constitutively express HBV, and mice that 
are delivered the HBV genome or an HBx-expressing plasmid by hydrodynamic 
tail vein injection. Although mouse hepatocytes cannot be directly infected with 
HBV, the use of tail vein-delivered DNA or HBV-transgenic mice allows studies of 
the impact of HBV replication on hepatocyte physiology; HBx-transgenic mice 
similarly aid in the study of HBx-mediated effects. While these are valuable tools, 
they do have their drawbacks as well. For example, there is no inflammatory 
response against HBV in an HBV-transgenic mouse, which could alter the 
cellular pathways activated in these models compared to a natural HBV infection. 
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Additionally, because some HBV-transgenic mice do not produce HBV cccDNA, 
there is some concern over whether this system accurately mimics all aspect of 
HBV replication in humans [110]. Despite this, mouse models have been 
instrumental in determining a number of important aspects of the HBV life cycle, 
including the requirement for HBx in HBV replication [28], and the oncogenic 
potential of both HBV [205] and HBx [84, 86].  
 More recently, two additional mouse models have been described that 
may greatly enhance our understanding of the HBV life cycle and HBV-
associated disease. The first of these systems is the humanized mouse model, in 
which the majority of the mouse liver has been repopulated with either primary 
human hepatocytes or human induced pluripotent stem cells. The use of these 
animals represents a significant advancement, as they support direct infection 
with HBV and can develop a chronic HBV infection [206, 207], therefore allowing 
studies of the impact of an HBV infection on the liver in a cellular context more 
similar to that seen in the human liver. Some of these chimeric mouse models 
include both a humanized liver and humanized immune cells, offering the unique 
opportunity to study the human immune response in a small animal model. 
Although different techniques for the development of the humanized mouse 
model exist, a number of groups have adapted their use for the study of HBV. 
These studies cover a broad range of aspects of HBV biology, including studies 
of the HBV-mediated immune response [207, 208], investigation of potential HBV 
therapeutics [209, 210], and aspects of the HBV life cycle such as particle 
formation [211], receptor binding [212], and cccDNA regulation [213].  
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 A second recently described mouse model expresses the human form of 
NTCP to allow receptor binding by HBV. Currently these mice are limited in their 
utility for studying HBV, as multiple groups have shown that while HBV can bind 
to human NTCP expressed in mouse cells, the HBV life cycle does not appear to 
proceed beyond receptor binding [102, 168, 169]. Conversely, as hepatitis D 
virus (HDV) utilizes HBV envelope proteins for its envelopment, hNTCP-
expressing mice have been used for the study of HDV infection [214]. Further 
work with NTCP-expressing systems may help to determine species specificity 
factors that could ultimately lead to the development of a hNTCP-expressing 
mouse model useful for the study of HBV infection. Together with the humanized 
liver model, these mouse models could greatly contribute to our understanding of 
the early stages of an HBV infection, including particle entry, HBV genome 
transport to the nucleus, and genome repair. 
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Table 1. In vitro model systems for studying HBV. 
Model System Source Characteristics 
Cell Lines 
HepG2 Human hepatoblastoma [160] 
Transformed cell line that is easy to grow 
and maintain. Serves as a model system for 
HBx-dependent HBV replication, although 
these cells cannot be directly infected by 
HBV. 
HepG2.2.15 
HepG2 with two integrated 
head-to-tail dimers of HBV 
genome [162] 
Stably replicates HBV and produces 
infectious virus; however, continuous 
passage since development has created a 
large separation from the parental HepG2 
cells so that differences between HepG2 
and HepG2.2.15 cells may not be HBV-
specific 
HepAD38 
HepG2 stably expressing 
HBV pgRNA that is 
controlled by a 
tetracycline-responsive 
promoter [163] 
Presence or absence of tetracycline (tet) 
allows cell line to act as its own baseline. 
HBV replication easily controlled, but only 
pgRNA expression is under tet-control, so 
many viral proteins are still made in the 
presence of tet. 
Huh7 Human hepatoma [161] 
Transformed cell line that is easy to grow 
and maintain. Cells cannot be directly 
infected by HBV. For reasons that remain 
unknown, HBV replication in these cells is 
HBx-independent 
PLC/PRF/5 Human hepatoma [215] 
Transformed cell line that is easy to grow 
and maintain. These cells express HBsAg 
from integrated HBV DNA 
HepaRG Human hepatoma [165] 
Transformed cell line, but differentiation can 
be induced to promote primary hepatocyte-
like characteristics. After differentiation, 
these cells can be directly infected with 
HBV, although the infection efficiency is low. 
Acquisition of a differentiated, hepatocyte-
like phenotype requires two-week 
maintenance in 2% DMSO prior to induction 
of differentiation; this process generates a 
mixed culture of hepatocytes and 
cholangiocytes. 
Primary Cells 
Cultured Primary 
Human Hepatocytes 
Hepatocyte isolation from 
liver tissue 
Natural target of an HBV infection; however, 
quickly lose susceptibility to an HBV 
infection after isolation and culture. These 
cells can be difficult to acquire, difficult to 
maintain in culture, and begin to de-
differentiate soon after isolation and plating. 
These cells can be difficult to transfect. 
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Cultured Primary 
Mouse/Rat 
Hepatocytes 
Perfused liver and 
isolation of hepatocytes 
Primary cells that can be cultured to 
maintain a "normal" phenotype and serve as 
a surrogate model for studies in primary 
human hepatocytes. . Support HBV 
replication although not direct HBV infection. 
Isolation requires access to animals and 
ability to reliably isolate high quality 
hepatocytes 
Liver Tissue 
Samples 
HCC and adjacent normal 
liver tissue; HBV and non-
HBV liver tissue 
Primary cells can give a more accurate 
profile of the liver RNA transcripts and 
expressed proteins than transformed cell 
lines. Disease versus normal tissue 
comparisons facilitate analysis of disease-
mediated differences; however, it is often 
difficult to determine if differences are a 
cause or consequence of the disease. 
Requires access to patient samples that is 
often hampered by a finite supply and 
limited access such that these samples are 
often only used for primary screens or final 
confirmation 
Peripheral Blood 
Mononuclear Cells 
(PBMCs) 
Circulation 
Easier to acquire than primary hepatocytes, 
but only support low levels of HBV infection 
and replication 
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Chapter 2. Introduction: Cellular Impact of HBV infection 
(Parts of this section have been published in [1] or submitted for publication in 
[2])
46 
	  
Liver Biology 
 The liver has the unique ability to regenerate, something that has been 
suggested as far back as Ancient Greece. The story of Prometheus tells us that, 
after climbing Mt. Olympus to steal fire from the Gods for the people of Greece, 
he was chained to a rock where everyday his liver was pecked out by a bird of 
prey. Every night his liver would regenerate, only for him to undergo the same 
daily torment, for eternity. While this tale may be a mythical exaggeration of the 
speed with which the liver can regenerate, the fact remains that liver turnover 
and regeneration are an important part of liver biology. In fact, following two-
thirds partial hepatectomy, the human liver can quickly recover both its mass and 
function. While surgery lowers liver function to ~37% of pre-operative function, 
within 10 days liver function is within 77% of pre-operative function, and the liver 
is fully functional within 12 weeks at roughly 75% of its original mass [216]. Up to 
80% of the cell mass of the liver is highly differentiated hepatocytes. Studies 
suggest that only 1 out of every 20,000 hepatocytes is dividing, while the 
remaining cells maintain a state of quiescence [217]. The pathways involved in 
liver regeneration primarily involve tight regulation of the cell cycle, as the 
process involves the coordinated exit from G0 and entry into the active cell cycle 
for millions of hepatocytes. It is interesting to point out, however, that research 
has shown this process is independent from hepatocyte dedifferentiation, as the 
liver is able to fully regenerate while still maintaining hallmark liver-specific 
functions (reviewed in [218]). 
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HBV and hepatocyte physiology 
 It is logical to assume that hepatotropic viruses such as HBV, which alter 
hepatocyte physiology as part of, or a consequence of their replication, may 
disrupt normal hepatocyte and overall liver functions. Many of these disruptions 
and alterations, either through viral replication or activities of viral proteins such 
as HBx, have been reviewed in detail elsewhere, and will only briefly be 
discussed here. For example, HBV has been shown to disrupt cell cycle 
regulation (reviewed in [101] and [219]), alter apoptotic pathways (reviewed in 
[220]), alter hepatocyte metabolism (reviewed in [35]), and alter miRNA 
expression and miRNA-mediated regulation (reviewed below and in [1]). Much of 
this work has centered around multiple signal transduction pathways involving 
Ras/mitogen-associated protein kinase(MAPK) (reviewed in [221]), mechanistic 
target of rapamycin (mTOR) (reviewed in [222]), PI3K/Akt [82, 223], and NF-κB 
(reviewed in [220]), among many others. Each of these pathways and factors, 
while also important for the virus, are main mediators of hepatocyte physiology. 
As such, disruption can have a major impact on hepatocyte function, which has 
generated a considerable amount of interest in their potential role as 
mechanisms for the development of HBV-associated HCC.  
 
HBV and cell cycle 
 As with many viruses, HBV must optimize the cellular environment for viral 
replication. In the case of HBV, this involves pushing hepatocytes from 
quiescence into an active cell cycle. For example, in primary rat hepatocytes, 
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HBV pushed cells from G0 into and through G1, but stalled progression before the 
cells were able to reach S phase, and this regulation of the cell cycle was 
required for HBV replication [30]. Studies in cell lines suggest a similar 
progression, with HBV stalling progression of the cell cycle before entry into S 
phase [224]. These results correlate well with the results of other studies showing 
that HBV replication is increased when the cell cycle is arrested in either G1 or 
G2, but HBV replication is decreased during S phase, when cellular DNA 
synthesis would be higher, depleting the pool of available nucleotides [225, 226].  
Much of the HBV-mediated regulation of the cell cycle appears to be 
through the activity of the HBx protein. Multiple studies have demonstrated in 
primary hepatocytes that HBx alters cell cycle regulators including decreased 
p15 and p16 expression and decreased DNA synthesis, and increased p21, p27, 
cyclin D1, and cyclin E expression [30, 167, 227]. Together these results suggest 
that HBx drives hepatocytes into the cell cycle but increases inhibitors that 
prevent progression beyond G1. 
HBV and metabolism 
 Because of the role of the liver as the primary metabolic organ, a growing 
body of research has begun to link HBV to altered metabolic pathways. HBV has 
been referred to as a "metabolovirus" due to the perceived intersection between 
HBV gene expression and control of cellular metabolism [228, 229]. Specifically, 
a number of groups have recently begun to examine the role of HBV in lipid 
metabolism, especially considering the well-established link between hepatocyte 
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lipids and various stages of the HCV life cycle(reviewed in [230]), and the recent 
identification of a bile salt transporter as a functional receptor for HBV.  
The importance of the liver as a metabolic organ has, for many years, 
created interest in the relationship between HBV and metabolism. Most 
prominently, however, the influence of HBV infection on hepatocyte metabolism 
was brought to the forefront with the identification of NTCP as a functional HBV 
receptor. This became especially interesting with the additional discovery that not 
only does the preS1 domain of L-HBsAg bind to NTCP, a bile acid transporter, 
but this binding interferes with the normal function of NTCP, suggesting 
competition for binding motifs within the receptor. Furthermore, point mutations in 
NTCP that abolished binding of preS1 also blocked the ability of the receptor to 
bind taurocholate [231], suggesting that by binding to NTCP HBV could 
dramatically alter hepatic bile acid uptake.  
Recently, this discovery was extended further using a biochemical profiling 
approach, in which human liver chimeric mice were infected with HBV and the 
impact on cholesterol metabolism was determined. Indeed, the study was able to 
demonstrate overall modest HBV-mediated changes in lipid metabolism, but 
specific factors involved in both cholesterol and bile acid metabolism were 
significantly altered (Fig. 8). For example, cholesterol 7α-hydroxylase (CYP7A1), 
the rate-limiting enzyme in the conversion of cholesterol to bile acids, was 
increased 12-fold in HBV infected mice; the two main transcriptional repressors 
of CYP7A1, nuclear farnesoid X receptor (FXR) and small heterodimer partner 
(SHP) were both down-regulated. In fact, of the 7 genes analyzed involved in 
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cholesterol metabolism 4 were significantly altered. Similarly, 4 of 6 genes 
involved in bile acid metabolism were significantly altered. In comparison, only 3 
of the 11 genes involved in lipid metabolism were altered. Interestingly, similar 
results on CYP7A1 were seen between mice infected with HBV, uninfected mice 
treated with the HBV entry inhibitor Myrcludex-B, which mimics the preS1 domain 
and binds to NTCP to block HBV infection, and in liver biopsy samples from 
chronically infected HBV patients [212]. Together these results indicate that the 
binding of HBV to NTCP is inhibiting bile acid uptake, which stimulates bile acid 
synthesis pathways.  
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Figure 8. Model of metabolic changes induced by HBV infection. Alterations in 
related metabolic pathways induced by binding of HBV to its receptor are shown. 
The potential impact of these alterations on HBV replication are also shown. 
Figure used with permission from [232]. 
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 One interesting caveat to these studies is the relatively novel use of a 
direct infection system, which drastically alters the question being asked in the 
experiment. For example, by also using the preS1 mimic Myrcludex-B, the 
studies described above [212] are specifically addressing the impact of receptor 
binding by HBV, and not the cellular impact of HBV replication. This is in contrast 
to much of the previous work, which has been done typically using systems that 
bypass the infection step. An example of the importance of this distinction is that 
while the study using HBV-infected human liver chimeric mice demonstrated that 
by binding to NTCP HBV alters the levels of FXR and SHP, previous work in an 
HBV-tg mouse model (which bypasses the infection step, among other 
differences) showed that depletion of FXR and SHP signaling did not diminish 
viral replication or transcription [233]. This suggests that although HBV binding to 
its receptor alters the expression of these transcription factors, this alteration may 
not be required for HBV replication. Further research would be needed to 
determine the relevance of similar contrasting results within different model 
systems. 
  In addition to the functional inhibition of a major bile salt transporter, 
evidence from other studies has suggested that HBV replication may be 
intimately associated with central metabolic pathways. For example, multiple 
transcription factors associated with hepatic metabolic processes, including 
HNFs [234, 235], peroxisome proliferator-activated receptors (PPARs) [235-237], 
and FXR [238-240] can all be recruited to the HBV genome (reviewed in [35]). 
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Also, bile acids used in vitro have been shown to increase HBV replication [240, 
241]. 
Beyond bile acid and cholesterol metabolism, induction of 
gluconeogenesis enhances HBV replication [242], and HBx has been shown to 
increase expression of multiple gluconeogenic genes [243], potentially 
contributing to its central role in HBV replication. Also, a recent RNA-seq analysis 
of Huh7 cells expressing HBV showed decreased expression of GLUT2, the 
main hepatic glucose transporter [244]. Investigation of fasting glucose levels on 
HBV replication also revealed a link, though minor, between the metabolic state 
of the cell and the level of HBV replication [235], and both gluconeogenesis and 
lipogenesis are under the same transcription factor control as HBV replication 
[245].  Studies have also linked metabolic changes to the effects of HBV proteins. 
For example, some of the earliest functions attributed to HBx involved its 
regulation of metabolic pathways, such as HBx-mediated activation of the Ras-
Raf-MAPK pathway [97, 246], a central pathway involved in the response to 
nearly all changes that affect metabolism [247]. Protein kinase C (PI3K) is also 
activated by HBx [248, 249], which correlates with recent results suggesting HBV 
and HBx activate the PI3K/Akt pathway resulting in reduced viral replication [82, 
223]. In addition, studies have shown that L-HBsAg with a mutant preS2 region 
activates mTOR signaling [250-252], ultimately resulting in increased lipogenesis 
[251]. 
Together, these studies support the characterization of HBV as a 
"metabolovirus," with the virus both being responsive to and causing significant 
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metabolic changes in the cell. While the clinical impact of this altered metabolic 
regulation remains inconclusive, there are studies that suggest that HBV can 
"help" reduce fatty liver disease (reviewed in [253]). The overall link between 
HBV and metabolic syndrome remains less clear, however studies which 
consider the impact of direct infection through a major metabolic receptor may 
help to enhance our understanding of the link between HBV and metabolic 
pathways, and how this relationship may impact the metabolic state of the liver 
as a whole. 
55 
	  
Chapter 3. Introduction: HBV and miRNAs 
(Parts of this section have been published in [1])
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 The identification of microRNAs (miRNAs) as mediators of RNA-induced 
silencing [254] has spawned an exciting new field of research into the role of 
miRNAs in cell physiology. As the central role of miRNAs in the regulation of 
cellular homeostasis has been established, it has become apparent that 
disruption of miRNA expression or function can contribute to the development of 
many diseases [255] including neurodegenerative, cardiovascular, and kidney 
diseases, and many cancers [256-259]. The results of numerous studies also 
support a role for miRNAs in many aspects of a viral infection and virus-
associated diseases and suggest that some viruses have developed 
mechanisms to utilize miRNAs and the miRNA machinery to optimize cellular 
conditions for virus replication and survival [260-263]. 
A number of groups have begun to examine the relationship between 
miRNAs and human hepatitis B virus (HBV) infection; these studies have 
produced compelling evidence that the interplay between HBV and cellular 
miRNAs is important to many facets of HBV replication and pathogenesis. The 
focus of this chapter will be to summarize these studies and our current 
understanding of the HBV-miRNA relationship as it relates to the overall liver 
miRNA profile, HBV replication and pathogenesis, and the development of HBV-
associated hepatocellular carcinoma (HCC).  
 
miRNA Overview 
 miRNAs are small, non-coding RNAs that are involved primarily in post-
transcriptional regulation of gene expression through translational repression or 
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degradation of targeted mRNAs [255, 264, 265]. Regulation of miRNAs, their 
biogenesis, and target identification have been described in detail elsewhere (for 
biogenesis and regulation see [264, 265] and for targeting see [255]) and are 
only briefly summarized here. Primary (pri-) miRNAs, the first product of the 
miRNA biogenesis pathway, are transcribed by RNA polymerase II, and may 
contain a single miRNA or a cluster of multiple miRNAs. Once transcribed, the 
capped and polyadenylated pri-miRNA is processed by a microprocessor 
complex, consisting of the double-stranded (ds) RNA binding protein 
DGCR8/Pasha and the RNase III enzyme Drosha to remove the flanking 
sequence from a hairpin structure, releasing a ~70-90 nucleotide (nt) precursor 
(pre-) miRNA hairpin. The pre-miRNA is then exported out of the nucleus and is 
further processed by the RNase III enzyme Dicer together with the dsRNA-
binding protein TAR RNA binding protein (TRBP). With unwinding and removal of 
one strand of the dsRNA, a single-stranded 20-23 nt mature miRNA is 
assembled with specific proteins, including a member of the Argonaut family of 
RNA-binding proteins, to form the mature RNA-induced silencing complex (RISC) 
[266-271]. Canonical RISC-mediated silencing is facilitated by complementary 
base pairing of a specific seed-sequence within nt ~2-7 at the 5’ end of the 
mature miRNA to a complementary target sequence, usually within the 3’ 
untranslated region (UTR) of the targeted mRNA. Once bound by RISC, target 
mRNAs are either translationally repressed through mRNA sequestration or 
degraded [255]. Recent evidence suggests that the majority of mRNAs that are 
targeted by miRNAs are regulated through mRNA destabilization and 
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degradation, although the degree to which translational repression contributes to 
silencing is still under investigation [272]. Recent application of transcriptome-
wide, target-identification techniques has expanded the rules of targeting beyond 
the seed-sequence regulated pathway to include non-seed sequence matching 
and target sites outside of the mRNA 3’ UTR [273-276]. The recognition of non-
seed sequence targeting of mRNAs has increased the complexity of predicting 
miRNA targets and highlights the importance of miRNA studies that use 
techniques such as high-throughput sequencing of RNA isolated by crosslinking 
immunoprecipitation (HITS-CLIP) or photoactivatable ribonucleoside-enhanced 
(PAR)-CLIP, which assess miRNAs and target mRNA contained within functional 
RISC complexes [275, 277-279]. 
Since the discovery of the first miRNA, lin-4, and the elucidation of the 
RNA-silencing pathway in C. elegans and subsequent identification of miRNAs in 
humans, the study of miRNA regulation and function has grown exponentially 
[254, 280, 281]. Evidence of this can be seen in the rapid growth of the miRBase 
registry, where the current version, miRBase v21, lists over 2500 unique human 
mature miRNAs [282, 283]. Importantly, considerable conservation of the 
sequence of many of these miRNAs exists across distant species, implying an 
essential role in cellular function. miRNAs have well-established roles in lipid 
metabolism [284], glucose metabolism [285], cell cycle regulation [286], and the 
immune response [287], and recent studies estimate that as many as 60% of all 
mRNAs in a mammalian cell can be regulated in some way by miRNAs [288]. 
This estimate can increase to over 90% when non-canonical target sites are 
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considered [289]. The same cellular signal transduction pathways that control the 
expression of protein-coding RNA transcripts can also regulate miRNA 
expression, and it is expected that disease-associated alterations to 
transcription-regulating pathways can also disrupt normal expression of miRNAs 
and affect cellular homeostasis. 
 
miRNAs in the liver 
 The miRNA profile of the liver is unique in that 50-70% of the total liver 
miRNA is a single miRNA, miR-122 [290, 291]. Few studies have specifically 
examined the miRNA profile of the normal liver. Those studies that have been 
conducted indicate that nearly 90% of the total miRNAs in the liver may be 
comprised of only about 10 miRNAs, including miR-122 [290, 292]. Multiple 
studies confirm abundant expression of members of the let-7 family as well as 
miR-125b, miR-92, miR-192, and miR-143. Other miRNAs, including miR-16, 
miR-126, and miR-199a/b have also been shown to be highly expressed in the 
normal liver [290, 292, 293]. Since hepatocytes account for 80% of the cell mass 
in the liver, miRNA profiling of liver tissue largely reflects miRNA expression in 
hepatocytes [294]. The recognition that only a small number of miRNAs are 
significantly expressed in the liver suggests that studies attempting to assign 
physiological consequences to a change in expression of an miRNA in the liver 
should consider observed changes in miRNA expression levels in the context of 
the percentage of the overall expression of that miRNA in the liver.  
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Viruses and the miRNA profile 
A growing number of studies into the relationship between miRNAs, 
replication of viruses, and virus-associated diseases demonstrate that many 
viruses disrupt, hijack, or subvert RNA-induced silencing processes (reviewed in 
[295]). Many of these virus-miRNA interaction studies have focused on the 
following questions: 1) Does the virus alter the cellular miRNA profile, and if so, is 
this through alteration of global miRNA processing or through direct miRNA 
regulation? 2) Do cellular miRNAs directly target viral RNA transcripts or the viral 
genome in the case of viruses that have an RNA genome? 3) Do cellular 
miRNAs influence viral replication or virus-associated diseases? 4) Does the viral 
genome encode miRNAs? 5) Can virus-mediated changes in miRNA expression 
be exploited for the development of novel biomarkers of viral infection or disease 
or for antiviral therapeutics? 
Because of the global disruption to cellular homeostasis that typically 
accompanies a viral infection, some degree of change to the cellular miRNA 
profile during an infection is to be expected. This alteration of the cellular miRNA 
profile could result in subsequent alteration of cellular mRNA expression, 
possibly as a mechanism for the virus to optimize the cellular environment for 
viral replication, persistence, or latency. Changes to miRNA expression have 
been detected following infection with various viruses, and in many cases, both 
altered miRNAs and mRNA targets that affect cellular physiology and the course 
of infection and disease have been identified. Examples of this include up-
regulation of the oncogenic miR-155 by the Epstein-Barr virus (EBV), which 
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promotes immortalization of infected B-cells [296]; up-regulation of miR-141 by 
enteroviruses, which reduces eIF-4E expression to favor cap-independent 
translation of viral transcripts [297]; and down-regulation of miR-203 by human 
papilloma virus (HPV), which increases expression of transcription factors to 
allow viral replication in differentiating cells [298]. In addition to direct regulation 
of miRNA expression, some viruses can express RNAs that are thought to act as 
natural miRNA sponges to competitively bind specific miRNAs, diverting them 
away from their endogenous targets [299, 300]. This can result in altered target 
mRNA expression and destabilization of the miRNA, likely favoring viral 
replication. One example of this is herpesvirus saimiri, which encodes a small 
non-coding RNA that binds and sequesters miR-27, resulting in decreased levels 
of mature miR-27 and increased levels of its mRNA targets [301]. 
In addition to altering the regulation of specific cellular miRNAs, viruses 
can disrupt global miRNA expression or processing. For example, poxviruses 
globally degrade host miRNAs through 3’ polyadenylation by a viral poly(A) 
polymerase and subsequent degradation by the host RNA-degradation 
machinery [263]. Adenoviruses encode a small noncoding RNA, VA1, that is 
bound by the Dicer/TRBP complex but inefficiently processed, resulting in a 
competitive inhibition of cellular miRNA processing and global down-regulation of 
host miRNA expression [262, 302]. Ebola virus [303], influenza virus [304], 
vaccinia virus [304], and nodamura virus [305] have also been shown to inhibit 
global RNA silencing through inhibition of the host-cell's RNA-mediated silencing 
machinery. 
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Host miRNAs have also been shown to directly target viruses with an RNA 
genome or viral RNA transcripts. Recent studies using PAR-CLIP in human 
immunodeficiency virus (HIV)-1-infected cells demonstrated that while HIV-1 
transcripts have multiple potential miRNA binding sites and make up a large 
percentage of the total cellular mRNA in HIV-infected cells, only a small 
percentage of RISC targets were HIV derived, indicating that, at least at early 
time points after infection of T cells, very few of these potential sites were being 
targeted by miRNAs. Of the miRNAs predicted to target HIV-1, only a small 
subset were able to directly bind to HIV-1 transcripts and could potentially be 
involved in regulating HIV expression through direct silencing [306]. Additional 
evidence of the antiviral effect of direct binding of HIV-1 by miRNAs has been 
presented elsewhere [307]. Similar direct-targeting has been proposed with miR-
32 and another retrovirus, primate foamy virus (PFV) [308]; however, the antiviral 
role of this miRNA in the context of an actual PFV infection remains unclear 
[309]. Direct targeting is not always detrimental to the virus, and studies have 
revealed an essential role for miR-122 in hepatitis C virus (HCV) replication 
through direct interaction at two sites in the 5’UTR of the HCV genome [310, 
311]. Because of this requirement for miR-122 binding, inhibiting miR-122 in vivo 
and in vitro has proven to be a promising potential therapeutic approach for 
blocking HCV replication and the development of HCV-associated diseases [312, 
313].  
It would seem that their small size, lack of immunogenicity, and potent 
regulatory effects would make miRNAs ideal tools for a virus to encode within its 
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genome; however, only a limited number of virus-encoded miRNAs have been 
identified. Early attempts to identify virus-encoded miRNAs led to the discovery 
of five miRNA precursors that clustered in two regions of the EBV genome, and 
these miRNAs were shown to efficiently target one of several predicted cellular 
mRNAs [314]. Subsequent studies of other virus families, however, have only 
conclusively shown that members of the herpesvirus and polyomavirus families 
encode miRNAs (reviewed in [315]). Studies directed towards identifying 
potential miRNAs of HCV and HIV-1 have not identified miRNAs encoded in the 
genomes of these viruses [316]. Although one study computationally predicted a 
mature miRNA sequence within the HBV genome [317], evidence from multiple 
studies, including deep-sequencing studies of the transcriptome of HBV-infected 
cells and whole livers, which would identify all small RNAs in an infected cell, 
suggest that miRNAs are not encoded within the HBV genome [171, 290, 314, 
318]. 
Methods used to analyze miRNA expression 
Experimental protocols typically used in determining HBV-mediated 
changes to miRNA expression include targeted approaches such as quantitative 
RT-PCR (qRT-PCR) and broader approaches such as microarray or deep 
sequencing of the cellular RNA transcriptome (Table 2). qRT-PCR is often used 
to analyze the expression level of a single miRNA, a small panel of miRNAs, or 
as a follow-up step for confirmation of results seen in broader studies such as 
miRNA microarray studies [319-325]. Although microarray and qRT-PCR are 
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reliable for assessing relative changes in miRNA expression, it is important to 
note that these techniques do not determine if the miRNAs are expressed at 
physiologically relevant levels. 
An increasing number of studies have begun using broader techniques 
such as qRT-PCR arrays and microarrays as a means of identifying expression 
changes in the population of miRNAs in cells. This has resulted in multiple 
attempts to independently establish an “HBV-mediated miRNA profile” by 
identifying miRNAs with altered expression in the presence of HBV. Despite the 
widespread use of these techniques, whether it is due to technical limitations, 
heterogeneity of the samples, or still unknown factors, observations in these 
HBV-miRNA studies have often differed. For example, a comparison of the 
results of three different microarray analyses of HepG2.2.15 miRNAs, all done 
using the same microarray platform, shows that the studies respectively identified 
18, 31, and 47 miRNAs with altered expression compared to the parental HepG2 
cells. Of these, only four were in common among all of the studies (miR-146a, 
miR-181a, miR-181d, and miR-338-3p), and only ten were in common between 
any two of the studies [326-328]. While this comparison highlights the potential 
variation between HepG2 and HepG2.2.15 cells, it also serves as an example of 
inconsistencies among HBV microarray studies and the need for follow-up 
studies to confirm altered miRNA expression. 
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Table 2. Methods for studying miRNA expression levels 
Strategy Advantages Disadvantages 
qRT-PCR 
Determines absolute 
expression levels, requires 
minimal bioinformatics 
analysis 
Amplifies single miRNAs at a 
time so is often used to 
determine expression of 
smaller numbers of miRNAs, 
requires prior knowledge of 
target 
miRNA 
microarray 
Can be used to determine 
expression changes for a 
larger group of miRNAs 
Data are fold change relative 
to a baseline and not absolute 
expression values, requires 
prior knowledge of target 
miRNAs 
Next-
generation 
sequencing 
Identifies the complete 
miRNome, determines 
absolute expression values 
in the context of all other 
cellular miRNAs 
Relatively expensive, requires 
extensive bioinformatics 
analysis 
66 
	  
 
 One approach that could aid in establishing a consensus HBV-mediated 
miRNA profile is the application of techniques such as transcriptome-wide next-
generation sequencing, which allows a determination of absolute miRNA levels 
instead of relative changes, as reported in microarray analyses. A determination 
of absolute miRNA levels is important because it distinguishes more abundantly  
expressed miRNAs from those present at only low levels. Abundant miRNAs 
have a higher potential to regulate cellular pathways in physiologically significant 
ways, whereas a several fold change in a low-abundance miRNA may have little 
effect. In one such study in primary treeshrew hepatocytes, the profile of all 
miRNAs expressed at a given time was established by deep-sequencing of 
primary treeshrew hepatocyte small RNAs. These studies identified 25 miRNAs 
that are both significantly expressed in the liver and show HBV-mediated 
expression changes. Interestingly, this included miR-146a, one of the four 
miRNAs consistently identified in the previously described microarray 
experiments, and miR-122 and let-7a, two highly abundant miRNAs in the liver. 
These results have particular relevance because of the use of infectious HBV 
instead of exogenous delivery of the viral genome by transfection or expression 
from an integrated transgene [171]. As the use of transcriptome-wide techniques 
expands, it will be informative to apply a deep-sequencing approach to a larger 
population of HBV-infected individuals to discover and understand the functional 
significance of any alterations in miRNA expression profiles in HBV-infected 
cells. In addition, techniques that specifically investigate functional miRNAs 
(discussed below) will help to determine the physiological impact of HBV-
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mediated alterations to the miRNA expression profile by identifying miRNAs that 
are actively involved in targeting, not simply the miRNAs with altered expression 
levels. 
Interplay between HBV and miRNAs 
Effects of HBV on host cell miRNA expression 
While there have been some inconsistencies in the results of studies that 
have sought to define HBV-induced changes in cellular miRNA expression 
profiles [171, 290, 320, 326-328], a small number of miRNAs have been 
identified more often than others as having expression changes that are 
associated with HBV infection. This chapter focuses first on these miRNAs, 
followed by a discussion on some additional miRNAs potentially altered by HBV 
(Fig. 9, Table 3).  
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Figure 9. miRNAs altered by HBV and HBx or in HBV-associated HCC. Venn 
diagram depicting miRNAs discussed in text that have altered expression levels 
in the context of HBV replication, HBx expression, and/or HBV-associated HCC. 
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miR-122 
The expression of miR-122 is highly specific to hepatocytes, where this 
single miRNA can account for 50 – 70% of the entire cellular miRNA population 
[290, 291]. miR-122 has a role in maintaining the differentiated phenotype of 
hepatocytes and is involved in the control of lipid metabolism, circadian rhythm, 
apoptosis, and iron homeostasis [284, 329-334]. The down-regulation of miR-122 
levels in HCC has been observed in many studies [290, 320, 335-337], 
consistent with the dedifferentiated status of transformed hepatocytes; the 
contribution of HBV infection to this down-regulation in the context of HBV-
associated HCC is less well characterized. The effect of HBV infection on the 
expression of miR-122 has often been studied by comparing its levels in 
uninfected cells with those in cells either stably or transiently transfected with the 
HBV genome. While many of these studies have found reduced levels of miR-
122 in HBV producing cells [323, 338-342], others have not [325, 327]. Similarly, 
a down-regulation of miR-122 was observed in some analyses of liver tissue from 
chronically HBV-infected patients as compared to normal liver tissue [342], but 
not in others [290, 320, 343]. On the other hand, HBV infection of primary tree 
shrew hepatocytes was reported to result in an increase in miR-122 levels [171]. 
It will be of interest to discover if this striking difference from reports of HBV 
down-regulation of miR-122 is due to the use of an authentic HBV infection 
system, as opposed to transfection of HBV genomic constructs into cell lines, or 
if it reflects an inherent difference between human and tree shrew hepatocytes. 
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A variety of hypotheses have been put forth to explain changes in miR-
122 expression in HBV-producing cells. One report suggested that HBV 
regulates the transcription of miR-122 through interactions between HBx and 
peroxisome proliferator-activated receptor (PPAR)γ that prevent ligand-induced 
activation of the miR-122 promoter by PPARγ [341]. However, decreased miR-
122 promoter activity is contrary to the established activation of multiple miR-
122-activating transcription factors such as HNF4α and CCAAT-enhancer-
binding protein α (C/EBPα) in cells with replicating HBV [339, 344-346]. 
In fact, an increase in miR-122 promoter activity in the presence of HBV, 
although with decreased levels of mature miR-122, has been reported [339]. It 
was proposed that this lower level of mature miR-122 was due to sequestration 
of miR-122 through binding to a conserved sequence detected at the 3’ end of all 
HBV transcripts (Fig. 10). This miRNA sponge effect, in turn, may lead to a 
derepression of cellular mRNAs normally targeted by miR-122, such as pituitary 
tumor-transforming gene 1 binding factor (PBF), resulting in increased cell 
proliferation [339]. However, it has been shown elsewhere that extremely high 
levels of competitive endogenous (ce)RNAs, or endogenous RNAs that act to 
sequester miRNAs away from their target mRNAs, are required before a sponge 
effect can be demonstrated to derepress cellular targets of an miRNA, and miR-
122 in particular [347]. It remains to be tested whether a natural infection with 
HBV results in high enough amounts of HBV RNAs to sequester miR-122 at 
levels sufficient to alter the targeting pattern of endogenous mRNAs. Another 
report investigating HBV- or HBx-mediated effects on miR-122 promoter activity 
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found no change to the miR-122 promoter activity, but suggested that HBx 
reduces the expression of Gld2, a poly(A) polymerase that can stabilize miRNAs 
through the addition of a single adenylate residue [348]; reduced expression of 
Gld2 would ultimately contribute to destabilizing and reducing miR-122 levels 
[340]. Clearly, a better understanding of the control of miR-122 expression will be 
necessary before conflicting reports of changes induced by HBV replication can 
be resolved, or the mechanism by which HBV gene products might affect miR-
122 transcription, stability, and function can be understood. 
Figure 10. Linear arrangement of overlapping ORFs and viral transcripts. 
Transcripts and ORF are aligned with each other according to genomic location 
and are to scale. Colored boxes on transcripts indicate proposed miRNA target 
sites discussed in text. 
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Table 3. HBV-mediated regulation of cellular miRNAs. 
miRNA Effect Sample Type Proposed Target 
Proposed 
Targeted 
Pathway 
Method of 
Detection Ref 
HBV-mediated regulation 
miR-
122 
Down HepG2.2.15 HO-1 
Inflammation 
and 
apoptosis 
qRT-PCR [349] 
Down 
HBV-
transfected 
HepG2/Huh7/
SK-Hep-01, 
HBV-
transgenic 
mice, HBV-
infected liver 
tissue 
PBF Cell proliferation qRT-PCR [339] 
Down HepG2.2.15 Cyclin G1 
Cell cycle 
regulation; 
p53-
mediated 
repression of 
HBV 
transcription 
in-situ 
hybridizati
on, qRT-
PCR 
[342] 
Down HepG2.2.15 NDGR3 Cellproliferation qRT-PCR [338]
Up 
HBV-infected 
primary 
treeshrew 
hepatocytes, 
HBV patient 
serum 
- - NGS, qRT-PCR [171] 
Up HBV patient serum - - microarray 
[321, 
350] 
let-7a/g Down 
HBV-
transfected 
HepG2 
- - microarray [328] 
let-7a Down 
HBV-
transfected 
HepG2 
- - qRT-PCR [351] 
let-7 
family Up HepG2.2.15 - - microarray [328] 
let-7a Up HepG2.2.15 - - microarray [325] 
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miR-
15/16 
family 
Down 
HBV-
transfected 
HepG2 
- - microarray [328] 
Down 
HBV-
transfected 
HepG2, 
HepG2.2.15, 
HBV-
transgenic 
mice, HBV-
associated 
HCC 
Bcl-2 Apoptosis qRT-PCR [352] 
Down HepG2.2.15 - - microarray [327] 
miR-22 Down HepG2.2.15 CDKN1A Cellproliferation qRT-PCR [353]
miR-
29c Down HepG2.2.15 TNFAIP3 
Cell
proliferation qRT-PCR [354]
miR-
125a-
5p 
Up HBV-infected liver tissue - - qRT-PCR [355] 
Up HepG2.2.15 - - microarray [326, 327] 
Up Transfected Cell Line - - qRT-PCR [351] 
miR-
125b Down 
HepG2.2.15, 
HBV-
transfected 
HepG2 
SCCND1 - microarray, qRT-PCR [356] 
miR-
181a Up 
HepG2.2.15, 
AdHBV-
infected 
HepG2 
E2F5 Cell proliferation qRT-PCR [357] 
mIR-
199b Down 
HBsAg+ liver
tissue - - microarray [326] 
miR-
372/373 Up HepG2.2.15 NFIB 
HBV
replication microarray [326]
miR-
501 Up HepG2.2.15 HBXIP 
HBV 
replication 
microarray
, qRT-PCR [325]
miR-
602 Up HepG2.2.15 RASSF1A 
Apoptosis, 
tumor 
suppressor 
microarray
, qRT-PCR [343] 
HBx-mediated regulation 
miR-
122 Down 
HBx-
expressing 
HepG2 
PPARγ miR-122 transcription qRT-PCR [341] 
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let-7 
family Down 
HBx over-
expressing 
HepG2, HCC 
Stat3 Cell proliferation 
microarray
, qRT-PCR [358] 
miR-
15/16 
family 
Down 
HBx-
expressing 
HepG2/Huh7/
SK-HEP-1 
cells 
CyclinD1 Cell cycle microarray, qRT-PCR [359] 
miR-21 Up 
HBx-
expressing 
HepG2/Huh7 
PDCD4, 
PTEN 
Akt, cell 
proliferation qRT-PCR [360] 
miR-21 Up 
HBx-
expressing 
MIHA 
- Cell migration qRT-PCR [361] 
miR-
29a Up 
HepG2.2.15, 
HBx-
expressing 
HepG2, HBx-
transgenic 
mice 
PTEN Akt, cell migration qRT-PCR [362] 
miR-
101 Down 
HepG2.2.15, 
HBx-
expressing 
HepG2 
DNMT3A DNA methylation qRT-PCR [363] 
miR-
143 Up 
HBx-
expressing 
HepG2, HBx-
transgenic 
mice 
FNDC3B Cell proliferation qRT-PCR [364] 
miR-
148a Down 
HBx-
expressing 
LO2/HepG2 
cells 
HPIP mTor qRT-PCR [365] 
miR-
152 Down 
HepG2.2.15, 
HBx-
expressing 
HepG2, HBx-
transgenic 
mice 
DNMT`1 DNA methylation 
microarray
, qRT-PCR [366] 
miR-
199a Up 
HBx-
expressing 
HepG2, 
HepG2.2.15, 
HBV infected 
HCC 
- - microarray, qRT-PCR [358] 
75 
	  
miR-
205 Down 
HBx-
expressing 
HepG2, HBV-
associated 
HCC 
 
DNA 
methylation, 
cell 
proliferation 
qRT-PCR [367] 
miR-
224 Up 
HBx-
transgenic 
mice 
Smad4 Cell proliferation 
in-situ 
hybridizati
on, qRT-
PCR 
[368] 
HBV-associated HCC 
miR-
122 
Down 
HBV-
associated 
HCC 
PBF Cell proliferation qRT-PCR [339] 
Down 
HBV-
associated 
HCC 
NDGR3 Cell proliferation qRT-PCR [338] 
let-7 
family Down HCC Stat3 
Cell 
proliferation 
microarray
, qRT-PCR [358] 
miR-
199a/b-
3p 
Down 
HCC liver 
samples 
(HBV and 
non-HBV) 
PAK4 ERK, cell proliferation 
NGS, qRT-
PCR [290] 
miR-
199b Down 
HBV-
associated 
HCC 
- - qRT-PCR [319] 
miR-22 Down 
HBV-
associated 
HCC 
CDKN1A Cell proliferation qRT-PCR [353] 
miR-
29c Down 
HBV-
associated 
HCC 
TNFAIP3 Cell proliferation qRT-PCR [354] 
miR-
101 Down 
HBV-
associated 
HCC 
DNMT3A DNA methylation qRT-PCR [363] 
miR-
143 Up 
HBV-
associated 
HCC 
FNDC3B Cell proliferation qRT-PCR [364] 
miR-
145 Down 
HBV-
associated 
HCC 
- - qRT-PCR [319] 
miR-
224 Up 
HBV-
associated 
HCC 
- - qRT-PCR [319] 
miR-
224 Up 
HBV-
associated Smad4 
cell 
proliferation 
in-situ 
hybridizati [368] 
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HCC on, qRT-
PCR 
miR-
501 Up 
HBV-
associated 
HCC 
HBXIP HBV replication 
microarray
, qRT-PCR [325] 
miR-
602 Up 
HCC liver 
samples 
(HBV and 
non-HBV) 
RASSF1A 
Apoptosis, 
tumor 
suppressor 
microarray
, qRT-PCR [343] 
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Let-7 family 
 
In humans, the let-7 family of miRNAs consists of 12 closely related 
miRNAs and represents some of the most highly expressed miRNAs in the liver. 
These miRNAs are classified as tumor-suppressor miRNAs, and the loss of 
members of the let-7 family is a common factor in the development of many 
forms of cancer, including HCC [369]. In addition, miRNA microarray and qRT-
PCR analyses have demonstrated that let-7 expression is altered in HepG2.2.15 
cells, HBV-transfected cell lines, HBx-expressing cell lines, and HBV-infected 
human liver samples [325, 326, 328, 351, 358]. In one study, multiple members 
of the let-7 family were identified by miRNA microarray as being down-regulated 
in HBx-expressing HepG2 cells, and a similar down-regulation of let-7a was 
shown in patients with HCC. Interestingly, this down-regulation of let-7a was 
correlated with an increase in cellular proliferation, in agreement with the 
established role of let-7 in the repression of cell proliferation factors such as Ras 
[370] and Myc [371]. These studies also demonstrated that both HBx expression 
and let-7 inhibition increased the levels of STAT3, a transcription factor that 
regulates cell proliferation, supporting the overall role of let-7 as an inhibitor of 
multiple proliferation pathways [358].  
Additional studies have shown that HBx can up-regulate the proteins 
Lin28A and Lin28B, known inhibitors of let-7 expression [372-374]. In fact, Lin28 
and let-7 form a double-negative feedback loop, with each inhibiting the 
expression of the other [375, 376]. Up-regulation of Lin28 expression has been 
observed in multiple HCC cell lines, HepG2.2.15 cells, and in HBx-transgenic 
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mice, and Lin28 up-regulation was directly linked to increased tumor growth in 
HBx-transgenic mice [377]. While levels of let-7 were not directly measured in 
these Lin28 studies, these observations suggest that HBx-mediated regulation of 
the Lin28/let-7 axis could play a role in the development of HBV-associated HCC. 
This suggestion is strengthened by the well-established oncogenic role of Lin28 
and tumor suppressive role of let-7 that has been linked to both let-7-
independent effects of Lin28 as well as to let-7 targeting of known oncogenes 
such as Ras and Myc, a let-7 effect that would be countered by up-regulation of 
Lin28 expression [369, 378]. 
miR-125 family 
The miR-125 family is one of the most studied miRNA families because 
lin-4, its homolog in C. elegans, was the first described miRNA [280]. Both miR-
125a and miR-125b display altered regulation in various diseases including HCC 
[290, 379]. Targets of this family include regulators of apoptosis, such as p53 
[380] and Bak1 [381], the stress response factor HuR [382], and the Lin28 
proteins [383]. Interestingly, miR-125a has been identified in multiple profiling 
studies as being up-regulated in HepG2.2.15 cells as compared to HepG2 cells, 
and recent studies have also demonstrated that miR-125a expression is up-
regulated in HBV-infected patient samples. A qPCR-based analysis of levels of 
miR-125a-5p in the liver directly correlated miR-125a-5p expression with liver 
HBV DNA levels and the severity of disease in chronically HBV-infected patients 
[355]. A follow-up study attempted to determine the mechanism for HBV-
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mediated up-regulation of miR-125a by examining the role of HBx in this same 
cohort of chronically HBV-infected HBV patients. Of these patients, those with 
high HBV viral load had 3.6-fold higher levels of HBx compared to patients with 
low viral load, which correlated with a 3-fold increase in the level of liver miR-
125a in the same patient groups. Transfection of HBx into HepG2 and Huh7 cells 
also increased the level of miR-125a expression [384]. While these data suggest 
a correlation between the levels of HBx and the levels of miR-125a, additional 
research is needed to determine the mechanism by which HBV may be 
regulating expression of miR-125a. Recently, miRNA microarray analysis of 
HepG2.2.15 cells and HBV-expressing HepG2 cells identified a set of 35 
miRNAs that exhibited similar regulation in both cell types when compared to 
HepG2 cells. Among these miRNAs, miR-125b was shown to be down-regulated 
in both HepG2.2.15 cells and HepG2 cells transfected with a HBV-expressing 
plasmid, and this regulation was subsequently confirmed by qRT-PCR [356]. 
While these results suggest opposing HBV-mediated regulation of miR-125a and 
miR-125b, which have the same seed sequence and might target a similar set of 
mRNAs, together they indicate that HBV is likely playing a role in regulating the 
miR-125 family.  
miR-199 family 
Analysis of the total miRNA population in normal liver samples by next-
generation sequencing of small RNAs identified members of the miR-199 family 
as being among the most abundant miRNAs in the liver, with miR-199a/b-3p 
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representing an average of 4.9% of the total miRNAs in the liver [290]. Because 
of the relative abundance of these miRNAs, changes in the levels of expression 
of miR-199 family members are likely to result in significant changes in the 
expression of mRNA targets. Although some studies suggest increased 
expression of miR-199a in HepG2.2.15 cells and HBV-positive liver samples 
[290, 385], many other studies report a down-regulation of miR-199 family 
members in HBV-expressing cells. This down-regulation has been shown in 
HepG2 cells transfected with a plasmid expressing the HBV genome, in 
HepG2.2.15 cells, and in HBV-infected patients [326, 328, 343, 386], and down-
regulated miR-199b has been proposed as a biomarker for early detection of 
HBV-associated HCC [319]. Additional studies are needed to determine the 
cellular impact of HBV-mediated altered miR-199 expression.  
miR-15 family 
The miR-15 family of miRNAs represents one of the earliest identified 
examples of a tumor-suppressor miRNA family [256]. Decreased expression of 
many of the six miR-15 family members (miR-15a, miR-15b, miR-16-1, miR-16-2, 
miR-195, miR-497) is common in multiple forms of cancer, including HCC, and 
their targets include important cellular factors such as regulators of the cell cycle 
and apoptosis [387, 388]. Studies have shown decreased expression of 
members of this family in cell lines transfected with a plasmid expressing the 
HBV genome, in HepG2.2.15 cells, in HBV-infected liver samples, in HBV-
associated HCC, and in cells expressing HBx [327, 328, 351, 359, 389-391]. This 
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alteration could be explained, in part, by the previously identified induction of c-
Myc by HBx [99, 359, 392] and c-Myc-mediated repression of the miR-15a/miR-
16 cluster [393]. Importantly, studies have confirmed the significance of this 
down-regulation of the miR-15a/16 cluster by demonstrating derepression of 
miR-15a/16 targets, including Cyclin D1, in HBx-expressing cells [359].  
Additional evidence of HBV-mediated regulation of the miR-15 family was 
obtained in two independent studies that suggested that HBV transcripts act as 
miRNA sponges to sequester miR-15 family members and decrease the 
interactions of miR-15 family members with endogenous targets. The first study 
used the TargetScan algorithm to identify four target sites for miR-15a and miR-
16-1 within a sequence contained in all HBV mRNA transcripts. Interestingly, 
while transfection of HepG2 cells with HBV altered the expression of 8 miRNAs 
(miR-210, miR-602, miR-199a, miR-125a, and miR-29a up; miR-15a, miR-16-1, 
let-7a down), this regulation was retained when HepG2 cells were transfected 
with a plasmid encoding an HBV genome with a premature stop codon 
preventing production of HBx. Additionally, transfection of a plasmid encoding 
either HBx or a mutant that made HBx RNA but not HBx protein resulted in 
decreased expression of miR-15a and miR-16-1. This implied that while HBx 
over-expression was able to down-regulate miR-15a and miR-16-1, this 
regulation was not through the HBx protein. Pull-down assays conducted in this 
study also demonstrated that miR-15a can bind HBx RNA, and it was 
hypothesized that HBx RNA acts as an miRNA sponge to decrease the levels of 
miR-15a available in the cell. Support of this hypothesis was shown by up-
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regulation of miR-15a targets, such as the cell cycle regulator Cyclin D1 and anti-
apoptotic Bcl-2, in the presence of HBx RNA [351]. It should be noted, however, 
that because this target site is located within the HBx transcript, it is also within 
all HBV RNA transcripts (Fig. 10). Therefore in cells with replicating HBV, each of 
the HBV transcripts would have the potential to have a similar sponge effect. 
Additional studies have shown that the levels of miR-15a and miR-16 are 
significantly decreased in transformed cell lines expressing HBV, in HBV-
transgenic mice, and in HBV-associated HCCs. Using TargetScan, another miR-
15/16 target site was identified within the region of the HBV genome shared in all 
HBV transcripts and independent from the previously identified miR-15/16 target 
sites [351] described above (Fig. 10). Transfection of a plasmid expressing this 
target site or a plasmid expressing a greater-than-unit length copy of the HBV 
genome reduced levels of miR-15a and miR-16, while expression of an HBV 
genome in which the target site was mutated caused no change in the levels of 
miR-15a or miR-16. Together, these results suggest that HBV transcripts can 
bind to miR-15a and miR-16 and may act as an miRNA sponge. In HBV-
associated HCC patient samples, a strong negative correlation was seen 
between expression of HBV transcripts and expression of miR-15/16, and a 
strong positive correlation was seen between HBV transcript levels and 
expression of the apoptosis inhibitor Bcl-2, a known target of the miR-15 family 
[352]. These data support the hypothesis that HBV transcripts can divert miR-15 
family members away from endogenous targets, as seen by increased 
expression of Bcl-2 and a significant decrease in apoptosis induction in cells 
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expressing HBV. Together, these studies suggest a mechanism, potentially in 
addition to the HBx-mediated activation of c-Myc previously described [359], by 
which HBV regulates the levels of the miR-15 family to optimize cellular 
homeostasis by decreasing apoptosis and modulating cell cycle regulators. As 
shown for miR-122 [347], it is important to point out that very high levels of the 
target transcript may be needed for an miRNA sponge to have a physiological 
effect, and it remains to be seen whether the levels of HBV transcripts in the cell 
reach this threshold [347].  
 
miR-17-92 cluster 
 The miR-17-92 cluster is composed of six miRNAs: miR-17, miR-18a, 
miR-19a, miR-19b-1, miR-20a, and miR-92a-1. This cluster is well characterized 
as having increased expression in multiple cancers and has been referred to as 
oncomir-1 due to its oncogenic potential [394]. Analysis of expression of this 
miRNA cluster in the HepAD38 cell line, in which expression of the HBV pgRNA 
and therefore HBV replication, is under the control of a tetracycline-responsive 
promoter, showed that both the precursor and mature forms of multiple members 
of the miR-17-92 cluster were significantly up-regulated in the presence of HBV 
replication. It was further shown that c-Myc inhibition blocked HBV-mediated up-
regulation of the miR-17-92 cluster, indicating that this regulation was through 
HBV-mediated activation of c-myc [395]. Interestingly, next-generation 
sequencing of the miRNAs in HBV-infected liver samples showed significant up-
regulation of miR-92a compared to normal tissue, and even higher expression in 
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HBV-associated HCC [290]. In contrast to observations in HepAD38 cells and 
patient samples, multiple studies have shown that members of the miR-17-92 
cluster are down-regulated in HepG2.2.15 cells [326-328]. These differences 
could reflect differences between the various cell types and assay methods used 
in these studies, and suggest that cellular context should be considered when 
interpreting these HBV-miRNA studies. 
 
Other miRNAs and miRNA-regulated pathways affected by HBV 
In addition to the miRNAs discussed above, other miRNAs and miRNA-
regulated pathways that are altered in the context of HBV replication have been 
described. Because these studies of HBV-mediated miRNA regulation have been 
identified in fewer, sometimes only single, studies, they have been grouped 
together and are discussed here. In addition, some of these miRNAs are not 
highly expressed in the liver, and therefore their physiological role during an HBV 
infection may require careful interpretation. For example, miR-501 was shown by 
microarray and qRT-PCR to be up-regulated in HepG2.2.15 cells compared to 
HepG2 cells and in liver samples from HBV-associated HCC patients with a high 
viral load compared to patients with a lower viral load. Up-regulation of miR-501 
led to increased targeting of hepatitis B X-interacting protein (HBXIP), a cofactor 
for the anti-apoptotic protein Survivin [325, 396]. Similarly, HBV-mediated up-
regulated of miR-602 was shown in a study examining normal liver samples, 
HBV-infected liver samples, and HBV-associated HCC samples; Ras association 
domain family 1 isoform A (RASSF1A), a target of miR-602, important tumor 
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suppressor, and regulator of apoptosis [397], was down-regulated in the 
presence of HBV. Increased miR-602 expression was confirmed in both 
HepG2.2.15 cells and HepG2 cells stably expressing HBx, and targeting of 
RASSF1A was blocked in these cells with the addition of a miR-602 inhibitor 
[343]. Another study demonstrated that HBV-associated HCCs and HepG2.2.15 
cells express increased levels of the miR-371/372/373 miRNA cluster and that 
this up-regulation caused a decrease in the levels of nuclear factor I/B (NFIB) 
[326]. A high-throughput sequencing analysis of the miRNAs expressed in the 
human liver, however, showed miR-501, miR-602, and the miR-371 cluster as 
having poor expression in the liver (< 10 transcripts per million reads) [290]. 
Alternatively, miR-181a, an miRNA over-expressed in numerous cancers, and 
shown to have moderate liver expression (~150 transcripts per million reads in 
normal liver) [290], was up-regulated in HepG2.2.15 cells and in HepG2 cells 
infected with an adenoviral vector containing a greater-than-unit length copy of 
the HBV genome [326-328, 357]. This up-regulation of miR-181a decreased 
expression of its predicted target E2F5, a transcription factor known to be 
involved in proliferation regulation, leading to increased cellular proliferation and 
tumor growth in nude mice [357].  
During an HBV infection, non-infectious HBsAg is secreted from the cell 
as empty viral particles, known as subviral particles, typically in a 1,000 to 
100,000-fold excess compared to infectious particles [398]. Next-generation 
sequencing of small RNAs from HepG2 cells over-expressing HBsAg showed 
that the miRNA profile is significantly altered in response to HBsAg expression. 
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Some of the miRNAs up-regulated by HBsAg expression are known or predicted 
to target the major histocompatibility complex class I-related molecules A or B 
(MICA or MICB), two ligands involved in activation of natural killer (NK) cells. 
miR-373, miR-107, and miR-29a/b, three miRNAs shown to be up-regulated in 
HBsAg-expressing cells, were each shown to target MICA or MICB, resulting in 
decreased surface expression of these ligands and decreased NK cell-mediated 
cell death [399]. Emerging evidence has supported a role for NK cells in the 
innate immune response to HBV [400], and HBV down-regulation of NK cell-
activating ligands such as MICA and MICB could contribute to the establishment 
of a chronic HBV infection and associated diseases. Further research is needed 
to determine the correlation between the amount of HBsAg expression required 
to induce expression of the MICA/MICB-regulating miRNAs and the amount of 
HBsAg that is present during a normal infection, but these studies suggest a 
potential role for MICA and MICB down-regulation in chronic HBV infection. 
An interesting aspect of miRNA-related research has been the recognition 
of miRNA-mediated regulatory networks, in which multiple cellular factors and 
miRNAs combine to form a cascade of cellular signals. Together these regulatory 
networks, involving factors such as NF-κB /Lin28/let-7/IL-6 or miR-124/IL-
6R/HNF4, are important for maintaining the normal function of the cell, and their 
disruption may be a cause of disease [401, 402]. Various studies have 
independently identified a number of HBx-mediated effects on cellular 
metabolism through disruption of cellular miRNAs (Fig. 11). When considered 
together, these studies could imply a regulatory mechanism through which HBx 
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modulates cellular metabolism by influencing the levels of specific miRNAs to 
regulate expression or activation of a group of important metabolism-related 
cellular factors. For example, one group demonstrated that HBx inhibits p53-
mediated activation of miR-148a, resulting in increased expression of the miR-
148a target, hematopoietic pre–B cell leukemia transcription factor–interacting 
protein (HPIP). This increase in HPIP activated Akt and extracellular signal-
regulated kinase (ERK), and ultimately mechanistic target of rapamycin (mTOR) 
[365]. HepG2.2.15 cells, HBx-transgenic mice, and cells over-expressing HBx 
each were also shown to have increased levels of miR-29a, which targets PTEN, 
a negative regulator of Akt activation, resulting in HBx-mediated Akt activation 
and increased cell migration [362]. Studies in HBx-transfected HepG2 and Huh7 
cells have also suggested that HBx up-regulates the oncogenic miR-21, resulting 
in decreased PTEN expression and increased Akt activation [360]. In yet another 
finding, HBV-associated tumors and tumors from HBx-transgenic mice were 
shown to have increased levels of miR-224. This directly correlated with low 
levels of autophagy activation and low levels of the miR-224 target Smad4, which 
when inhibited results in increased tumorigenicity [368]. Together these results 
support a role for HBx-mediated regulation of miRNA expression in the overall 
regulation of the metabolic processes of the cell. Because HBx modulates the 
levels of Akt activation through altered miRNA expression, HBx might also 
control the level of mTOR activation and autophagy to optimize the cellular 
environment for HBV replication. 
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HBx-mediated regulation of miRNAs has also been suggested to play a 
role in altered DNA methylation. Two different groups demonstrated HBx 
regulation of DNA methylation through HBx down-regulation of miR-101 and 
miR-152. In one study, miR-152 was down-regulated in HepG2.2.15 cells and in 
HepG2 cells expressing HBx, and this correlated with an increased expression of 
the miR-152 target DNA methyltransferase 1 (DNMT1). Increased DNA 
methylation by DNMT1, including at sites epigenetically silenced in HBV-
associated HCC, was seen in cells treated with an inhibitor of miR-152 [403]. 
Similar results were observed with miR-101 and its target DNA methyltransferase 
3A; HBx-mediated down-regulation of miR-101 increased expression of DNMT3A 
and increased DNA methylation by DNMT3A [363]. Interestingly, additional 
evidence suggests that expression of both miR-122 [341] and miR-205 [404] may 
be regulated through HBx-mediated alteration of methylation of their transcription 
promoters. Taken together, these studies suggest that HBx can regulate 
expression of miRNAs to affect epigenetic modulation of gene expression.  
Figure 11. Model of potential HBx-mediated metabolic regulatory network. 
Potential regulatory network involving HBx-regulated miRNAs and their 
downstream targets. See text for abbreviations and description. 
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Effects of cellular miRNAs on HBV replication 
The role of cellular miRNAs during viral infections of mammalian 
cells has been a matter of debate. In general, miRNAs could act as a cellular 
anti-viral defense, as siRNAs do in plants and lower eukaryotes, or miRNAs 
could be exploited by the virus to help establish a cellular environment that 
promotes virus replication or persistence. In the preceding discussion, the impact 
of HBV replication and HBV proteins on miRNA expression was discussed; in the 
following sections, evidence indicating that cellular miRNAs can directly affect the 
outcome of an HBV infection will be discussed(Table 3).  
miR-122 
The high abundance and liver-specific expression of miR-122 has led 
many groups to investigate its effects on the replication of hepatotropic viruses. 
While miR-122 is a required factor for HCV replication (reviewed in [405]), the 
effects of miR-122 on HBV replication remain less clear. Multiple studies, 
including those using libraries of miRNA mimics or miRNA inhibitors to examine 
the impact of miRNAs on HBV replication, failed to identify miR-122 as a 
candidate regulator of HBV replication [324, 385, 406]. A growing body of 
evidence, however, suggests that there is a correlation between miR-122 levels 
and the presence of replicating HBV or the expression of HBV gene products. 
While many studies have examined alterations of miR-122 levels in the presence 
of replicating HBV (discussed above), others have found evidence for the down-
regulation of HBV gene expression by miR-122. The various mechanisms that 
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have been considered, including the direct targeting of HBV transcripts by miR-
122, and indirect effects where miR-122 can suppress cellular targets that affect 
HBV replication, are discussed below. 
One of the first studies to demonstrate miR-122-mediated effects on HBV 
gene regulation utilized Huh7 cells, which express moderate amounts of miR-
122, and HepG2 cells, which express very low levels of miR-122. After co-
transfection of Huh7 cells with a plasmid encoding the HBV genome and a miR-
122 inhibitor, HBsAg and HBeAg were increased compared to cells transfected 
with HBV and a control miRNA inhibitor, indicating a negative regulatory effect of 
miR-122 on HBV gene expression. Similarly, when miR-122 was over-expressed 
in HBV-transfected HepG2 cells, HBsAg and HBeAg levels significantly 
decreased [349]. In the same series of experiments, however, the over-
expression of miR-122 was shown to decrease levels of heme oxygenase-1 (HO-
1), and miR-122 inhibitors increased HO-1 levels. Consistent with the previously 
demonstrated role of HO-1 as a suppressor of HBV replication [407], over-
expression of HO-1 in HepG2 cells was sufficient to inhibit HBV protein 
production. Conversely, siRNA knockdown of HO-1 resulted in increased HBsAg 
and HBeAg, suggesting an indirect, but positive, regulatory effect of miR-122 on 
HBV replication. To explain these seemingly contradictory effects of miR-122 on 
HBV gene expression, a double regulatory mechanism was proposed in which 
miR-122 represses both HBV and HO-1, but the anti-HBV effects are dampened 
by the reduced ability of HO-1 to inhibit HBV replication [349]. 
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Another indirect mechanism of miR-122 regulation of HBV replication may 
be mediated through the activity of cyclin G1, a known target of miR-122 [334]. 
Cyclin G1 interacts with p53 [408], preventing p53 binding to HBV enhancer I and 
II elements, which normally suppresses HBV transcription, thus relieving 
repression of HBV transcription. A down-regulation of miR-122 in HBV-infected 
cells, then, would result in a feed-forward loop by allowing increased levels of 
cyclin G1 expression, increased sequestration of p53, and further increases in 
HBV transcription [342]. 
Additional studies support the conclusion that miR-122 can suppress the 
expression of HBV proteins or HBV replication [321, 323, 338-340]. For instance, 
it has been shown that HepG2.2.15 cells express lower levels of miR-122 than 
the already low levels found in HepG2 cells, and when miR-122 is over-
expressed in HepG2.2.15 cells, there is a decrease in the production of HBV 
proteins [338]. It should be noted, however, that while direct infection with HBV 
increased miR-122 levels in both HepG2 cells stably transfected to express the 
HBV receptor and in primary treeshrew hepatocytes, neither miR-122 over-
expression nor inhibition had any impact on HBV replication [171]. Although only 
a single study, the use of models of direct infection with HBV that more closely 
mimic an authentic HBV infection suggest that this study may more accurately 
reflect miR-122 effects on HBV replication and HBV protein expression during a 
natural HBV infection. 
Direct targeting of HBV RNAs by miR-122 has been explored as a 
mechanism of post-transcriptional repression, and potential binding sites have 
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been identified in conserved regions of the HBV genome (Fig. 10) [323, 339]. 
One potential miR-122 binding site was identified in the HBV pgRNA, just 
downstream of the core protein ORF and within the polymerase ORF. miR-122 
targeting of this site was investigated in studies with various HBV plasmids that 
included sequence variations at this site or in studies with miR-122 mimics 
carrying mutations designed either to prevent or restore miR-122 interactions 
with this site. HBsAg and HBeAg levels were reduced in HepG2 cells expressing 
HBV and co-transfected with a miR-122 mimic, but only when the HBV-
expression plasmid and miR-122 mimic carried either wild type HBV sequence or 
compensating mutations to allow complementary interactions [323]. These 
studies provide evidence that miR-122 regulates HBV replication through direct 
targeting of HBV transcripts. These studies also raise the interesting question, 
however, of why or how HBV, a very narrowly hepatotropic virus, has adapted to 
replicate in the same cells that express a potentially antiviral miRNA at unusually 
high levels. The authors propose that reduced viral replication mediated by miR-
122 promotes HBV persistence by preventing excessive cell damage or a strong 
immune response. It is also possible, however, that the miR-122 binding site in 
HBV RNAs is not available for targeting by miR-122 in infected cells, either due 
to binding of other proteins at that site or to secondary structure in the RNAs. 
Similar masking of potential miRNA binding sites has been demonstrated in HIV-
1 mRNAs [306, 409]. Additional experiments addressing these issues could help 
to explain how HBV tolerates the potentially anti-viral effects of miR-122. 
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miR-125 family 
A study in the PLC/PRF/5 cell line, which expresses HBsAg from 
integrated HBV DNA, demonstrated that miR-125a down-regulates expression of 
HBsAg through direct targeting of HBV RNAs [410]. Using a computational 
approach, seven potential miRNA target sites were identified within a conserved 
995bp sequence of the HBV polymerase and HBsAg ORFs. Assays using 
luciferase reporter constructs, in which the target site is cloned into the luciferase 
3' UTR, in a panel of human liver cancer cell lines confirmed targeting of one of 
these sites by miR-125a; this effect was lost when the predicted region 
complementary to the miR-125a seed sequence was mutated. Although the 
effects on HBV replication were not analyzed directly in this study, down-
regulation of HBsAg expression was observed when a miR-125 mimic was 
transfected into PLC/PRF/5 cells, whereas transfection of a miR-125a inhibitor 
into these cells increased HBsAg expression [410].  
Another recent study correlated the regulation of miR-125a-5p expression 
to the opposing effects on HBV replication that are observed following treatment 
of HBV-expressing cells with either iron or TGFβ [411]. HepG2.2.15 cells were 
treated with either iron, which significantly increased HBV replication, or TGFβ, 
which significantly decreased HBV replication, and the expression of 814 
miRNAs was measured by high-throughput sequencing. Two miRNAs showed 
opposing regulation under these treatment conditions: TGFβ increased miR-
125a-5p and miR-21 expression whereas iron decreased miR-125a-5p and miR-
21 expression. In these studies, transfection of a miR-125a-5p mimic abrogated 
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the iron-induced increase in HBV replication; however, inhibition of miR-125a-5p 
did not block the TGFβ-mediated decrease in HBV replication. When taken 
together with the results of the previously discussed study, these miR-125a-5p 
studies suggest a regulatory network in which miR-125a-5p decreases HBV 
replication through control of HBsAg translation. As with some other miRNAs that 
inhibit HBV replication, miR-125a-5p is paradoxically up-regulated in HBV-
expressing cells and HBV-infected patients [326, 327, 355]. In the studies that 
describe HBV-mediated up-regulation of antiviral miR-125a, this up-regulation 
was proposed to be a potential mechanism for HBV to regulate its own 
replication by controlling the levels of cellular miRNAs that inhibit the virus; 
additional studies are needed to validate this hypothesis. 
In addition to studies examining miR-125a, a study identified miR-125b as 
down-regulated in HBV-expressing cells and showed that miR-125b negatively 
regulates HBV replication. In this study, HepG2.2.15 cells over-expressing miR-
125b had decreased levels of HBV DNA and HBV proteins, and this effect was 
lost when the cells were transfected with a miR-125b inhibitor. This effect was 
proposed to be through regulation of the miR-125b target sodium channel, non-
voltage-gated 1 alpha (SCNN1A) [356]; however, further experiments will be 
needed to verify that this target is, in fact, playing a role in HBV regulation. 
 
miR-15 family 
The miR-15 family has also been shown to regulate HBV replication. In 
one study that described the ability of HBV transcripts to act as miR-15a and 
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miR-16-1 sponges, over-expression of miR-15a or miR-16-1 decreased HBV 
replication in HepG2 cells transfected with a plasmid containing the HBV genome 
and decreased HBx expression in cells transfected with an HBx-expressing 
plasmid [351]. While the mechanism(s) of miR-15a/16 regulation of replication 
was not directly examined, multiple miR-15a/16 targets were disrupted by the 
sponge effect of the HBV transcripts. Among these targets, Cyclin D1 has 
previously been shown to be up-regulated by HBx, and this up-regulation may be 
required for HBV replication in primary rat hepatocytes [30]. Consequently, 
regulation of members of the miR-15 family could influence HBx-mediated 
alteration of the cell cycle and regulation of HBV replication. 
Another study identified a complex regulatory cascade in which miR-15b 
may be playing a role in establishing HBV persistence. Expression of miR-15b 
was decreased in cell lines expressing HBx or stably expressing HBV, and 
ectopic expression of miR-15b in HepG2.2.15 cells increased HBV replication 
and increased production of viral antigens. In contrast, inhibition of miR-15b 
decreased HBV replication in HepG2.2.15 cells. Because HBV transcript levels 
were increased in the presence of over-expressed miR-15b, the authors 
reasoned that miR-15b was not likely directly targeting viral transcripts, unlike 
what had been shown for other members of this miRNA cluster [351, 352]. 
Instead, the authors hypothesized that miR-15b could be modulating activity at 
one of the viral transcription promoter or enhancer regions. After identifying the 
Enhancer I region as the regulatory region affected by miR-15b, the transcription 
factor HNF1α, which represses Enhancer I activity, was identified as a target of 
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miR-15b. Targeting of HNF1α by miR-15b resulted in increased viral replication, 
which ultimately created a negative feedback loop that decreased the levels of 
miR-15b [391]. While further studies are needed to determine how these findings 
relate to other studies that demonstrated that miR-15 family members inhibit HBV 
replication, together each of these studies supports the hypothesis that members 
of this miRNA family could be involved in regulation of HBV replication. 
miR-199a-3p 
In addition to studies describing HBV-mediated regulation of miR-199 
family members, there is evidence that these miRNAs may play a role in 
regulating HBV replication. For example, in experiments where a pool of 
antisense miRNAs was used to screen for inhibitors of HBV replication, both 
miR-199a-3p and miR-210 were shown to inhibit HBV replication in HepG2.2.15 
cells. This study used antisense oligonucleotides against 328 known human 
miRNAs to detect the loss of miRNA-dependent effects on HBV replication and 
surface antigen secretion. The predicted target sites of miR-199-3p and miR-210 
within surface antigen and the PreS1 coding sequences were cloned into a 
luciferase reporter vector to confirm functional targeting of the sites [385]. 
Interestingly, these sites are located in different transcripts across HBV 
genotypes, and the miR-210 target site is not completely conserved, which 
potentially alters the interpretation of these studies. The fact that miR-199a/b-3p 
is a highly abundant miRNA in the liver and is up-regulated in HBV-infected liver 
[290] suggests that miR-199a-3p could be effective in targeting and regulating 
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HBV during an infection. As with a number of other miRNAs reported to be 
inhibitory to HBV, the level of this anti-HBV miRNA was shown to be higher in 
HepG2.2.15 cells than HepG2 cells [385], potentially as a mechanism to control 
the level of viral replication.  
 
miR-17/92 cluster 
 Members of the miR-17-92 cluster of miRNAs have also been identified as 
regulators of HBV replication through direct targeting of viral transcripts. For 
example, inhibition of miR-20a and miR-92a-1, both members of the miR-17-92 
miRNA cluster, increased the levels of HBV RNAs. Predicted target sites for 
these miRNAs within the HBx and polymerase ORFs were identified 
computationally, and confirmed using a luciferase reporter construct in which 
~450bp of the HBV genome that included the predicted target sites was cloned 
downstream of the luciferase ORF [395]. Unfortunately, these studies were 
limited to this reporter assay and did not extend to analyses of mutated sites 
within the HBV genome nor did they introduce mutations into their reporter 
construct to attempt to inhibit targeting, so additional studies are needed to 
confirm this miRNA-mediated regulation of HBV. 
 
Other miRNAs 
While the most commonly studied miRNAs that have been proposed to 
regulate HBV replication are described above, additional miRNAs have been 
shown to regulate HBV replication. For example, the results of one study showed 
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that HBV-mediated up-regulation of miR-501 led to increased targeting of HBXIP, 
an inhibitor of HBV replication, resulting in increased HBV replication [325]. 
Increased levels of the miR-371/372/373 miRNA cluster, which was observed in 
HBV-associated HCCs and HepG2.2.15 cells, were also shown to increase HBV 
replication, and this occurred primarily through miR-372 and miR-373 targeting of 
nuclear factor I/B (NFIB), an inhibitor of HBV replication. Increased miR-372 and 
miR-373 levels increased HBV Enhancer I and core promoter activity, potentially 
through decreased NFIB-mediated transcriptional repression [326]. 
Libraries of miRNA mimics have been transfected into HBV-expressing 
cells to identify miRNA-dependent changes in the level of HBV replication. In one 
study in HepG2 cells, miR-141, miR-125a, and miR-125b were identified as 
negative regulators, and miR-98 as a positive regulator, of HBV replication. 
PPARα, a transcription factor required for HBV replication, was identified as a 
target of miR-141 [324]. Using a similar library of miRNA mimics in HepG2.2.15 
cells, another study identified miR-1, miR-146, and miR-214 as enhancing HBV 
replication and miR-210 as inhibiting HBV replication. miR-1 was further shown 
to enhance HBV replication by targeting histone deacetylase 4 (HDAC4), 
ultimately transactivating the HBV core promoter through enhanced farnesoid X 
receptor α(FXRA) expression [406]. There did not appear to be overlap between 
the identified miRNAs in these two studies, although a similar study utilizing a 
pool of antagomirs transfected into HepG2.2.15 cells did identify miR-210 as an 
inhibitor of HBV replication [385]. 
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Finally, a purely computational approach was used to predict six potential 
miRNA target sites within the HBV genome by compiling results from four 
commonly used target prediction algorithms. Using a previously published next-
generation sequencing dataset of miRNAs expressed in HBV-infected and 
normal liver samples, liver expression of the predicted miRNAs was examined. 
Four of the six predicted miRNAs were shown to be expressed in the liver in this 
sequencing dataset, but because no experimental data were presented to 
support the predicted target sites, it remains to be seen whether these predicted 
miRNA targets in the HBV genome are actually targeted [412]. Moreover, the 
expression levels of each of these miRNAs, as determined in the next-generation 
sequencing dataset described above, was extremely low, and well below the 
threshold value set by the original study [290]. This raises the question of 
whether these four miRNAs are expressed at high enough levels to have 
functional relevance for affecting HBV replication, and underscores the 
importance of considering the cellular context of miRNA expression when using 
computational approaches. 
 
HBV-mediated regulation of miRNA machinery 
 Recent studies have attempted to correlate HBV replication and protein 
expression with alterations in the cellular miRNA processing machinery. In 
HepG2 cells stably expressing HBV, the RISC protein Ago2 co-localized in 
multiple intracellular compartments with HBcAg and HBsAg, and this co-
localization seemed to occur specifically, as it was not seen between Ago2 and 
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HBx. Knockdown of Ago2 with siRNA decreased HBV DNA and HBsAg 
secretion, implying that Ago2 is important for HBV replication [350]. As is the 
case with some other viruses, it was proposed that HBV might utilize some of the 
non-silencing related functions of Ago2, such as its role in P-body formation 
[413]. This is an interesting hypothesis that warrants further study, as it could 
lead to a better understanding of cellular influences on HBV replication. These 
findings are, however, in direct contrast to studies that used siRNA knockdown of 
multiple components of the miRNA machinery, including Ago2, in HepG2 cells 
transfected with a plasmid expressing the HBV genome. In these studies, 
knockdown of the miRNA machinery increased HBV replication, implying an 
overall inhibitory role for miRNAs in HBV replication [351]. Further studies will be 
required to determine if either effect is relevant to a natural HBV infection.  
Two additional studies took a more direct approach and quantified the 
levels of miRNA machinery elements in HBV-expressing cells. In one study, 
levels of Drosha were significantly down-regulated in HepG2.2.15 cells compared 
to HepG2 cells, an effect that was proposed to be due to HBx-mediated 
regulation of SP1 and AP-2 transcription factors [414]. In another study, it was 
shown that HepG2.2.15 cells and HepG2 cells expressing HBV have lower levels 
of DGCR8 than HepG2 cells, potentially through HBV-mediated up-regulation of 
the transcription factor YY1. It was shown that YY1 inhibits DGCR8 promoter 
activity, and that HepG2.2.15 cells express higher levels of YY1 than HepG2 
cells. Although both of these studies showed a decrease in essential miRNA 
machinery components, no quantification of miRNA levels was conducted, and 
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further studies are needed to determine the impact of this regulation on the 
cellular miRNA profile.  
 
miRNAs and HBV-associated HCC 
Since HBV is the leading worldwide risk factor for developing HCC, many 
studies assessing the relationship between HBV and miRNAs have attempted to 
correlate the cellular impact of changes to the miRNA profile or specific miRNAs 
to tumorigenesis. There are also multiple studies describing the utility of serum or 
liver miRNA profiles as early detection markers for HCC. While the importance of 
miRNAs as they relate to HCC, particularly in the context of HBV-associated 
HCC is described below, more extensive reviews of miRNAs in HCC are found in 
[415, 416]  
There are many reasons for the high mortality rate of HCC, but foremost 
among these are the lack of early detection methods and effective treatments 
(reviewed in [417]). As with all cancers, HCC develops in an environment of 
cellular proliferation. In a normal liver only about 1 in 20,000 hepatocytes is 
undergoing mitosis at a given time, so the uncontrolled proliferation associated 
with HCC requires a signal that induces and maintains hepatocyte proliferation 
[217]. Many HBV-related miRNA studies have attempted to identify miRNA 
targets that are directly involved in increasing cellular proliferation. For example, 
in one study, decreased levels of miR-122 during HBV replication resulted in 
increased pituitary tumor-transforming gene 1 (PTTG1) binding factor (PBF) 
expression. This led to enhanced proliferation and invasiveness of HCC cells and 
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tumorigenicity in vivo through PBF-mediated activation of the PTTG1 
transcription factor. Importantly, decreased miR-122 and increased PBF were 
confirmed in liver samples from patients with chronic hepatitis or HBV-associated 
HCC [339]. Similar relationships have been seen with miR-29c and its target 
TNFAIP3 [354], miR-22 and its target CDKN1A [353], and miR-143 and its target 
FNDC3B [364]. While the majority of these studies demonstrate altered 
regulation of their respective miRNAs in HBV-associated HCC samples, what is 
often lacking in these studies is direct confirmation of inverse expression of the 
identified mRNA target in the HCC samples. Because of the lack of an effective 
model system for studying HBV and HBV-associated HCC, for most studies the 
mRNA target identification and validation was performed in cell lines, without a 
definitive ability to confirm that the target is regulated by the miRNA in the 
original cell or tissue samples. Because of the heterogeneity of tumors, and the 
use of already transformed cell lines for confirmatory studies, it is difficult to 
determine which factors are involved in HCC development and which are 
consequences of the systems being used. This could be contributing to the 
extensive number of factors being identified as HCC-related miRNA-target 
pathways.  
Profiling studies of miRNAs in HBV-associated HCC have mainly focused 
on identifying a distinct set of miRNAs that could be used for early detection or 
progression of disease. A study specifically designed to determine the 
effectiveness of using miRNAs as diagnostic markers utilized 454 sequencing 
and bioinformatics to show that using a panel of miRNAs was more effective at 
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predicting HCC recurrence after resection than single miRNAs, validating this 
profile-based approach [336]. Profiling studies have incorporated PCR-based 
arrays, microarrays, and next-generation sequencing to address the question of 
which miRNAs are consistently altered at various stages of HCC development. 
One example is the use of next-generation sequencing of small RNAs from 
normal liver samples, HBV-infected liver samples, HBV-associated HCC 
samples, HCV-infected liver samples, HCV-associated HCC samples, and non-
viral HCC samples to characterize miRNA expression in the various etiologies of 
HCC. From these studies, it was concluded that there is not a distinct influence of 
HBV or HCV on the miRNA profile compared to normal tissue. In HCC, however, 
there was a significant reduction of multiple miRNAs, regardless of HCC etiology. 
Only one, miR-199a/b-3p, was consistently altered, and its down-regulation 
correlated with decreased patient survival. Confirmation of the sequencing 
results by qRT-PCR showed that 40 out of 40 HBV-associated HCC samples had 
a significant decrease in miR-199a/b-3p while only 45% had decreased miR-122. 
Additional studies showed that miR-199a/b-3p has tumor-suppressor capability; 
increased expression of miR-199a/b-3p in cell lines or with adeno-associated 
virus (AAV)-mediated delivery in human HCC-bearing nude mice inhibited tumor 
growth and increased tumor necrosis [290].  
In another study, qRT-PCR was used to analyze expression of 188 
miRNAs in liver samples from normal liver, chronic HBV infected livers, chronic 
HCV-infected livers, HBV-associated HCC, and HCV-associated HCC. In 
contrast to the profiling study described above [290], each of these groups could 
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be segregated from its parent group based solely on a specific panel of miRNAs, 
indicating that miRNA expression profiles can differentiate between HBV and 
HCV, and between normal liver, chronically HBV- or HCV-infected livers, and 
HBV- or HCV-associated HCC. An investigation of the altered miRNAs and their 
putative targets suggested that pathways involved in apoptosis, DNA damage, 
recombination, and signal transduction were often affected in tumors from HBV-
infected patients, while pathways involved in the immune response, antigen 
presentation, cell cycle control, proteasome activity, and lipid metabolism were 
more often affected in tumors from HCV-infected patients. Interestingly, a strong 
correlation between changes in miRNA expression in HBV- and HCV-infected 
liver samples and corresponding studies done in HBV or HCV cell line models 
was also seen, supporting the use of cell lines as models for miRNA studies with 
these viruses [320]. 
Instead of directly comparing miRNA expression in HCC and normal 
tissue samples, another approach has been to examine miRNA expression 
through the multiple stages of HBV-associated HCC development. In one such 
study, qRT-PCR was used to examine a panel of seven miRNAs (miR-221, miR-
21, miR-224, miR-10b, miR-145, miR-199b, and miR-122) in dysplastic nodules, 
small HCCs, and normal liver tissue from HBV-infected patients. While there was 
altered expression of these miRNAs at various stages of HCC development, 
altered expression of miR-145, miR-199b, and miR-224 occurred in pre-
malignant dysplastic nodules and was maintained through the development of 
HBV-associated HCC. This study suggests that because of their consistently 
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altered expression from the early stages of HCC, miR-145, miR-199b, and miR-
224 might be useful as markers for the early detection of HBV-associated HCC 
[319].  
 The current methods for screening and diagnosis of HCC involve a 
combination of imaging techniques, serum assays, and histology [418, 419]. 
Many of these tests are either invasive, in the case of liver biopsy, or unreliable, 
in the case of serum proteins such as AFP [420]. Identification of an HCC-
associated serum miRNA profile could relieve the need for invasive procedures 
and offer a reliable and specific method of detection. It has previously been 
shown that miRNAs in the serum are stable and reproducibly detected, 
supporting their use as serum biomarkers [421]. A number of studies have 
characterized the serum miRNA profile in HBV-infected patients. A panel of 13 
miRNAs that differentiated HBV-infected and HBV-associated HCC samples from 
control and HCV samples was identified in one study that used Solexa 
sequencing followed by confirmation with qRT-PCR to analyze serum miRNAs of 
513 patients [422]. Another study examined the expression of 723 miRNAs 
followed by confirmation of specific miRNAs with qRT-PCR in 137 plasma 
samples; these data were used to generate a panel of 7 miRNAs that was able to 
reliably diagnose HCC (sensitivity 83.2%, specificity 93.9%), chronic HBV 
infection (sensitivity 79.1%, specificity 76.4%), and cirrhosis (sensitivity 75.0%, 
specificity 91.1%) in an independent cohort of 390 patients [322]. Although the 
development of HCC is a multi-stage process, and probably not caused by 
disruption of a single or a small handful of miRNAs, cumulatively, the results of 
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these studies suggest that the use of an miRNA profile for early detection of 
HCC, especially in the serum, could prove to be an important diagnostic tool. 
Moreover, the significant contribution of HBV infection to the worldwide burden of 
HCC makes understanding the role of miRNAs in the development of HBV-
associated HCC an important research goal. 
Study of functional miRNAs 
Studies involving changes in miRNA expression levels have taught us 
much about the cellular impact of miRNA-mediated targeting and the 
mechanisms associated with regulating miRNA expression, but direct studies of 
miRNA function have lagged behind. While initial studies of miRNA function and 
abundance relied on hybridization-dependent techniques such as northern blot, 
the development of PCR-based assays allowed the generation of more 
quantitative results for determining the expression level of precursor and mature 
miRNAs [423]. In addition, targeting assays were developed which allowed the 
confirmation of individual predicted mRNA targets, typically through the use of 
cloning a target sequence into a reporter construct [424]. The development of 
algorithms that predicted miRNA targets based on accepted guidelines, such as 
matches within the miRNA seed sequence and specific target site location within 
the mRNA, enhanced the prediction of miRNA-regulated mRNAs. Together these 
techniques have contributed the majority of results to a large body of research 
describing specific miRNAs and their functions as regulators of specific mRNA 
targets.  
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 Recently, significant leaps, specifically in the fields of next-generation 
sequencing (NGS) and bioinformatics, have increased the already large gap 
between the number of identified miRNAs and experimentally verified targets of 
these miRNAs. Multiple studies have used NGS to establish the miRNome, or 
profile of miRNA expression in a cell, of many different cell types and species. 
Where these, and previous studies had been lacking, however, is the parallel 
high-throughput identification and verification of mRNAs targeted by miRNAs. For 
example, NGS of miRNAs from the livers of hepatocellular carcinoma patients 
established expression levels for all of the miRNAs in these cells, but only a 
single target, the miR-199a/b-3p target PAK4, is identified and experimentally 
verified. This gap between identified miRNAs and verified targets is underscored 
by studies that have demonstrated that a single miRNA has the potential to 
regulate hundreds of mRNAs [288, 425]. 
 While many studies examine changes in miRNA expression levels and 
use this information to infer biological significance, it is well accepted that 
miRNAs act more as a fine-tuning mechanism than mediating on/off-type protein 
regulation [426-428]. Because of this, changes in the absolute expression levels 
of specific miRNAs may not be as important to normal cellular physiology as 
previously thought. This shift in thinking has been the result of advancing 
technology and a better understanding of what regulates both miRNA expression 
and function. For example, studies have shown that replicating cells have a 
distinctly different profile of miRNAs involved in active targeting than similar non-
replicating cells. Specifically, cells in vivo appear to maintain a pool of RISC-
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associated miRNAs that remain unbound to target mRNAs, while cell lines have 
a much larger pool of RISC-associated miRNAs bound to target mRNAs [429, 
430]. Additionally, multiple studies have shown that the expression level of a 
miRNA does not always directly correlate with the level of that miRNA in RISC 
[431]. And finally, it has become increasingly clear that in a given cell type, the 
majority of the miRNA pool is made up of only a handful of highly expressed 
miRNAs. For example, an analysis of the miRnome of the human liver showed 
that less than 10 miRNAs make up nearly 90% of all miRNAs in the cell [290]. 
While the liver is a unique case because of the extremely high expression (50-
70% of the total liver miRNAs [290, 291]) of a single miRNA, miR-122, similar 
top-heavy miRNA profiles have been shown for multiple cell types and tissues 
[292, 293]. This observation is important because additional studies have 
suggested that only the most abundant miRNAs in a cell actively play a role in 
miRNA-mediated targeting [432]. 
 As our overall understanding of these concepts has developed, so too has 
our ability to investigate miRNA function, specifically on a transcriptome-wide 
scale. These transcriptome-wide assays have greatly contributed to the way 
miRNA-mediated targeting is understood, by allowing the high-throughput 
identification of profiles of targets of miRNAs. The first of these types of assays 
utilized the well established technique of cross-linking RNA to RNA-binding 
proteins using UV light [433] followed by immunoprecipitation of RNA:protein 
complexes for downstream identification of targets of RNA-binding proteins. 
Since the original description of this protocol, called cross-linking and 
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immunoprecipitation (CLIP) [434], it has been used extensively coupled with 
downstream analyses such as microarray or RT-PCR of isolated RNAs. The 
technique was greatly enhanced with the downstream linkage to next-
generation/high-throughput sequencing. This new approach, HITS-CLIP, could 
identify entire profiles of targets on a transcriptome-wide scale with single base 
pair resolution and without prior knowledge of the target, enhancing the ability to 
identify RNA-binding targets and recognition sequences [435]. Application of this 
technique to the Argonaut (Ago) family of RNA-binding proteins allowed the 
identification of an entire profile of targets within the RISC complex, and therefore 
mRNAs which were actively being targeted by miRNAs [278] (Fig. 12).  
Soon after the development of this Ago HITS-CLIP method, which utilizes 
254nm UV light to non-specifically cross-link all RNAs to amino acids such as 
Phe, Trp, Tyr, Cys and Lys [436], an alternative CLIP-based protocol was 
reported [279]. In this protocol, called photoactivatable ribonucleotide-enhanced 
(PAR)-CLIP, a photoactivatable ribonucleotide, 4-thiouridine (4-SU), was 
incorporated into newly synthesized RNAs followed by exposure to 365nm UV 
light. This UV exposure specifically cross-links RNAs containing 4-SU, allowing 
these RNA:protein complexes to then be immunoprecipitated. An unexpected 
byproduct of this approach was the introduction of a 4-SU-dependent mutation (T 
-> C) in the resulting sequence, allowing the specific identification of cross-links, 
and supporting RNA:protein interaction with direct proof of physical interaction. 
Similar to HITS-CLIP, this approach was also applied to identification of miRNA 
targets through the immunoprecipitation of Ago2 [279] (Fig. 12). Since the 
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development of these techniques (reviewed in [437]), other, similar 
transcriptome-wide techniques have been developed which allow the 
investigation of miRNA function on a broad scale. These include cross-linking 
ligation and sequencing of hyrbids (CLASH) [275], and RISC-trap [277]. 
The main differences between the HITS-CLIP and PAR-CLIP protocols lie 
within the approach to crosslinking the RNA:protein complex. Two different 
approaches are used to cross-link the complexes, and understanding the 
difference between the two has become a key point in utilizing these protocols. 
Specifically, in the HITS-CLIP protocol cells are irradiated with 254nm UV light to 
achieve a non-specific crosslinking of all RNA molecules to any amino 
acids/proteins in the immediate vicinity. On the other hand, in the PAR-CLIP 
protocol cells are first treated with a photoactivatable ribonucleotide, typically 4-
SU, which will induce cross-links to proteins when exposed to 365nm UV light. 
Because of this difference, in the context of transient binding such as would be 
expected for miRNA-mediated targeting, these protocols actually address 
different questions. For the HITS-CLIP protocol, the identified target RNAs 
represent the entire pool of RNAs being targeted by a specific RNA binding 
protein. Because cross-linking with 365nm UV light requires a photoactivatable 
nucleotide to be incorporated into RNA, the PAR-CLIP protocol is more 
accurately addressing the pool of newly synthesized target RNAs. In some 
experimental contexts, these questions may lead to the same result; in other 
contexts, such as changes in the target profile in response to stimuli, these 
questions could have drastically different answers. Because of this it is important  
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Figure 12. Experimental flowchart of CLIP-based techniques. See text for 
descriptions and abbreviations. 
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to keep these distinctions in mind when applying these protocols and interpreting 
data.  
While multiple groups have begun to investigate the relationship between 
HBV and cellular miRNAs, the majority of these studies have investigated the 
impact of HBV replication on the expression of cellular miRNAs, without 
considering alterations in miRNA-mediated targeting independent of changes in 
the levels of miRNAs, or considering the expression level of the miRNA of 
interest in the context of the total miRNA content of the cell. While a growing 
body of evidence exists to suggest that HBV does, in fact, alter the expression of 
miRNAs, only limited data exists to support functional changes to miRNA-
mediated silencing in response to these expression changes. This information, 
however, is extremely important to understanding the role that miRNAs may be 
playing during HBV replication, as well as how altered miRNA expression may be 
contributing to HBV-associated pathogenesis. Because of the established role of 
HBV, and specifically HBx, in regulating multiple cellular pathways, it is likely that 
the virus does alter the expression of at least a subset of cellular miRNAs; 
however, until techniques that investigate the functional impact of these 
expression changes are applied to studies of HBV, the role of miRNAs in 
regulating HBV replication and HBV-associated disease will remain incompletely 
understood.  
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Chapter 4. Materials and Methods 
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Isolation and maintenance of cultured primary rat hepatocytes. Primary rat 
hepatocytes (PRHs) were isolated by a two-step perfusion protocol as previously 
described [438]. Briefly, PRHs were isolated from 5-7 week old male Sprague-
Dawley rats. Rat livers were perfused for 10 min with 1X Liver Perfusion Buffer 
(Life Technologies), a balanced salt solution to cleanse the liver and prevent 
clotting, followed by a 5 min perfusion with a collagenase buffer containing 0.5 
µM CaCl2 and 23 µg/ml Liberase Blendzyme (Roche). Both perfusions were 
performed at a flow rate of 30 ml/min. Following perfusion, the liver was removed 
and mechanical disruption was used to homogenize the liver. After filtration of 
cells though cheesecloth, hepatocytes were isolated by a series of centrifugation 
steps with two spins at 700 rpm for 2 min and 1 spin at 1100 rpm for 3 mins.  
For culture of PRHs, cells were maintained in William's E medium (Life 
Technologies) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 4 
µg/ml insulin, 2.2 µg/ml transferrin, 2.7 ng/ml selenium (0.4X ITS, Life 
Technologies), 5 µg/ml hydrocortisone, 5 ng/ml epidermal growth factor, 10 µg/ml 
gentamycin, and 2% dimethyl sulfoxide and maintained at 37°C in 5% CO2; 
medium was changed daily. Unless otherwise noted, cells were plated on tissue 
culture dishes coated with rat-tail collagen (150-200 µg/ml). For studies using 6 
cm tissue culture dishes, cells were seeded at a concentration of ~3.5 x 106 
cells/plate. For studies using 6-well tissue culture plates, cells were seeded at a 
concentration of ~1.5 x 106 cells/well. 
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Maintenance of cell lines. For studies using cell lines, all cells were maintained 
at 37°C in 5% CO2. Ad293 cells were maintained in 1X Dulbecco's modified 
Eagles medium supplemented with 10% FBS and 100 U/ml penicillin/100 µg/ml 
streptomycin. Huh7 cells were maintained in 1X Roswell Park Memorial Institute 
1640 medium supplemented with 10% FBS and 100 U/ml penicillin/100 µg/ml 
streptomycin.  
Recombinant adenovirus infections. The generation of the recombinant 
adenoviruses used in these studies has been described previously [89]. Briefly, 
recombinant adenoviruses encoding either hrGFP alone (AdGFP), hrGFP along 
with a greater-than-unit-length copy of the HBV genome (AdGFP-HBV or 
AdHBV), and hrGFP along with the HBx (AdGFP-HBx or AdHBx) were used for 
studies in PRHs. These viruses are unable to replicate in PRHs after infection, 
but the use of AdHBV is able to recapitulate all of the post-infection stages of the 
HBV life cycle.  Cells were infected in the minimum volume required to cover the 
cells, dependent on the culture plate (i.e. 150 µl in a 6 cm plate). Cells were 
incubated for 1 h 15 min at 37°C in 5% CO2 with rocking every 15 mins to 
maintain even coverage of cells by virus. Fresh medium was then added back to 
the cells, without removing infection medium. Medium was changed on infected 
cells daily after infection until collection.  
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RNA extraction, cDNA synthesis, and next-generation sequencing for RNA-
seq analysis. For the primary RNA-seq dataset, a single rat liver was used, and 
total RNA was isolated from triplicate samples of uninfected, AdGFP-HBV- or 
AdGFP-infected PRHs at indicated time points for a total of 24 samples. 
Uninfected PRHs at 0 hr were purified hepatocytes collected prior to plating. RNA 
was isolated from all samples following the total RNA protocol from the mirVana 
RNA isolation kit (Life Technologies). Total RNA was submitted to the Drexel 
University College of Medicine Center for Genomic Sciences (DUCOM CGS) for 
quality control, polyA selection, cDNA library preparation, and sequencing. The 
cDNA library was prepared using the TruSeq Stranded mRNA Prep Kit (Illumina), 
and was sequenced using the Illumina NextSeq 500 platform over two runs with 
75 cycle High Output kits (ver. 1). One uninfected 24 hr sample was lost during 
cDNA library creation, leaving a final total of 23 samples sequenced.  
For the secondary RNA-seq dataset, total RNA was isolated using the 
mirVana RNA isolation kit from triplicate samples of PRHs; these PRHs were 
isolated from a separate rat liver than was used to generate the primary dataset. 
The PRHs were infected with either AdGFP or AdGFP-HBV 24 hrs after plating. 
Total RNA was divided for use in downstream miRNA analyses (see below) or for 
quality control, polyA selection, cDNA library preparation, and the first round of 
sequencing by Genewiz, Inc (South Plainfield, NJ). cDNA library preparation was 
done using the NEBNext Ultra RNA Library Preparation Kit (New England 
Biolabs), and the first round of sequencing was done using the Illumina 
HiSeq2500 platform to generate 1 x 50 bp reads. The cDNA library was then 
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used for a second round of sequencing by the DUCOM CGS using the Illumina 
NextSeq 500 platform to generate an additional set of 1 x 75bp reads. Analysis of 
sample variation within the secondary dataset showed one sample, a GFP 48 hr 
replicate, was an outlier and was removed from subsequent analysis. 
Importantly, downstream analysis of differential gene expression showed very 
high overlap between differentially expressed genes in the two sequencing runs 
within this dataset. 
Quality of sequencing reads from all datasets was confirmed using 
FastQC (v0.11.2) [439]. 
Mapping of RNA-Seq reads. For read alignments, custom genome and 
transcript references were created to account for reads mapping to either cellular 
mRNAs or HBV, GFP, or pAdEasy (adenoviral vector) transcripts present in the 
samples. Two individual reference genomes/annotations were assembled 
containing either the Rn5 or Rn6 version of the rat genome. For reasons that will 
be discussed in more detail below, the majority of analysis was ultimately done 
using the Rn5 reference. To construct the Rn5 reference genome, the Rnor_5.0 
build of the Rattus norvegicus reference FASTA was downloaded from Ensembl. 
The genomic sequence of HBV serotype ayw (Accession X02496.1) and the 
pAdEasy1 sequence (Accession AY370909.2) were each downloaded from 
GenBank. The sequence of hrGFP was extracted from within the complete 
sequence for Shuttle vector phcAd.DYS-FL (Accession EU048698.1). These 
sequences were concatenated into a complete reference genome to be used for 
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read alignment. Similarly, gene set information for the Rnor_5.0 build of the rat 
genome was downloaded from Ensembl (5.0.78, updated 07-2014). Gene 
information for HBV serotype ayw, downloaded from GenBank, was used to 
create a custom gene annotation file with uniform formatting to match the Rn5 
gene set information. Both pAdEasy1 and hrGFP were treated as single features, 
and an appropriate gene annotation file was created for each. These four gene 
annotation files were concatenated to form a single reference gene annotation 
file for use in counting reads per transcript. Similarly, to construct the Rn6 version 
of the rat genome and gene annotation, the Rnor_6.0 build of the Rattus 
norvegicus genome and the Rnor_6.0 gene annotation (RefSeq Assembly 
Accession GCF_000001895.5) were downloaded from Ensembl and 
concatenated with the HBV, pAdEasy-1, and hrGFP sequences as described for 
Rn5. 
Multiple alignment algorithms were used to independently map all samples 
to the custom reference. Specifically, the Burrows-Wheeler Aligner mem 
algorithm (BWA, v0.7.10) [440], the STAR aligner (v2.4.0h) [441], and TopHat2 
(v2.0.13) [442] utilizing Bowtie2 (v2.2.4) [443] were each used for aligning reads 
to the reference genome. To align sequencing reads, individual, de-multiplexed 
sequencing run files were concatenated into a single FASTA file per sample. 
Additionally, the reference genome was indexed for each aligner using indexing 
scripts within each specific aligner. Using the indexed reference, reads were then 
aligned using options specific for each aligner. For BWA, reads were aligned 
using 14 threads and a minimum seed length of 20b, and SAM output was 
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immediately converted to BAM using the sambamba view tool. For STAR, a 
number of aligner specific options were used to indicate output as coordinate-
sorted BAM, the number of mismatches allowed relative to the read length, and 
input decompression format to use. Also, the STAR aligner was instructed to 
create an additional file of reads mapped to the transcriptome coordinates in 
addition to the alignment to genomic coordinates. For TopHat2, the aligner was 
supplied with an indexed reference genome and annotation, the prefix for output 
BAM files, and was run using 14 threads. Aligner options were as shown below: 
bwa mem -t 14 -k 20 RefGenome.fa.gz InputFile.fq.gz > Output.sam 
STAR --genomeDir RefGenomeDir --runThreadN 14 \ 
--quantMode  TranscriptomeSAM \ 
--outSAMtype BAM SortedByCoordinate \ 
--outFilterMismatchNoverLmax 0.05 --readFilesIn InputFile.fq.gz \ 
--readFilesCommand zcat --outFileNamePrefix OutputPrefix 
tophat -o OutputPrefix -p14 --transcriptome-index=TxRefPrefix \ 
RefGenomeDir InputFile.fq.gz 
Importantly, only uniquely mapping reads were retained by filtering with 
Sambamba (v0.5.0) [444] using a mapping quality of ≥1 for BWA, 255 for STAR, 
or 50 for TopHat. General mapping statistics were generated using the 
Sambamba flagstat tool or directly by the STAR aligner.  
Generating count tables. A series of Bioconductor packages for R (v3.1.2, 
"Pumpkin Helmet") [445] were used to create a table of counts for the number of 
reads mapping to each transcript in the reference gene set using the BWA or 
120 
	  
STAR mapped reads. Specifically, these packages were RSamtools (v1.18.2) 
[446], GenomicFeatures (v1.18.3), and GenomicAlignments (v1.2.1) [447]. 
  
 txdb <- makeTranscriptDbFromGFF(gtf_file, format ="gtf", \ 
  species = "Rattus norvegicus", miRBaseBuild = "RGSC3.4") 
  
 genes <- exonsBy(txdb, by ="gene") 
  
 se <- summarizeOverlaps(features = genes, reads = bamfiles, 
  mode = "Union", singleEnd = T, ignore.strand = T, fragments = F) 
 
The output of this workflow was a data table with counts per annotated feature 
per sample, suitable for direct use in the differential expression analysis. In 
addition, counts per feature were normalized using the reads per kilobase of 
transcript per megabase library size (RPKM) method [448] by dividing total 
counts aligned to each feature by the kilobase length of that feature and the total 
number of millions of reads in the sample. As independent confirmation of results 
of the BWA/STAR pipelines, the "Tuxedo" pipeline [449] was also utilized to 
determine differential gene expression. For this pipeline, TopHat-aligned reads 
were assembled into a set of expressed transcripts, and counts of these 
transcripts were determined using Cufflinks (v2.2.1) as described below. 
 
Differential Gene Expression Analysis. While independent differential gene 
expression analyses were tested, the majority of differential gene expression 
analysis was done using the DESeq2 (v1.6.3) [450] package in R. This involved 
using DESeq2 to shrink the data to remove bias introduced by outlying samples. 
Then, individual contrasts (e.g. HBV_24 vs. GFP_24, Uninfect_0 vs. 
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Uninfect_24) were conducted within the DESeq2-generated object on raw counts 
normalized by the median ratio method [451]. To produce the DESeq2-generated 
normalized count object, the following tools were used: 
dds <- DESeqDataSet(se, design = ~ condition) 
dds <- estimateSizeFactors(dds) 
DES <- DESeq(dds) 
To facilitate individual comparisons, a function was defined to do sample 
comparisons within the global DESeq2-generated object. This function utilizes 
the DES object, along with sample definition, input of gene names, and average 
RPKM values to generate a final output data table with statistical analysis for all 
genes within the given comparison. Differential gene analysis was also 
determined using the edgeR (v3.8.5) [452] package in R. For both DESeq2 and 
edgeR analyses, significant differential gene expression was determined using 
an FDR adjusted p-value of 0.05 (adjusted with the Benjamini-Hochberg
adjustment [78]). Venn diagrams were generated using the Venny tool [453]. 
Additional data visualization was done using R, including the ggplot2 (v1.0.0) 
[454] package within R. To follow general convention, and to give an estimated 
idea of expression levels, plotting was done using RPKM values; however, 
statistical significance was generated using the median ratio normalized values 
within DESeq2. Further, analysis functions were defined to assemble all 
analyzed data across all comparisons for a given gene name or Ensembl ID for 
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ease of data interpretation, as well as graphing functions which similarly utilized 
the full dataset to graph expression levels for specified genes or Ensembl IDs. 
 For the Tuxedo pipeline, differential gene analysis was performed using 
the Cuffdiff package. Each assembled transcript file, along with the reference 
transcriptome, was merged to a single annotation file using the Cuffmerge 
package. DEG were then determined using Cuffdiff by supplying the treatment 
groupings (Uninfect_0, Uninfect_24, Uninfect_48, Uninfect_72, GFP_24, 
HBV_24, GFP_48, HBV_48), custom reference genome, the transcript 
quantifications from Cufflinks, and the merged annotation file (Cuffmerge output). 
Significant differential expression was determined with a q-value of 0.05, and 
Cuffdiff output was visualized using the CummeRbund package (v2.8.2) for R. 
 
 cuffmerge -o OutputPrefix -g TxRef -s RefGenomeDir -p 14 assemblies.txt 
 
 cuffdiff -p 14 -o OutputPrefix -b RefGenome.fa \ 
  -L Group1,Group2,...GroupN CuffmergeOutput.gtf \ 
  ./Group1Rep1,./Group1Rep2,..../Group1RepN \ 
  ./Group2Rep1,./Group2Rep2,..../Group2RepN \ 
  ./GroupNRep1,./GroupNRep2,..../GroupNRepN 
 
 For all analysis pipelines, transcript lengths and gene names for 
corresponding Ensembl IDs were retrieved from the biomart database using the 
biomaRt package [455] in R. To get gene names the database was accessed as 
follows: 
  
  
 
 
123 
genes <- rownames(DES) 
mart <- useMart(biomart = "ensembl", dataset = 
"rnorvegicus_gene_ensembl") 
marts <- getBM(attributes = c("ensembl_gene_id", 
"external_gene_name"), filter = "ensembl_gene_id", 
values = genes, mart = mart) 
Similarly, to construct a data frame of transcript lengths, the following code was 
used: 
attributes <- c("ensembl_gene_id","transcript_length") 
cDNA <- getBM(mart = mart, attributes = attributes, filters = 
"ensembl_gene_id", values = genes) 
cDNA <- cDNA[order(cDNA[,1]),] 
cDNA <- subset(cDNA, !duplicated(cDNA[,1])) 
HBV and Adenovirus Genome Coverage. Coverage per base of both the HBV 
genome and the pAdEasy-1 sequence was determined using bedtools coverage 
(v2.22.0) [456]. To do this, the bedtools coverage tool was supplied with the 
sorted BAM files and a bed file containing the annotation information for the HBV 
or pAdEasy-1 feature. The parameters for bedtools coverage are shown below: 
bedtools coverage -d -ibam InputFile.bam \ 
-g FeatureAnnot.bed > Output.txt 
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Output files were then combined, and reads per base were normalized to the 
total number of reads in the sample. Normalized reads per base were then 
averaged among samples to generate the average reads at each base across 
the genome. 
For the purposes of plotting HBV, the bases of the HBV genome were 
reordered relative to the polyA signal, so that 10 bases after the last base of the 
polyA signal became base 3182, and the 11th base after the polyA signal was 
used as base 1. It has previously been reported that the HBV transcripts continue 
for 10bp after the polyA signal [457]. Normalized average reads per base were 
plotted across the reordered sequence.  
In addition, relative coverage across the HBV genome was determined 
using bedtools coverage to quantitate total reads mapping to sliding bins across 
the entire HBV genome. For this quantification a bed file was created containing 
172b bins with 86b overlap. Parameters for quantifying reads per bin are below: 
bedtools coverage -s -abam InputFile.bam -b Bins.bed > Output.txt 
These same steps were taken to quantitate genome-mapping reads for the 
pAdEasy sequence. Normalized average reads per base were plotted across the 
pAdEasy-1 sequence and relative coverage was determined by counting genes 
in 5000bp bins in 2500bp increments, with a final 2 bins containing only the 
bases up to the final base of the sequence. 
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Pathway Analysis and Gene Ontology. Two tools were used for pathway 
enrichment and gene ontology analysis. Pathway analysis on specific gene 
subsets, such as within time point comparisons, was done using the Biomart 
online enrichment tool (www.biomart.org) [458]. Additional pathway analysis 
involving full datasets was carried out using the iPathwayGuide online tool 
(Advaita Bio, http://www.advaitabio.com/ipathwayguide). Briefly, differential 
expression analysis results from DESeq2 were uploaded to the iPathwayGuide 
tool. The uploaded data contained differential expression analysis results for 
each comparison, across all genes. A fold change of 1.5 and an adjusted p-value 
of 0.05, both derived from uploaded DESeq2 output, were used as cut-offs for 
significant differences in expression. Pathways were considered significantly 
altered by an Impact Analysis, a combination of over-representation analysis and 
pathway perturbation [459, 460]. For over-representation analysis, the number of 
altered genes associated with a pathway was compared between treatment and 
control groups. To determine pathway perturbation, the significance of a 
particular gene to a pathway was considered in determining the overall impact on 
the pathway by examining all annotated functions/interactions of the gene.  
Metabolomic Profiling. To establish HBV-mediated changes to primary 
hepatocyte metabolite profiles, PRHs were infected with AdGFP, AdGFP-HBV, or 
AdGFP-HBx 24 hr after plating. Quadruplicate samples were generated for each 
treatment type, and the experiment was duplicated from an independent rat liver, 
for a total of 8 samples per treatment type. Cells were collected 48 hr after 
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plating (24 hr after infection) or 72 hr after plating (48 hr after infection). Frozen 
cells were sent to Metabolon, Inc. (Durham, NC) for processing, QC, and 
metabolomic profiling. Briefly, proteins were precipitated with methanol under 
vigorous shaking, and the resulting samples were divided into aliquots for 
analysis by Ultrahigh Performance Liquid Chromatography-Tandem Mass 
Spectroscopy (UPLC-MS/MS) with positive ion mode electrospray ionization, 
analysis by UPLC-MS/MS with negative ion mode electrospray ionization, 
analysis by UPLC-MS/MS polar platform (negative ionization), and analysis by 
Gas Chromatography-Mass Spectroscopy (GC-MS). Data analysis, including raw 
data extraction, subsequent peak identification, metabolite profiling 
(quantification and normalization), and statistical analyses of differential 
expression, were completed by Metabolon. Significant differences were 
determined by ANOVA with a p-value ≤ 0.05. 
 
Liver miRNA qPCR array. Expression of a panel of liver-enriched miRNAs was 
determined using the Liver miFinder miRNA qPCR array platform (Qiagen). For 
each sample, 1 µg total RNA (described above for secondary dataset), was 
reverse transcribed using the miScript RT II kit following the manufacturer's 
protocol (Qiagen). cDNA quality was assured using the miScript miRNA QC 
qPCR array plate (Qiagen) before proceeding to miRNA expression analysis, 
which measures expression of a panel of 84 liver-enriched miRNAs. For qPCR 
arrays, each cDNA sample was applied to a single 96-well plate, and qPCR was 
carried out according to the manufacturer's protocol using a Bio-rad CFX96 
127 
thermocycler. Cycling conditions were 95°C for 10 min, followed by 40 cycles of 
94°C for 15 sec, 55°C for 30 sec, and 70°C for 30 sec with a 1°C/sec ramp 
speed. Data analysis and differential expression were determined using the 
miScript miRNA PCR array data analysis tool (Qiagen, 
http://pcrdataanalysis.sabiosciences.com/mirna/arrayanalysis.php). 
Crosslinking and Immunoprecipitation (CLIP)-based Protocols. The work 
involving the CLIP protocols centered on protocol optimization, and as such each 
step will be described in more detail in the Results section. Steps of the protocol 
were optimized individually, but a generalized, complete protocol is described 
here and represents adaptation of multiple CLIP protocols, including [278, 279, 
461, 462] (Fig. 12). 
Ultraviolet irradiation. For ultraviolet (UV) irradiation of cells, ~1 x 107 cells 
or ~2-3 x 107 cells were plated in 10 cm or 15 cm tissue culture plates, 
respectively. For PRH experiments, plates were coated with 150-200 µg 
rat-tail collagen and 3-4 15 cm plates were typically used. Prior to UV 
treatment, cells were washed once on ice with cold 1X phosphate buffered 
saline (PBS) containing protease inhibitors (EDTA-free complete protease 
inhibitor cocktail, Roche). PBS was removed and the uncovered tissue 
culture dish was placed on ice in a UV cross-linker, approximately 3 in 
from light source. For 254 nm UV light, a UVP CL1000 cross-linker was 
used for 3 x 400 mJ/cm2 treatments. For 365 nm UV exposure, a 
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Stratalinker 2400 was used for 3 x 150 mJ/cm2 treatments. Cells were 
then collected in cold 1X PBS with protease inhibitors, and pelleted at 
1500 rpm and 4°C for 5 mins. Cell pellets were flash frozen and stored at -
80°C for later use. 
Making Antibody-coated Beads. Immunoprecipitation was done using 
antibody-coated Protein G Dynabeads (Life Technologies) to analyze Ago 
expression or Ago:RNA complexes. 100 µl beads per sample were first 
washed 3 times with antibody coating buffer (0.1 M sodium phosphate pH 
8.0, 0.1% NP-40, 5% glycerol). Total beads were then resuspended in 3-
4x initial bead volume in antibody coating buffer with a pan-Ago antibody 
(Clone 2A8, Millipore). ~5 µg was used for every 400 µl of beads. Beads 
were incubated overnight at 4°C on a rocker. After incubation, beads were 
washed one time with antibody binding buffer and 2 times with freshly 
made 1X PMPG (1X PBS, 2% Empigen). Beads were stored in 500 µl 1X 
PMPG at 4°C until use.  
Immunoprecipitation of Ago:RNA complexes. For the immunoprecipitation, 
pelleted cells were resuspended in 3 cell pellet volumes of 1X PMPG with 
1 U/µl rRNAsIn (Promega) and incubated on ice for 10 mins. The samples 
were then treated with 10U RQ1 DNase (Promega) and incubated at 37° 
for 10mins in a thermomixer at 1200 rpm. 1 U/µl RNase T1 was added 
and incubated at 37°C for 10mins in a thermomixer at 1200 rpm. Cell 
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lysate was then cleared in a pre-chilled TLA45 rotor by spinning at 44,000 
rpm (90,000 x g) for 45 min. Cleared lysates were then incubated with 50 
µl uncoated Protein G beads on a rocker at 4°C for 1 hr. The antibody-
coated beads were then divided evenly into the appropriate number of 
aliquots and the supernatant was removed. Cleared lysate was then 
removed from the uncoated beads and antibody-coated beads were 
resuspended in the appropriate lysate sample. The samples were 
incubated on a rocker at 4°C for at least 3 hr to overnight, followed by 
removal of the supernatant, which was saved for analysis of 
immunoprecipitation efficiency. Finally, the beads were washed twice with 
1X PMPG and twice with 5X PMPG (5X PBS, 2% Empigen).  
Western blotting. Western blotting was done to visualize Ago expression 
and confirm immunoprecipitation of Ago. Western blotting was done using 
standard techniques using the clone 2A8 pan-Ago antibody (Millipore), 
anti-Ago2 (Santa Cruz Biotechnology), or anti-β-actin (Sigma). 
Radiolabel Ago:RNA complexes. To visualize immunoprecipitated 
complexes, RNA was end-labeled with 32P. First, the RNA, still bound to 
the antibody-coated beads, was washed once with dephosphorylation 
buffer (50mM Tris pH 8.0, 100mM NaCl, 10mM MgCl2). The beads were 
then resuspended in 100µl dephosphorylation buffer supplemented with 
1mM DTT and 0.5U/µl calf intestinal phosphatase and incubated in a 
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thermomixer shaking at 1200rpm and 37° for 10mins. The beads were 
then washed two times with dephosphorylation wash buffer (50mM Tris 
pH 7.5, 20mM EGTA, 0.5% NP-40) and two times with PNK buffer (50mM 
Tris pH 7.5, 50mM NaCl, 10mM MgCl2). To label RNA, the beads were 
resuspended in 100µl PNK buffer supplemented with 5mM DTT, 25µCi γ-
32P ATP, and 0.5U/µl T4 polynucleotide kinase (New England Biolabs), 
and incubated for 30mins at 37° in a thermomixer at 1200rpm. 1µl of 
10mM unlabeled ATP was added and incubation was continued for an 
additional 5 mins. To remove excess 32P the beads were then washed 5 
times with PNK buffer. 
Visualization of radiolabeled complexes. After labeling RNA, the beads 
were resuspended in 50µl 2X Laemli sample buffer (4% SDS, 20% 
glycerol, 120mM Tris pH 6.8) and denatured for 10min at 100°. 
Supernatant was then loaded on a 10% Bis-Tris NuPAGE gel and run at 
130mA constant amperage at 4° in 1X MOPS running buffer (Life 
Technologies). Samples were then electrotransferred to nitrocellulose 
membrane in 1X NuPAGE transfer buffer (Life Technologies) at 35mA and 
4° overnight. Nitrocellulose membrane was then visualized by exposure to 
X-ray film with phosphorescent rulers to orient bands and determine 
correct band size. Unbound Ago is ~95kD, with Ago bound to RNA 
fragments generating a smear upwards with a concentrated band between 
~110-130kD. 
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Isolation of Immunoprecipitated RNA. To isolate RNA, radioactive bands 
at the expected size were excised from the nitrocellulose and treated with 
200µl of 4mg/ml proteinase K (Roche) for 20min at 37° in a thermomixer 
at 1200rpm. 200µl of 1X PK buffer/7M Urea (100mM Tris pH 7.5, 50mM 
NaCl, 10mM EDTA with 0.42g Urea per ml) was added and incubation 
was continued for an additional 20mins. RNA was extracted by adding 
400µl 25:24:1 acid phenol:chloroform:isoamyl alcohol and continued 
incubation for an additional 20mins. Samples were then spun at 
16,000rpm at room temperature for 10mins. The aqueous layer was 
transferred to a new tube and RNA was precipitated with 50µl 3M sodium 
acetate, 1ml 100% ethanol, and 3.75µg glycogen at -20° overnight. 
3H-Uridine Uptake and Incorporation. Approxiamately 24 hr after plating of 
PRHs, cells were incubated with medium containing 50µCi 3H-uridine. 
Culture medium and total RNA, isolated using TRIzol according to the 
manufacturer's instructions (Life Technologies), were collected 
immediately after adding (0 hr), or at 1 hr, 2 hr, 4 hr, and 24 hr. 
Radioactivity was measured using a scintillation counter and values were 
normalized to total volume of medium collected or total amount of RNA. 
TBE/7M Urea gel. Isolated RNA size was analyzed by urea gel 
electrophoresis. Isolated radio-labeled RNA samples were run on a 12% 
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TBE/7M Urea gel at 100V in 1X TBE running buffer. Radio-labeled 10bp 
Decade RNA marker (Life Technologies) was used according to the 
manufacturer's instructions. 
Data Accession. RNA sequencing data from both datasets was deposited in the 
Gene Expression Omnibus and is available as a GEO SuperSeries using 
accession number GSE68113. 
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Chapter 5. Results: Transcriptome-wide analysis of HBV-mediated changes 
in gene expression 
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Adenovirus infection of cultured primary rat hepatocytes 
Because of the narrow host range of HBV, PRHs cannot be directly 
infected with HBV. Most systems that mimic a natural infection, including cultured 
primary human hepatocytes, have proven to be limited by low efficiency of 
infection or sample to sample variability [165, 183, 463, 464]. Alternatively, 
recombinant adenovirus can be used as a surrogate vehicle for the delivery of 
the HBV genome, allowing studies of steps of the HBV life cycle post-entry, 
including replication and viral protein expression [82, 89, 465]. Contrary to 
infection with purified HBV, using recombinant adenovirus allows a very high 
infection efficiency of cultured primary hepatocytes. Similarly, cultured PRHs 
have served as an effective model for studying the cellular effects of the post-
infection stages of the HBV life cycle, and effects seen in PRHs correlate well 
with HBV-mediated effects seen in cultured primary human hepatocytes [82, 
167]. Using recombinant adenovirus expressing a greater than unit length copy 
of the HBV genome, we routinely achieve a high infection efficiency (>75%) in 
cultured PRHs and have previously identified HBV-mediated cellular changes 
and the presence of HBV replication as early as 24 hr post-infection [29].  
For the transcriptome studies described here, uninfected PRHs were 
collected before plating (0 hr), and at 24 hr, 48 hr, and 72 hr after plating. In 
addition, PRHs were infected at 24 hr after plating with either an adenoviral 
vector expressing hrGFP alone (AdGFP), or expressing hrGFP and a greater 
than unit length copy of the HBV genome (AdHBV). Infected PRHs were 
collected at 48 hr (24 hr after infection) and 72 hr (48 hr after infection) (Fig. 
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13A). Infection of PRHs with either AdGFP or AdHBV resulted in an ~85% 
infection efficiency, as determined by GFP expression (Fig. 13B). In addition, 
HBV replication was measured by Southern blot for HBV core particle associated 
DNA. While HBV replication intermediates were clearly visible at 72 hr after 
plating (48 hr after infection) in AdHBV infected cells (Fig. 13C, upper panel), a 
low level of replication at 48 hr (24 hr after infection) was also visible when the 
film was exposed for a longer time (Fig. 13C, bottom panel), confirming the 
presence of replicating HBV in our system. Together with previously published 
reports [29, 30, 82], these results support the use of PRHs infected with HBV-
expressing adenovirus as a model for studying the cellular impact of HBV 
replication.  
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Figure 13. Confirmation of experimental system for primary RNA-seq 
dataset. A. Experimental setup for primary dataset. B. PRHs were infected with 
either AdGFP or AdHBV and infection efficiency was determined by monitoring 
GFP expression at 48 hr and 72 hr (24 hr and 48 hr post-infection). C. HBV 
replication was monitored by Southern blot analysis of HBV core particle-
associated DNA. Blot was exposed for 1 day (upper panel) or 7 days (lower 
panel) to allow visualization of HBV replication at both 48 hr and 72 hr.
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Analysis of RNA-seq Data 
A simplified workflow of the complete RNA-seq analysis is shown in Fig. 
14. While multiple tools were used for independent cross-validation at each step,
the analysis reported here was done with a pipeline consisting of: STAR aligner > 
Sambamba filter for unique reads > GenomicAlignments (within R) > DESeq2 
(within R) > iPathwayGuide.  This pipeline was selected form the others 
described (see Materials and Methods) for multiple reasons.  The STAR aligner, 
which is optimized for use with RNA-seq data, consistently outperformed the 
BWA aligner, particularly when comparing speed, while allowing control of 
aspects such as length of overhangs for matching across intronic regions, etc. 
The use of DESeq2 over edgeR for statistical analysis of differential expression 
was due to a combination of significant annotation and support of the DESeq2 
package as well as the potential to control additional aspects of the analysis 
including time course studies.  Finally, each of these tools was chosen over the 
"Tuxedo package" for multiple reasonse.  First, despite the popularity of this 
package for RNA-seq analysis, the package has little annotation and 
documentation outside of the manual, making analysis and troubleshooting 
difficult to control and optimize.  Also, while it is presented as a tool to look at 
gene expression from RNA-seq data, this package is really more appropriate for 
question specifically addressing alternative transcript expression, which was not 
the question we were asking in our analysis.  For these reasons we chose the 
pipeline that we felt best allowed us to answer the questions of differential gene 
expression in our system. 
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Figure 14. Work-flow for RNA-seq analysis pipelines. Diagram of multiple 
pipelines used for RNA-seq analyses.  
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Table 4. Overview of RNA-sequencing for primary dataset. 
Sample Total Reads Mapped 
% 
Mapped 
Uniquely 
Mapped 
% Unique 
Mapped 
% 
Unmapped 
Multi-
mapping 
Reads 
% 
Multiple 
Mapping 
Total Mappings 
of Reads 
Uninf 0 hr 1 37.03 34.24 92.48% 30.89 83.43% 7.52% 3.35 9.05% 40.53 
Uninf 0 hr 2 37.66 35.55 94.38% 32.21 85.52% 5.62% 3.34 8.86% 41.55 
Uninf 0 hr 3 36.43 33.95 93.20% 30.71 84.31% 6.80% 3.24 8.89% 39.74 
Uninf 24 hr 1 34.64 31.94 92.22% 28.02 80.90% 7.78% 3.92 11.31% 39.40 
Uninf 24 hr 2 45.74 43.03 94.07% 37.84 82.73% 5.93% 5.19 11.34% 53.01 
Uninf 48 hr 1 39.69 37.03 93.29% 32.58 82.08% 6.71% 4.45 11.21% 45.66 
Uninf 48 hr 2 40.57 36.70 90.46% 32.40 79.87% 9.54% 4.30 10.59% 45.10 
Uninf 48 hr 3 43.95 41.01 93.32% 35.82 81.51% 6.68% 5.19 11.81% 52.14 
AdHBV 48 hr 1 44.40 41.78 94.08% 36.85 82.99% 5.92% 4.93 11.09% 51.16 
AdHBV 48 hr 2 44.44 41.21 92.73% 36.42 81.96% 7.27% 4.79 10.77% 50.24 
AdHBV 48 hr 3 41.48 38.16 91.99% 33.68 81.19% 8.01% 4.48 10.80% 46.89 
AdGFP 48 hr 1 45.56 42.86 94.08% 37.80 82.97% 5.92% 5.06 11.12% 52.36 
AdGFP 48 hr 2 46.73 43.77 93.67% 38.65 82.72% 6.33% 5.12 10.95% 53.19 
AdGFP 48 hr 3 44.49 41.53 93.35% 36.60 82.27% 6.65% 4.93 11.08% 50.75 
Uninf 72 hr 1 44.59 40.28 90.33% 35.55 79.73% 9.67% 4.73 10.60% 50.92 
Uninf 72 hr 2 36.99 34.23 92.55% 30.53 82.55% 7.45% 3.70 10.00% 41.36 
Uninf 72 hr 3 40.47 38.08 94.10% 34.07 84.18% 5.90% 4.02 9.92% 45.30 
AdHBV 72 hr 1 36.58 33.72 92.17% 30.09 82.24% 7.83% 3.63 9.93% 40.48 
AdHBV 72 hr 2 40.48 36.99 91.38% 33.08 81.71% 8.62% 3.91 9.67% 44.23 
AdHBV 72 hr 3 40.09 37.41 93.31% 33.45 83.44% 6.69% 3.96 9.87% 44.64 
AdGFP 72 hr 1 42.45 39.69 93.50% 35.47 83.55% 6.50% 4.23 9.95% 47.52 
AdGFP 72 hr 2 39.18 36.44 93.00% 32.55 83.08% 7.00% 3.89 9.92% 43.52 
AdGFP 72 hr 3 37.67 33.60 89.20% 29.66 78.74% 10.80% 3.94 10.45% 42.21 
*Values represent millions of reads
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Sequencing of the primary dataset resulted in ~35-47 million reads per 
sample, for a total of ~950 million reads across 23 samples (Table 4). 
Importantly, all samples had between 89% and 95% of total reads mapping, with 
a high percentage of uniquely mapping reads (~80-86%). Investigation of the 
Euclidean distance, or overall transcriptome similarity, between all samples 
showed that time point was the principal variable, with samples grouped by 
replicate and treatment within each time point (Fig. 15A). Overall, a total of 
20,700 transcripts (78% of features in the gene annotation) were identified in the 
RNA-seq analysis as having at least one read aligned, and 12,343 genes had at 
least 1 aligned read in all samples. After normalization of the data by calculating 
reads per kilobase of transcript per megabase library size (RPKM), 8,033 genes 
had an RPKM value of at least 1 in each sample. The mean RPKM value across 
all samples was 16.23, and the mean RPKM was 49.42 for genes with an RPKM 
≥1. Additionally, the distribution of average RPKM per transcript was uniform 
between the eight sample groups (Fig. 15B). These results indicate a strong 
degree of coverage, a general uniformity in transcriptome composition, and a 
lack of global shifts in transcript levels across samples. Therefore, it is unlikely 
that any differences seen in subsequent analysis are the result of sequencing or 
sample bias, and are instead the result of time point or treatment-mediated 
effects. 
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Figure 15. Primary RNA-seq dataset overview. A. Euclidean sample distance 
was mapped allowing unbiased ordering of samples based on sample similarity. 
B. Plot of distribution of average RPKM values per sample. 
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HBV-mapping reads 
HBV has a unique and highly compact genomic organization that results in 
every base being used within at least one open reading frame. As part of this 
compact organization, all of the viral transcripts share the same polyadenylation 
(polyA) signal, creating a series of overlapping transcripts with each longer 
transcript a 5' sequence extension of each of the shorter transcripts [466]. For 
example, as the shortest transcript, the transcript encoding the HBV X protein 
(HBx) is also included in the 3' end of all other HBV transcripts. It would be 
expected, therefore, that since multiple transcripts contain the HBx sequence, a 
higher number of reads in this RNA-seq analysis should be generated from the 
HBx region of the HBV genome than from other regions of the genome. Similarly, 
we expect to see an incremental decrease in coverage as we move away from 
the polyA signal toward the 5' end of the transcripts, and as the number of viral 
transcripts incorporating each base decreases.  
To test this, we reordered the HBV genomic sequence such that the 
TATAAA polyA signal plus 10bp [457] were situated at the 3' end of the 
sequence, and we lined up the transcripts with each aligned by the 3' end to 
show the overlapping nature of the transcripts (Fig. 16A). We then plotted depth 
per base across the HBV sequence and identified a distinct pattern of expression 
that was reproduced in AdHBV-infected PRHs at both time points (48 hr and 72 
hr) in both the primary (Fig. 16B) and secondary datasets (data not shown, 
secondary dataset described below). To account for variation in coverage due to 
sequencing bias, the genome (organized as described above) was broken 
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Figure 16. Mapping HBV-derived reads. A. HBV transcripts were aligned 
based on the location of the shared polyA signal plus an additional 10 bases. 
Genomic transcripts are greater than genome length, with the terminally 
redundant portion apparent as overlap within the same transcript. B. Average 
reads per base (normalized to library size) from AdHBV 48 hr and 72 hr samples 
were plotted along the HBV genome/transcripts. C. The HBV genome was 
broken down into 172 base sliding bins with 50% overlap between bins. Average 
number of reads per bin for AdHBV infected PRHs at 48 hr and 72 hr were 
plotted. 
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down into overlapping bins (172bp bins with 86bp overlap), and total reads were 
counted within each bin (Fig. 16C). Apart from a slightly higher level of coverage 
at the beginning of the sequence, an obvious pattern of increased base usage 
was seen from 5' to 3' approaching the polyA signal, as expected. It is possible 
that higher coverage at the beginning of the sequence could be due to variable 
lengths of the transcripts after the polyA signal which would wrap around to the 
earlier bases on the figure; however, additional studies would be needed to 
address this hypothesis. While these results do not allow us to determine the 
kinetics of expression for the individual HBV transcripts, they do support the 
overall hypothesis of overlapping transcripts with bases closer to the polyA signal 
being transcribed in more transcripts. 
Adenovirus-mapping reads 
Because we used recombinant adenovirus as the delivery vehicle for the 
HBV genome, we investigated the potential expression of adenoviral genes in 
our system. Although reads that mapped to the pAdEasy-1 sequence were 
detected in all infected samples, plotting reads per base across the genome 
showed nearly all reads clustered within a very small part of the viral genome 
(Fig. 17A). When breaking down the genome into overlapping bins (5000bp bins 
with 2500bp overlap), an average of 95% of all mapping reads aligned to a 
region that makes up less than 1.5% of the total pAdEasy-1 sequence (Fig. 17B-
C). This ~420bp region is adjacent to the multiple cloning site of the pAdEasy-1 
plasmid, and therefore is immediately downstream of inserted DNA for both
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Figure 17. Mapping adenovirus-derived reads. A. Average reads per base 
(normalized to library size) from AdHBV 48 hr (light grey), AdHBV 72 hr (dark 
grey), AdGFP 48 hr (green), and AdGFP 72 hr (red) was plotted along the 
sequence of the pAdEasy-1 vector. B. The pAdEasy-1 sequence was broken 
down into 5kb sliding bins with 50% overlap between bins. Average number of 
reads per bin (for both the + and - strand) were plotted for 48 hr samples. C. 
Reads per bin were plotted for 72 hr samples as in B. 
Figure'4'
48hrs'
72hrs'
A'
B'
C'
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constructs (GFP and HBV). The sequence correlating to the mapped reads 
encompasses the coding region for adenovirus protein IX (pIX), which is a minor 
adenoviral capsid protein that may play a role in packaging of the adenovirus 
genome [467]. Previous studies have shown that the use of the CMV promoter to 
drive expression of genes inserted into pAdEasy-1 can also cause expression of 
pIX, and at a higher level than other promoters tested in the pAdEasy-1 vector 
[468]. This correlates well with our findings, as AdHBV infected cells have higher 
levels of pIX transcript compared to AdGFP infected cells, and expression of HBx 
has been previously shown to activate the CMV promoter [469]. Our data 
suggests that pIX is the only adenoviral transcript that is expressed with any 
abundance, supporting the use of this system as a mechanism for the delivery of 
exogenous DNA with minimal adenoviral transcript expression. 
Differential expression analysis 
We next examined differential gene expression across our dataset. For 
differential expression analysis, all samples were analyzed together within 
DESeq2, followed by individual comparisons within the uninfected cells (e.g. 
Uninfected 0 hr vs Uninfected 24 hr) and within the infected cells (e.g. AdGFP 48 
hr vs AdHBV 48 hr). In addition, differentially expressed genes (DEG), defined as 
genes with an adjusted p-value after multiple testing correction of < 0.05, in each 
comparison were also intersected with DEG from each other comparison to 
determine the number of genes that are differentially expressed in both groups 
(Table 5, upper half of chart). A 2-fold threshold was also sometimes used to 
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emphasize biological significance, and number of overlapping DEG with ≥ 2-fold 
change in both comparisons was also calculated (Table 5, bottom half of chart). 
For infection comparisons, AdGFP was treated as the control to negate any 
potential adenovirus-mediated effects. 
Culture-dependent Expression Changes 
We first analyzed differential gene expression by investigating which 
genes had the highest variance from the mean expression value across all 
samples, i.e. those with the highest Z-scores, or most standard deviations away 
from the mean. Within the top 100 genes with the highest Z-scores, the majority 
exhibited time-dependent changes in gene expression. This is clearly seen by 
the clustering of samples by time point, with treatment-type clustering within each 
time point set (Fig. 18A). 
Pairwise comparisons of different time points in the uninfected cells 
support the observation of time as the principal variable in the dataset (Table 5, 
rows 1-6). Within the first 24 hr after plating the PRHs, there were 10,245 DEG, 
and this trend continued upwards as time progressed resulting in 11,323 DEG 
between isolation of PRHs at 0 hr and 72 hr after plating. In fact, the shift 
between 0 hr and 24 hr was large enough that the inclusion of the 0 hr samples 
in the analysis of expression variation distorted the clustering of samples to the 
point that all non-0 hr time points looked nearly identical by comparison (Fig. 
18B). Since the 0 hr time point samples were collected immediately after
Table 5. Differentially expressed genes within and between each comparison. 
Row	   Comparison	   DE	  genes	  
Genes	  with	  ≥	  
2	  Fold	  Change	  
Comparison	  Intersection	  
U0	  to	  
U24	  
U0	  to	  
U48	  
U0	  to	  
U72	  
U24	  
to	  
U48	  
U24	  
to	  
U72	  
U48	  
to	  
U72	  
G48	  
to	  
H48	  
G72	  
to	  
H72	  
G48	  
to	  
G72	  
H48	  
to	  
H72	  
G48	  
to	  
H72	  
H48	  
to	  
G72	  
1	   Uninf	  0hr	  to	  Uninf	  24hr	   10245	   5846	   8764	   8662	   7196	   7470	   5078	   2749	   4071	   5202	   5543	   5914	   5731	  
2	   Uninf	  0hr	  to	  Uninf	  48hr	   11056	   6740	   4602	   9957	   7907	   8137	   5589	   2980	   4364	   5714	   6117	   6471	   6289	  
3	   Uninf	  0hr	  to	  Uninf	  72hr	   11323	   6862	   4377	   5771	   7891	   8401	   5734	   2934	   4399	   5874	   6263	   6605	   6418	  
4	   Uninf	  24hr	  to	  Uninf	  48hr	   9431	   3284	   1801	   2482	   2407	   7993	   4956	   2660	   3815	   5079	   5482	   5759	   5582	  
5	   Uninf	  24hr	  to	  Uninf	  72hr	   10188	   4177	   2106	   2692	   3020	   2556	   5445	   2663	   4051	   5616	   5885	   6100	   6146	  
6	   Uninf	  48hr	  to	  Uninf	  72hr	   6698	   1586	   793	   1110	   1150	   916	   1181	   2157	   3034	   5488	   4800	   4764	   5396	  
7	   GFP	  48hr	  to	  HBV	  48hr	   3323	   115	   60	   84	   90	   71	   73	   44	   2064	   2205	   2341	   2580	   2534	  
8	   GFP	  72hr	  to	  HBV	  72hr	   5070	   512	   256	   333	   371	   256	   325	   175	   56	   3065	   3320	   3732	   3460	  
9	   GFP	  48hr	  to	  GFP	  72hr	   6973	   1814	   841	   1172	   1239	   1001	   1272	   1268	   77	   215	   5289	   5316	   5705	  
10	   HBV	  48hr	  to	  HBV	  72hr	   7447	   1899	   876	   1239	   1244	   1009	   1173	   1054	   54	   215	   1246	   6135	   5460	  
11	   GFP	  48hr	  to	  HBV	  72hr	   7910	   2007	   947	   1262	   1305	   1007	   1184	   1006	   56	   261	   1274	   1458	   5152	  
12	   HBV	  48hr	  to	  GFP	  72hr	   7713	   2132	   996	   1391	   1418	   1149	   1446	   1286	   65	   242	   1493	   1393	   1143	  
*Top half of table (Orange) represents DEG in common between the two comparisons listed
*Bottom half of table (Green) represents DEG in common and with ≥ 2-fold change in each comparison 148 
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Figure 18. Most variable genes across all hepatocyte samples. A. The top 
100 most variable genes across all samples were visualized by heatmap. Gene 
expression variation was calculated by Z-score, with red indicating an increase in 
expression compared to the mean across all samples, and blue indicating a 
decrease in expression. Uninfected 0 hr samples were removed from the 
analysis to prevent a heavy bias due to the large changes within the first 24 hr. 
B. The top 100 most variable genes across all samples visualized by heatmap as 
in A but including Uninfected 0 hr samples. 
A. 
B. 
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Figure 19. Differential gene expression in uninfected hepatocytes. Gene 
expression changes between cultured and unplated PRHs were plotted as the 
log10 RPKM value for genes in Uninfected 0 hr samples versus the log2 fold 
change compared to Uninfected 0 hr for genes in the indicated comparison. 
Yellow diamonds indicate DEG that were only differentially expressed in the first 
24 hr, red squares represent DEG at 24 hr and 48 hr but not 72 hr, and blue 
circles represent DEG at 24 hr, 48 hr, and 72 hr. 
C. 
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hepatocyte purification without spending any time in culture, a number of these 
changes are likely the result of cellular adaptation to the culture environment. 
Two observations support this. The first is that, overall, the number of DEG is 
going down with each 24 hr comparison (i.e. 0 hr to 24 hr, 24 hr to 48 hr, and 48 
hr to 72 hr). Second, the percentage of DEG with ≥ 2-fold change steadily 
decreased in each time comparison after the 0 hr to 24 hr comparison (Table 5). 
Although a large number of genes were differentially expressed as a result 
of isolation and plating, when examining the three potential 48 hr to 72 hr 
comparisons, ~65% of DEG in the uninfected PRHs in this time comparison are 
also differentially expressed in this time comparison in both AdGFP and AdHBV-
infected PRHs. This similarity across treatment types indicates that a specific 
subset of genes is altered in a time-dependent fashion, regardless of treatment 
type, and despite minimal morphological changes observed over the time-course 
of the experiment. However, it is important to note that while 55% of all genes 
were DEG from 0 hr to 72 hr, most DEG in this analysis had low levels of 
expression or small fold changes (Fig. 19). Only 58% of DEG from 0 hr to 72 hr 
had an RPKM value ≥ 1 in all samples and only 24% had an RPKM ≥ 1 and a 
fold change ≥ 2. Similarly, 61% of the DEG that are in common between all three 
48 hr to 72 hr comparisons have an RPKM value ≥ 1, but only 2% have an 
RPKM value ≥ 1 and a fold change ≥ 2. For the 48 hr to 72 hr comparison in 
particular, these cutoffs alter the interpretation of DEG, as a pathway analysis of 
the full set of common DEG identified ion binding and intracellular signaling as 
pathways associated with the these DEG, but a pathway analysis of only the 
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DEG with an RPKM value ≥ 1 and a fold change ≥ 2 identified multiple cell cycle 
and DNA replication pathways. Overall, this highlights the importance of 
considering differential expression analyses in the context of the biological 
significance of the changes identified, especially when these include genes 
expressed at very low levels.  
By analyzing differential gene expression over the time course of our 
experiment, we established a baseline understanding of what is happening to 
cultured PRHs after isolation from the liver. Based on the large number of DEG, 
the process of culturing and maintaining the PRHs is a significant variable in the 
use of this model, and therefore these changes are important to address, 
although, as described above, the biological relevance of changes to minimally 
expressed genes must also be part of this consideration. For example, pathway 
analysis of DEG in uninfected time-based comparisons identified multiple 
metabolic processes, as well as pathways associated with focal adhesions as 
being significantly altered under these conditions. On the other hand, while the 
number of DEG seems high between the 0 hr and later time points, these 
changes are not completely reflective of the overall transcriptome. For example, 
analyzing the correlation between the total expression profiles of 0 hr and 24 hr 
uninfected PRHs showed a very high correlation (r2 = 0.87). A relatively high 
correlation (r2 = 0.65) is even maintained between 0 hr and 72 hr uninfected 
PRHs, despite 55% of the genes being identified as differentially expressed 
between these samples. Similar correlations were previously seen when 
comparing cultured hepatocytes to in vivo liver samples, and is in stark contrast 
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to the correlation between hepatocyte cell lines and in vivo liver samples (r2 = 
0.1) [470], supporting the use of the PRHs model as a biologically relevant 
system. However, similar to acknowledging that cell lines express a 
transcriptome that is significantly different than a normal hepatocyte, it is 
important to consider that cultured PRHs are also changing due to experimental 
conditions, regardless of treatment. 
 
HBV-mediated Expression Changes 
 Although the largest sets of DEG were seen when comparing time points, 
HBV had a distinct effect on gene expression (Table 5, rows 7 & 8). For example, 
3,323 genes were DE when comparing expression between 48 hr AdHBV-
infected PRHs and 48 hr AdGFP-infected PRHs. Of these, only 115 had a ≥ 2-
fold change, including several cell cycle regulators previously linked to HBV-
mediated changes in hepatocyte physiology. These include CDK2, CDK1, 
CCNE1 (Cyclin E1), and CCNE2 (Cyclin E2) [30, 227, 471, 472] (and reviewed in 
[101]). When comparing expression at 72 hr, there were 5,070 DEG between 
AdGFP-infected cells and AdHBV-infected cells, and only 512 of these had ≥ 2-
fold change (Table 5). In particular, 25 members of the solute carrier (SLC) family 
of transmembrane proteins had an HBV-mediated ≥ 2-fold change at 72 hr, 
including up-regulation of Glut1 (SLC2A1), and down-regulation of Glut2 
(SLC2A2). Glut2 is the primary transporter of glucose between the blood and the 
liver, and has previously been reported to be down-regulated by HBV [244].  
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Of the total HBV-mediated changes, 2,064 genes were DE at both 48 hr 
and 72 hr, including CDK1 and two of the SLC genes (SLCO5A1, SLC29A). 56 of 
these genes had a ≥ 2-fold change at both time points (Table 5, row 8), including 
down-regulation of Wnt11, which has been associated with development of HCC 
[473], and up-regulation of G0s2, which was originally described as a regulator of 
early stages of the cell cycle, but is now well established as being involved in the 
regulation of lipolysis and activation of apoptosis [474-476] (and reviewed in 
[477]). To further isolate changes in gene expression that are specifically 
mediated by HBV, genes that were also differentially expressed in corresponding 
time-mediated comparisons (AdGFP 48 hr to 72 hr, AdHBV 48 hr to 72 hr) were 
removed, resulting in 408 genes that are differentially expressed at both 48 hr 
and 72 hr solely due to the expression of HBV (Fig. 20A [yellow and blue 
overlap], C-D [red squares]). This subset of genes, described as the "HBV-
specific" subset, is listed with expression level and fold change values in Table 6.  
Table 6. "HBV-specific" subset of differentially expressed genes. 
RPKM	   Fold	  Change	  
Gene	   Ensembl	  ID	   Uninf	  0hr	  
Uninf	  
24hr	  
Uninf	  
48hr	  
Uninf	  
72hr	  
HBV	  
48hr	  
HBV	  
72hr	  
GFP	  
48hr	  
GFP	  
72hr	  
HBV	  to	  
GFP	  48h	  
HBV	  to	  
GFP	  72h	  
Clec4m	   ENSRNOG00000001017	   0.0	   0.3	   0.8	   0.5	   2.3	   2.8	   1.0	   0.6	   2.34	   4.41	  
Fam107a	   ENSRNOG00000033261	   0.0	   0.0	   0.3	   0.3	   0.1	   0.1	   0.2	   0.2	   -­‐2.02	   -­‐2.99	  
Itgb8	   ENSRNOG00000006569	   0.0	   0.0	   1.0	   1.0	   0.3	   0.3	   0.6	   0.8	   -­‐1.85	   -­‐2.83	  
Fut1	   ENSRNOG00000020995	   0.0	   0.4	   0.2	   0.2	   0.6	   0.8	   0.2	   0.3	   2.79	   2.71	  
Serpina5	   ENSRNOG00000009855	   0.5	   0.2	   0.3	   0.5	   0.2	   0.1	   0.3	   0.4	   -­‐1.71	   -­‐2.61	  
Lurap1	   ENSRNOG00000023459	   0.3	   0.7	   1.2	   1.1	   0.5	   0.4	   0.9	   1.0	   -­‐1.73	   -­‐2.47	  
Galnt12	   ENSRNOG00000008099	   0.0	   0.4	   1.8	   2.8	   1.3	   1.1	   2.0	   2.5	   -­‐1.56	   -­‐2.28	  
B3gnt9	   ENSRNOG00000015172	   0.0	   0.4	   0.5	   0.8	   1.2	   1.0	   0.7	   0.5	   1.68	   2.17	  
Il5ra	   ENSRNOG00000005954	   0.0	   0.2	   0.8	   0.4	   2.0	   1.6	   1.1	   0.8	   1.75	   2.09	  
42253.00	   ENSRNOG00000043182	   0.0	   0.2	   2.6	   3.3	   1.6	   1.4	   2.5	   2.9	   -­‐1.59	   -­‐2.06	  
Lilra5	   ENSRNOG00000027808	   0.1	   0.1	   2.6	   1.5	   0.7	   0.6	   1.6	   1.2	   -­‐2.32	   -­‐2.03	  
Krt20	   ENSRNOG00000027139	   0.0	   0.2	   0.3	   0.5	   0.3	   0.2	   0.5	   0.5	   -­‐1.96	   -­‐2.00	  
Eps8	   ENSRNOG00000007047	   0.0	   0.2	   0.4	   0.2	   0.7	   0.6	   0.4	   0.3	   1.55	   1.99	  
Zfp354b	   ENSRNOG00000029678	   0.3	   1.2	   1.2	   0.8	   2.0	   2.3	   1.5	   1.2	   1.35	   1.91	  
Btc	   ENSRNOG00000002728	   0.1	   9.2	   15.4	   19.6	   9.9	   8.6	   15.4	   16.5	   -­‐1.57	   -­‐1.91	  
Ccdc23	   ENSRNOG00000007404	   1.4	   8.4	   7.0	   9.7	   4.9	   4.1	   6.4	   7.9	   -­‐1.33	   -­‐1.90	  
LOC100125368	   ENSRNOG00000043289	   1.0	   0.8	   0.7	   0.5	   1.5	   1.7	   0.9	   0.9	   1.65	   1.88	  
Rdh5	   ENSRNOG00000040155	   13.3	   6.3	   2.2	   1.1	   2.8	   3.0	   2.0	   1.6	   1.39	   1.88	  
Stxbp5l	   ENSRNOG00000002496	   0.4	   0.5	   0.3	   0.2	   0.5	   0.5	   0.3	   0.3	   1.60	   1.87	  
Cav1	   ENSRNOG00000006694	   0.1	   15.6	   122.1	   133.5	   59.1	   53.3	   99.4	   100.0	   -­‐1.71	   -­‐1.86	  
Mafb	   ENSRNOG00000016037	   12.3	   0.6	   1.0	   0.8	   0.6	   0.5	   0.9	   1.0	   -­‐1.59	   -­‐1.84	  
Sytl4	   ENSRNOG00000003526	   0.7	   0.9	   1.4	   1.2	   0.9	   0.7	   1.4	   1.2	   -­‐1.48	   -­‐1.79	  
Cd274	   ENSRNOG00000016112	   1.3	   0.2	   0.5	   0.5	   1.5	   1.6	   0.6	   0.9	   2.44	   1.77	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Tspan17	   ENSRNOG00000018122	   0.0	   5.8	   14.7	   18.6	   9.7	   8.3	   14.6	   14.7	   -­‐1.52	   -­‐1.75	  
Slc1a3	   ENSRNOG00000016163	   0.1	   0.2	   0.5	   0.5	   0.3	   0.3	   0.4	   0.5	   -­‐1.65	   -­‐1.73	  
Slc16a6	   ENSRNOG00000000245	   0.9	   2.4	   2.4	   2.2	   5.2	   5.2	   3.1	   3.1	   1.64	   1.70	  
Gatsl2	   ENSRNOG00000001484	   0.3	   0.4	   0.7	   0.8	   0.5	   0.5	   0.7	   0.8	   -­‐1.62	   -­‐1.70	  
Ccnjl	   ENSRNOG00000003893	   0.0	   0.0	   0.4	   0.6	   0.2	   0.2	   0.3	   0.4	   -­‐1.66	   -­‐1.68	  
Hspa4l	   ENSRNOG00000010819	   1.6	   2.3	   3.2	   2.8	   4.5	   5.0	   3.2	   3.0	   1.41	   1.65	  
Pomgnt2	   ENSRNOG00000019492	   0.9	   1.9	   2.1	   2.1	   1.4	   1.0	   2.0	   1.7	   -­‐1.48	   -­‐1.64	  
Mir568	   ENSRNOG00000036329	   4.7	   22.4	   21.0	   24.5	   15.1	   11.6	   21.4	   19.2	   -­‐1.43	   -­‐1.63	  
AABR06018038.2	   ENSRNOG00000028120	   0.0	   0.3	   0.2	   0.2	   0.5	   0.4	   0.2	   0.3	   1.78	   1.63	  
Slc36a4	   ENSRNOG00000011455	   0.1	   0.7	   1.9	   1.8	   1.3	   1.2	   1.8	   1.9	   -­‐1.41	   -­‐1.60	  
Lin52	   ENSRNOG00000043441	   2.5	   2.4	   3.3	   2.7	   4.6	   4.5	   3.0	   2.8	   1.49	   1.59	  
Mtfr1	   ENSRNOG00000021359	   6.4	   6.1	   8.4	   8.0	   12.4	   13.7	   9.0	   8.7	   1.35	   1.59	  
Chst14	   ENSRNOG00000045997	   0.1	   1.1	   2.7	   3.8	   2.0	   1.9	   2.6	   3.0	   -­‐1.34	   -­‐1.58	  
Mybl1	   ENSRNOG00000021669	   0.5	   2.7	   3.1	   3.2	   6.3	   5.7	   4.1	   3.6	   1.51	   1.58	  
Ccdc38	   ENSRNOG00000021892	   1.4	   1.2	   1.1	   1.0	   0.7	   0.6	   1.1	   0.9	   -­‐1.52	   -­‐1.57	  
RGD1564541	   ENSRNOG00000012564	   1.8	   5.1	   4.5	   4.8	   3.0	   3.0	   4.4	   4.8	   -­‐1.49	   -­‐1.56	  
Zfp358	   ENSRNOG00000000974	   1.3	   6.3	   10.7	   13.0	   7.4	   7.2	   10.7	   11.4	   -­‐1.45	   -­‐1.56	  
Cflar	   ENSRNOG00000012473	   5.6	   3.0	   6.9	   6.7	   10.5	   12.3	   7.9	   8.0	   1.31	   1.56	  
Hes6	   ENSRNOG00000020194	   48.0	   16.1	   19.7	   21.9	   13.9	   12.5	   18.2	   19.6	   -­‐1.33	   -­‐1.55	  
Snx21	   ENSRNOG00000015181	   6.2	   6.0	   6.7	   7.0	   4.5	   3.9	   5.9	   6.0	   -­‐1.33	   -­‐1.53	  
Tceal1	   ENSRNOG00000002387	   0.3	   2.9	   5.5	   7.2	   3.8	   3.7	   4.9	   5.7	   -­‐1.32	   -­‐1.52	  
Gjb3	   ENSRNOG00000014372	   0.0	   5.2	   8.5	   8.3	   14.4	   14.9	   9.9	   9.8	   1.43	   1.52	  
Tgfbr1	   ENSRNOG00000007036	   2.6	   3.7	   6.5	   8.5	   5.7	   5.2	   7.5	   8.0	   -­‐1.33	   -­‐1.52	  
Hdac8	   ENSRNOG00000003122	   1.9	   2.9	   4.4	   5.5	   3.6	   3.2	   4.3	   4.9	   -­‐1.20	   -­‐1.52	  
Gdpd1	   ENSRNOG00000005596	   4.3	   5.4	   12.1	   12.7	   8.2	   7.5	   11.1	   11.5	   -­‐1.37	   -­‐1.52	  
Ntpcr	   ENSRNOG00000019922	   14.8	   12.8	   9.0	   11.5	   7.2	   6.5	   8.6	   9.9	   -­‐1.21	   -­‐1.52	  
Nop58	   ENSRNOG00000016486	   4.3	   38.5	   29.5	   27.5	   54.7	   52.2	   37.4	   34.8	   1.44	   1.51	  
AABR06068818.1	   ENSRNOG00000027116	   0.2	   21.7	   9.4	   9.1	   6.6	   5.3	   9.5	   8.1	   -­‐1.47	   -­‐1.51	  
RGD1309821	   ENSRNOG00000023208	   4.8	   2.6	   3.3	   4.7	   2.5	   2.4	   3.3	   3.7	   -­‐1.37	   -­‐1.51	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Nuak2	   ENSRNOG00000000034	   5.0	   4.0	   13.3	   15.5	   8.1	   8.0	   11.6	   12.1	   -­‐1.46	   -­‐1.50	  
Tmsb4x	   ENSRNOG00000047931	   142.1	   1067.6	   3756.3	   3975.1	   2633.7	   2232.9	   3256.0	   3390.1	   -­‐1.25	   -­‐1.50	  
Sec31b	   ENSRNOG00000025781	   0.3	   0.7	   0.6	   0.7	   0.3	   0.4	   0.5	   0.5	   -­‐1.63	   -­‐1.50	  
Iqcb1	   ENSRNOG00000038868	   0.8	   1.5	   2.7	   2.9	   1.9	   1.7	   2.5	   2.6	   -­‐1.33	   -­‐1.50	  
Gmeb1	   ENSRNOG00000010910	   0.7	   2.5	   3.4	   3.3	   5.1	   5.3	   4.2	   3.6	   1.20	   1.49	  
Lrrc16b	   ENSRNOG00000025518	   0.0	   0.5	   0.6	   0.7	   0.4	   0.3	   0.6	   0.5	   -­‐1.46	   -­‐1.49	  
Pak1ip1	   ENSRNOG00000023799	   1.4	   11.5	   7.5	   6.6	   12.1	   12.5	   8.5	   8.5	   1.40	   1.48	  
Sh3bgr	   ENSRNOG00000028238	   0.0	   2.0	   14.3	   16.2	   8.1	   9.3	   11.9	   14.0	   -­‐1.49	   -­‐1.48	  
Ppp2r3b	   ENSRNOG00000049270	   0.5	   2.3	   3.4	   3.6	   6.0	   6.1	   3.9	   4.2	   1.52	   1.48	  
Abhd14b	   ENSRNOG00000012073	   113.5	   47.9	   16.1	   22.3	   13.3	   11.8	   16.9	   17.6	   -­‐1.29	   -­‐1.48	  
Actn2	   ENSRNOG00000017833	   0.3	   1.0	   0.4	   0.4	   0.6	   0.6	   0.4	   0.4	   1.62	   1.48	  
LOC691909	   ENSRNOG00000028771	   0.3	   1.9	   2.4	   3.3	   1.7	   1.7	   2.2	   2.5	   -­‐1.30	   -­‐1.48	  
LOC100363915	   ENSRNOG00000013520	   2.2	   28.7	   28.2	   22.9	   55.4	   51.1	   34.4	   34.9	   1.59	   1.48	  
Arl6ip5	   ENSRNOG00000006818	   12.2	   114.4	   110.1	   127.0	   81.1	   77.0	   106.0	   114.6	   -­‐1.33	   -­‐1.47	  
Marcksl1	   ENSRNOG00000009113	   0.0	   0.4	   3.5	   4.4	   2.5	   2.5	   3.7	   3.8	   -­‐1.50	   -­‐1.47	  
Neil1	   ENSRNOG00000018577	   2.6	   4.9	   4.5	   5.6	   3.1	   3.2	   4.2	   4.7	   -­‐1.39	   -­‐1.46	  
Larp1b	   ENSRNOG00000038366	   16.5	   16.8	   14.8	   13.9	   10.4	   9.8	   14.4	   14.3	   -­‐1.40	   -­‐1.45	  
Sdad1	   ENSRNOG00000022229	   0.8	   9.2	   6.0	   5.5	   9.2	   9.2	   7.1	   6.4	   1.28	   1.44	  
Nap1l3	   ENSRNOG00000029087	   0.2	   1.8	   1.8	   1.9	   1.2	   1.1	   1.7	   1.6	   -­‐1.46	   -­‐1.44	  
Srms	   ENSRNOG00000013003	   2.0	   29.5	   4.2	   3.4	   5.6	   6.0	   4.2	   4.2	   1.32	   1.44	  
Lrp3	   ENSRNOG00000011451	   14.0	   4.7	   4.1	   4.8	   3.1	   2.9	   3.8	   4.2	   -­‐1.23	   -­‐1.44	  
Rmi1	   ENSRNOG00000019108	   3.8	   8.6	   14.7	   13.6	   22.5	   24.0	   17.8	   16.8	   1.24	   1.44	  
Cep76	   ENSRNOG00000021918	   0.9	   2.2	   4.0	   3.3	   7.3	   6.2	   4.9	   4.4	   1.47	   1.44	  
Kitlg	   ENSRNOG00000005386	   0.0	   3.3	   7.3	   7.9	   15.6	   15.7	   10.3	   11.0	   1.49	   1.44	  
Tspan5	   ENSRNOG00000015913	   0.1	   2.0	   3.5	   4.7	   3.0	   2.9	   4.1	   4.2	   -­‐1.37	   -­‐1.44	  
Fam25a	   ENSRNOG00000010401	   0.0	   1.7	   83.7	   90.1	   45.4	   51.2	   63.7	   74.2	   -­‐1.42	   -­‐1.43	  
Cdc42se1	   ENSRNOG00000021112	   7.8	   28.7	   41.6	   35.2	   54.6	   57.9	   45.9	   40.8	   1.17	   1.43	  
Nek3	   ENSRNOG00000012757	   2.2	   4.1	   3.3	   3.0	   2.3	   2.0	   3.0	   2.9	   -­‐1.29	   -­‐1.43	  
Rasl10a	   ENSRNOG00000008951	   0.3	   2.6	   5.1	   8.5	   3.9	   4.7	   5.5	   6.7	   -­‐1.42	   -­‐1.43	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Gstz1	   ENSRNOG00000047708	   175.9	   44.1	   13.0	   15.9	   8.9	   8.4	   10.9	   12.2	   -­‐1.25	   -­‐1.43	  
Ago1	   ENSRNOG00000027320	   1.0	   2.5	   5.4	   4.6	   3.4	   3.1	   5.2	   4.4	   -­‐1.52	   -­‐1.43	  
Ttll4	   ENSRNOG00000017129	   1.1	   4.5	   5.8	   4.3	   8.5	   7.4	   6.4	   5.2	   1.29	   1.42	  
Rhpn1	   ENSRNOG00000007597	   0.0	   2.1	   3.9	   3.8	   2.1	   2.4	   3.3	   3.5	   -­‐1.56	   -­‐1.42	  
Ccdc64	   ENSRNOG00000001145	   0.3	   1.7	   3.2	   2.8	   5.5	   5.6	   3.6	   3.9	   1.48	   1.42	  
Nradd	   ENSRNOG00000020936	   0.1	   0.5	   23.9	   30.3	   15.5	   17.5	   21.4	   25.0	   -­‐1.40	   -­‐1.42	  
Dhtkd1	   ENSRNOG00000023587	   70.5	   4.3	   3.1	   2.8	   2.0	   1.6	   2.6	   2.3	   -­‐1.33	   -­‐1.42	  
AABR06058720.1	   ENSRNOG00000014180	   1.4	   2.3	   1.6	   2.2	   1.1	   1.2	   1.6	   1.7	   -­‐1.41	   -­‐1.42	  
Ahnak2	   ENSRNOG00000028545	   0.0	   1.0	   2.0	   2.0	   1.5	   1.4	   2.3	   2.0	   -­‐1.51	   -­‐1.41	  
Gpsm1	   ENSRNOG00000018666	   0.2	   2.0	   5.4	   6.4	   4.4	   4.2	   5.6	   6.0	   -­‐1.29	   -­‐1.41	  
Trmt61a	   ENSRNOG00000011398	   0.6	   11.9	   6.6	   5.9	   9.0	   9.0	   6.9	   6.4	   1.27	   1.41	  
Vasn	   ENSRNOG00000004141	   3.1	   6.5	   12.8	   15.0	   9.1	   9.2	   12.6	   13.2	   -­‐1.40	   -­‐1.41	  
Cnnm2	   ENSRNOG00000020113	   1.2	   1.4	   1.8	   2.0	   1.5	   1.3	   1.9	   1.8	   -­‐1.24	   -­‐1.41	  
Mthfr	   ENSRNOG00000008553	   1.4	   3.4	   4.1	   3.4	   7.6	   6.1	   4.9	   4.3	   1.53	   1.41	  
Trak2	   ENSRNOG00000010881	   2.5	   22.9	   119.6	   117.6	   82.7	   76.3	   116.0	   107.7	   -­‐1.42	   -­‐1.40	  
Sec24a	   ENSRNOG00000004563	   7.0	   5.5	   6.1	   4.7	   8.3	   8.2	   6.6	   5.9	   1.24	   1.39	  
Bloc1s6	   ENSRNOG00000037160	   3.5	   11.2	   13.2	   14.4	   10.1	   9.2	   12.6	   13.0	   -­‐1.27	   -­‐1.39	  
Akap17b	   ENSRNOG00000009746	   0.5	   1.0	   1.2	   1.2	   0.8	   0.8	   1.3	   1.1	   -­‐1.66	   -­‐1.39	  
Nrcam	   ENSRNOG00000004067	   0.2	   0.9	   1.3	   1.0	   1.7	   1.6	   1.3	   1.2	   1.24	   1.39	  
Slc12a6	   ENSRNOG00000005196	   0.3	   0.9	   1.9	   2.3	   1.4	   1.5	   1.8	   2.0	   -­‐1.32	   -­‐1.38	  
Nbeal2	   ENSRNOG00000027880	   0.6	   1.8	   2.1	   1.8	   3.2	   3.1	   2.6	   2.3	   1.22	   1.38	  
Gar1	   ENSRNOG00000009877	   1.3	   16.6	   8.6	   9.0	   13.3	   13.7	   9.4	   10.0	   1.39	   1.38	  
Rhob	   ENSRNOG00000021403	   21.5	   54.4	   54.1	   61.6	   42.0	   42.4	   54.4	   59.2	   -­‐1.31	   -­‐1.38	  
Rn50_X_0564.1	   ENSRNOG00000051191	   0.4	   2.5	   3.3	   4.1	   2.2	   2.6	   3.1	   3.6	   -­‐1.46	   -­‐1.38	  
Unc93b1	   ENSRNOG00000017703	   1.0	   6.6	   8.9	   10.1	   7.0	   6.8	   8.6	   9.5	   -­‐1.24	   -­‐1.38	  
AABR06047726.1	   ENSRNOG00000032182	   0.7	   1.8	   2.1	   1.9	   3.0	   3.5	   2.2	   2.5	   1.33	   1.38	  
Rhpn2	   ENSRNOG00000011885	   2.2	   3.7	   4.9	   4.3	   8.2	   8.1	   6.2	   6.0	   1.31	   1.38	  
Acbd4	   ENSRNOG00000003108	   6.7	   7.2	   5.8	   6.9	   4.5	   4.3	   5.3	   5.9	   -­‐1.19	   -­‐1.38	  
Mpzl1	   ENSRNOG00000003248	   0.1	   0.6	   1.4	   1.6	   1.1	   1.0	   1.4	   1.4	   -­‐1.33	   -­‐1.38	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Serf1	   ENSRNOG00000017945	   5.5	   17.9	   19.3	   24.7	   15.0	   15.2	   18.3	   21.0	   -­‐1.23	   -­‐1.38	  
Zfp90	   ENSRNOG00000020087	   0.2	   2.1	   2.3	   2.7	   2.0	   1.8	   2.5	   2.5	   -­‐1.28	   -­‐1.37	  
Inpp5b	   ENSRNOG00000048506	   0.7	   0.6	   0.8	   0.9	   1.3	   1.4	   0.9	   1.1	   1.35	   1.37	  
Pard6b	   ENSRNOG00000010883	   0.9	   3.8	   4.1	   4.5	   3.6	   3.2	   4.9	   4.4	   -­‐1.39	   -­‐1.36	  
Ptprv	   ENSRNOG00000005277	   0.0	   0.1	   0.8	   0.9	   0.6	   0.6	   0.9	   0.9	   -­‐1.47	   -­‐1.36	  
Mblac2	   ENSRNOG00000016252	   1.8	   3.3	   5.6	   5.1	   4.3	   3.8	   5.9	   5.2	   -­‐1.38	   -­‐1.36	  
Rrp9	   ENSRNOG00000012927	   1.2	   13.1	   9.2	   9.8	   12.8	   14.1	   10.0	   10.5	   1.25	   1.36	  
Nol9	   ENSRNOG00000010109	   1.4	   10.7	   9.8	   8.8	   13.3	   13.6	   11.1	   10.1	   1.18	   1.36	  
Nup153	   ENSRNOG00000001456	   2.9	   8.0	   11.0	   10.1	   17.7	   17.5	   13.0	   13.0	   1.34	   1.35	  
Chuk	   ENSRNOG00000022485	   13.7	   13.8	   12.8	   11.0	   17.4	   17.6	   14.0	   13.1	   1.23	   1.35	  
Pknox1	   ENSRNOG00000001184	   1.6	   2.5	   4.2	   3.2	   4.7	   4.6	   3.8	   3.4	   1.22	   1.35	  
P4ha1	   ENSRNOG00000050655	   3.2	   7.1	   10.1	   10.2	   15.4	   16.2	   12.0	   12.1	   1.27	   1.35	  
Tmx3	   ENSRNOG00000045740	   3.7	   9.6	   18.3	   17.0	   23.4	   24.5	   19.8	   18.3	   1.17	   1.35	  
Sidt2	   ENSRNOG00000017871	   18.7	   20.7	   29.1	   29.9	   20.1	   19.4	   28.1	   26.4	   -­‐1.42	   -­‐1.35	  
R3hdm4	   ENSRNOG00000011489	   14.5	   22.8	   22.1	   25.6	   17.8	   16.3	   21.6	   22.1	   -­‐1.23	   -­‐1.35	  
Ptbp2	   ENSRNOG00000010827	   0.9	   3.6	   5.1	   6.5	   4.6	   4.4	   5.5	   6.0	   -­‐1.23	   -­‐1.35	  
Tmem59	   ENSRNOG00000009778	   87.1	   80.4	   121.0	   128.2	   96.5	   87.0	   110.9	   118.0	   -­‐1.17	   -­‐1.34	  
Tsr1	   ENSRNOG00000002980	   3.7	   16.7	   14.1	   12.5	   21.9	   21.4	   17.0	   16.1	   1.27	   1.34	  
Dph1	   ENSRNOG00000003116	   2.1	   17.2	   9.1	   8.8	   11.8	   12.3	   10.0	   9.3	   1.16	   1.34	  
Zc3h10	   ENSRNOG00000040281	   0.7	   1.9	   2.5	   3.4	   2.3	   2.3	   2.8	   3.1	   -­‐1.25	   -­‐1.34	  
Hs6st1	   ENSRNOG00000014516	   2.7	   10.4	   17.7	   17.9	   12.3	   12.5	   16.0	   16.8	   -­‐1.32	   -­‐1.34	  
Mxd4	   ENSRNOG00000015033	   20.2	   52.6	   89.1	   103.8	   70.7	   67.8	   87.9	   91.6	   -­‐1.26	   -­‐1.34	  
Paics	   ENSRNOG00000002101	   5.5	   11.7	   13.8	   11.5	   18.6	   18.2	   14.5	   13.8	   1.27	   1.34	  
Fam20a	   ENSRNOG00000003969	   9.5	   11.3	   7.2	   10.6	   6.5	   6.5	   7.9	   8.8	   -­‐1.23	   -­‐1.33	  
Dexi	   ENSRNOG00000002635	   13.8	   11.6	   13.6	   15.6	   10.6	   10.7	   13.0	   14.4	   -­‐1.24	   -­‐1.33	  
Myo1d	   ENSRNOG00000003276	   5.9	   7.2	   13.9	   15.0	   10.6	   10.7	   12.7	   14.3	   -­‐1.22	   -­‐1.33	  
Zfp36l1	   ENSRNOG00000030024	   119.7	   73.4	   79.7	   84.9	   62.1	   60.5	   80.3	   81.1	   -­‐1.31	   -­‐1.33	  
Srebf1	   ENSRNOG00000003463	   102.0	   21.5	   7.8	   6.7	   10.1	   9.7	   8.0	   7.4	   1.25	   1.33	  
Mettl16	   ENSRNOG00000002764	   1.6	   6.9	   6.2	   6.4	   9.1	   10.0	   7.0	   7.6	   1.28	   1.33	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Galnt11	   ENSRNOG00000008117	   9.5	   5.6	   7.6	   8.6	   6.2	   5.6	   7.7	   7.5	   -­‐1.25	   -­‐1.32	  
AABR06026181.1	   ENSRNOG00000025804	   1.9	   4.6	   3.2	   2.5	   4.4	   4.4	   3.4	   3.4	   1.27	   1.32	  
Ttc21b	   ENSRNOG00000005868	   1.3	   2.7	   5.3	   6.0	   4.4	   4.1	   5.1	   5.5	   -­‐1.18	   -­‐1.32	  
Gfer	   ENSRNOG00000013370	   9.5	   16.2	   10.9	   9.8	   15.7	   14.7	   12.0	   11.2	   1.29	   1.32	  
Mesdc1	   ENSRNOG00000012349	   0.4	   2.7	   4.6	   5.1	   7.4	   8.3	   5.6	   6.4	   1.29	   1.32	  
RGD1559896	   ENSRNOG00000018836	   2.2	   7.1	   14.1	   15.2	   10.4	   9.5	   13.3	   12.7	   -­‐1.30	   -­‐1.32	  
Sh3bgrl	   ENSRNOG00000002280	   29.2	   29.1	   141.7	   150.6	   112.4	   103.5	   132.2	   137.6	   -­‐1.19	   -­‐1.32	  
Abcd3	   ENSRNOG00000011929	   39.5	   24.7	   22.6	   25.1	   19.3	   18.2	   22.7	   24.2	   -­‐1.19	   -­‐1.32	  
Mid1ip1	   ENSRNOG00000003228	   21.7	   26.9	   15.9	   18.0	   24.3	   23.7	   17.8	   18.2	   1.35	   1.32	  
Palld	   ENSRNOG00000010107	   4.1	   22.6	   73.2	   64.1	   43.3	   44.6	   67.4	   59.1	   -­‐1.58	   -­‐1.31	  
Fam110b	   ENSRNOG00000009114	   0.5	   2.6	   9.4	   8.0	   7.0	   6.1	   8.6	   8.1	   -­‐1.24	   -­‐1.31	  
Azin2	   ENSRNOG00000042650	   0.1	   2.9	   12.9	   12.3	   9.7	   8.1	   11.4	   10.7	   -­‐1.19	   -­‐1.31	  
Ndufb10	   ENSRNOG00000014568	   53.8	   69.4	   44.5	   50.7	   38.0	   32.2	   46.2	   42.6	   -­‐1.23	   -­‐1.31	  
Rrs1	   ENSRNOG00000007240	   3.9	   14.9	   9.4	   9.4	   13.4	   13.0	   10.7	   10.0	   1.23	   1.31	  
Lamc1	   ENSRNOG00000002680	   2.3	   20.6	   60.7	   74.7	   56.0	   54.9	   65.4	   72.5	   -­‐1.18	   -­‐1.31	  
Prdx2	   ENSRNOG00000003520	   40.4	   106.5	   151.9	   183.2	   132.5	   122.7	   150.4	   161.9	   -­‐1.15	   -­‐1.31	  
Eif2s1	   ENSRNOG00000009432	   12.4	   68.0	   56.2	   52.1	   78.1	   82.2	   63.6	   63.5	   1.21	   1.31	  
Sdr9c7	   ENSRNOG00000004459	   17.4	   11.1	   9.1	   7.9	   11.2	   10.6	   9.1	   8.2	   1.21	   1.30	  
Riok2	   ENSRNOG00000012692	   2.3	   13.2	   10.7	   9.6	   13.0	   13.7	   10.8	   10.6	   1.18	   1.30	  
Pgs1	   ENSRNOG00000002949	   1.7	   9.2	   8.5	   7.6	   11.5	   10.9	   9.5	   8.4	   1.19	   1.30	  
Orai1	   ENSRNOG00000001336	   10.8	   25.4	   38.3	   43.3	   26.0	   27.6	   36.9	   36.3	   -­‐1.44	   -­‐1.30	  
Ttll7	   ENSRNOG00000031997	   0.3	   2.7	   6.7	   6.4	   9.1	   9.8	   7.7	   7.6	   1.16	   1.30	  
Rfxap	   ENSRNOG00000028382	   2.8	   8.1	   6.4	   8.1	   5.5	   5.9	   7.1	   7.7	   -­‐1.31	   -­‐1.30	  
Haus8	   ENSRNOG00000023534	   0.8	   5.9	   7.0	   6.3	   10.3	   9.0	   7.8	   7.0	   1.31	   1.30	  
Ppp1r14a	   ENSRNOG00000020676	   9.2	   31.5	   41.2	   46.3	   25.6	   29.4	   34.2	   38.6	   -­‐1.35	   -­‐1.30	  
LOC691931	   ENSRNOG00000010875	   3.3	   5.0	   7.5	   6.6	   10.1	   11.1	   7.9	   8.6	   1.25	   1.30	  
Rnf126	   ENSRNOG00000009028	   5.0	   9.1	   9.9	   9.2	   13.7	   14.1	   11.4	   10.9	   1.18	   1.30	  
Nf2	   ENSRNOG00000007948	   2.3	   6.0	   10.3	   10.5	   7.6	   7.5	   9.9	   9.8	   -­‐1.32	   -­‐1.30	  
Rbm15	   ENSRNOG00000047499	   1.8	   3.2	   3.2	   3.1	   4.9	   4.3	   3.8	   3.4	   1.29	   1.30	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Lrp8	   ENSRNOG00000013064	   0.0	   1.4	   1.5	   1.6	   2.5	   2.6	   1.8	   2.1	   1.38	   1.29	  
Suco	   ENSRNOG00000026542	   2.7	   2.6	   5.6	   5.4	   7.5	   7.6	   6.0	   6.0	   1.24	   1.29	  
Alkbh8	   ENSRNOG00000024525	   0.8	   1.5	   1.6	   1.5	   2.1	   2.1	   1.6	   1.7	   1.29	   1.29	  
Scamp1	   ENSRNOG00000010774	   6.2	   10.3	   12.1	   13.8	   9.8	   9.7	   11.7	   12.6	   -­‐1.20	   -­‐1.29	  
Csrnp1	   ENSRNOG00000033433	   3.0	   4.3	   5.6	   5.5	   4.8	   4.2	   5.9	   5.5	   -­‐1.25	   -­‐1.29	  
RGD1307315	   ENSRNOG00000013690	   0.2	   3.0	   3.2	   3.4	   2.3	   2.2	   3.0	   2.9	   -­‐1.34	   -­‐1.29	  
Ssna1	   ENSRNOG00000011093	   27.1	   37.6	   27.9	   26.4	   35.6	   35.5	   26.9	   27.9	   1.30	   1.29	  
Gna11	   ENSRNOG00000005446	   4.4	   9.0	   12.6	   13.2	   18.6	   19.6	   14.0	   15.4	   1.31	   1.29	  
Galt	   ENSRNOG00000014766	   14.1	   10.3	   10.6	   12.5	   9.6	   8.2	   11.0	   10.7	   -­‐1.17	   -­‐1.28	  
Urb1	   ENSRNOG00000002080	   0.8	   3.3	   3.5	   3.5	   5.1	   4.9	   3.9	   3.9	   1.30	   1.28	  
Helb	   ENSRNOG00000004189	   0.7	   1.7	   2.9	   2.8	   3.9	   3.8	   3.2	   3.0	   1.19	   1.28	  
Cdk10	   ENSRNOG00000016088	   7.1	   27.7	   24.0	   21.8	   32.0	   33.9	   28.0	   26.7	   1.13	   1.28	  
Nudt9	   ENSRNOG00000002186	   9.9	   35.1	   18.7	   18.6	   23.6	   25.8	   20.1	   20.3	   1.16	   1.28	  
Hnrnpf	   ENSRNOG00000014562	   15.1	   47.4	   49.0	   44.9	   69.9	   65.6	   54.6	   51.8	   1.26	   1.28	  
Twistnb	   ENSRNOG00000010750	   1.9	   7.0	   7.0	   7.1	   9.6	   10.0	   7.9	   7.9	   1.20	   1.28	  
Alg12	   ENSRNOG00000004591	   2.9	   10.1	   5.7	   5.6	   7.3	   7.7	   6.0	   6.1	   1.20	   1.28	  
Atf2	   ENSRNOG00000001597	   5.8	   6.4	   11.0	   10.8	   14.9	   15.4	   12.0	   12.2	   1.22	   1.27	  
Cnpy2	   ENSRNOG00000003549	   40.3	   54.9	   61.7	   69.6	   49.7	   46.8	   56.7	   60.1	   -­‐1.16	   -­‐1.27	  
Ocrl	   ENSRNOG00000003875	   1.2	   2.9	   3.8	   3.7	   3.0	   2.6	   3.5	   3.3	   -­‐1.21	   -­‐1.27	  
Mybbp1a	   ENSRNOG00000015236	   4.9	   28.8	   23.1	   21.6	   28.9	   29.9	   25.3	   23.8	   1.13	   1.27	  
Scap	   ENSRNOG00000020853	   8.4	   12.4	   13.7	   15.6	   12.8	   11.5	   14.2	   14.7	   -­‐1.13	   -­‐1.27	  
Desi2	   ENSRNOG00000004524	   3.7	   10.7	   10.3	   10.2	   14.7	   14.1	   10.8	   11.2	   1.34	   1.27	  
Ttc3	   ENSRNOG00000001682	   1.9	   6.4	   15.5	   15.6	   12.3	   11.2	   16.0	   14.3	   -­‐1.32	   -­‐1.27	  
Chd6	   ENSRNOG00000016744	   0.9	   1.2	   2.2	   2.8	   1.9	   2.0	   2.3	   2.5	   -­‐1.20	   -­‐1.26	  
Fam120b	   ENSRNOG00000001487	   3.0	   3.8	   4.3	   5.0	   3.7	   3.4	   4.4	   4.3	   -­‐1.21	   -­‐1.26	  
Spast	   ENSRNOG00000027136	   2.0	   4.1	   4.9	   5.3	   4.2	   3.8	   5.0	   4.8	   -­‐1.20	   -­‐1.26	  
Btaf1	   ENSRNOG00000017938	   2.1	   4.1	   4.9	   4.5	   6.5	   6.9	   5.3	   5.5	   1.22	   1.26	  
Tomm40	   ENSRNOG00000018556	   7.1	   36.2	   28.2	   24.1	   37.5	   34.2	   30.7	   27.4	   1.20	   1.26	  
Nudt18	   ENSRNOG00000011831	   5.2	   24.5	   18.7	   21.9	   14.3	   14.4	   17.2	   18.3	   -­‐1.22	   -­‐1.26	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Atp6v0a1	   ENSRNOG00000036814	   8.4	   9.3	   7.6	   7.7	   5.2	   5.5	   7.2	   7.0	   -­‐1.39	   -­‐1.26	  
Thumpd3	   ENSRNOG00000006941	   3.6	   14.6	   11.9	   11.6	   14.4	   15.0	   12.7	   12.0	   1.12	   1.26	  
Phka1	   ENSRNOG00000003063	   0.6	   1.1	   1.8	   2.0	   1.5	   1.4	   1.8	   1.7	   -­‐1.20	   -­‐1.26	  
Ccdc181	   ENSRNOG00000002860	   0.6	   8.2	   8.1	   8.4	   6.5	   5.7	   7.6	   7.2	   -­‐1.20	   -­‐1.26	  
Zmym3	   ENSRNOG00000003707	   2.3	   5.0	   5.6	   7.0	   4.7	   4.8	   5.6	   6.1	   -­‐1.19	   -­‐1.25	  
Ndfip1	   ENSRNOG00000013562	   68.9	   112.6	   116.7	   130.3	   97.4	   93.7	   114.5	   118.3	   -­‐1.19	   -­‐1.25	  
Rabac1	   ENSRNOG00000020233	   37.1	   80.3	   82.6	   82.8	   65.8	   55.7	   77.0	   70.4	   -­‐1.19	   -­‐1.25	  
Capn1	   ENSRNOG00000020935	   2.6	   13.5	   17.2	   16.8	   13.6	   12.7	   17.0	   16.0	   -­‐1.26	   -­‐1.25	  
Ppp4r1	   ENSRNOG00000013733	   3.7	   12.4	   17.6	   17.5	   23.2	   24.2	   19.4	   19.5	   1.18	   1.25	  
Taf1d	   ENSRNOG00000010921	   2.5	   23.8	   14.7	   14.8	   19.6	   20.9	   16.2	   16.9	   1.19	   1.25	  
Gpatch4	   ENSRNOG00000018969	   0.5	   6.7	   4.7	   4.5	   6.8	   6.0	   5.3	   4.8	   1.27	   1.25	  
Ddx56	   ENSRNOG00000004670	   4.9	   21.4	   12.9	   12.3	   17.1	   15.8	   14.0	   12.8	   1.20	   1.25	  
Wdr5	   ENSRNOG00000008212	   3.1	   15.8	   12.8	   14.2	   17.7	   18.0	   14.5	   14.6	   1.20	   1.25	  
Chmp7	   ENSRNOG00000016939	   5.8	   11.4	   15.2	   14.3	   11.7	   11.6	   15.0	   14.7	   -­‐1.31	   -­‐1.25	  
Rad52	   ENSRNOG00000009742	   3.0	   12.5	   9.7	   10.7	   7.8	   7.1	   9.4	   9.0	   -­‐1.22	   -­‐1.25	  
Hdac7	   ENSRNOG00000008308	   0.1	   1.9	   10.9	   11.7	   8.7	   8.8	   11.1	   11.1	   -­‐1.29	   -­‐1.25	  
Shisa5	   ENSRNOG00000020667	   5.5	   9.9	   12.7	   14.5	   10.5	   10.6	   12.4	   13.3	   -­‐1.20	   -­‐1.25	  
Rabepk	   ENSRNOG00000018591	   1.6	   5.0	   4.7	   5.6	   4.3	   3.9	   5.1	   4.9	   -­‐1.21	   -­‐1.25	  
Cactin	   ENSRNOG00000039852	   1.7	   6.2	   5.8	   5.6	   7.7	   7.6	   6.6	   6.1	   1.14	   1.25	  
Ppp1r13b	   ENSRNOG00000012653	   1.1	   2.2	   3.9	   4.3	   3.1	   3.3	   3.8	   4.2	   -­‐1.26	   -­‐1.24	  
Pomk	   ENSRNOG00000014628	   3.1	   11.0	   11.0	   12.2	   9.4	   9.1	   10.8	   11.4	   -­‐1.17	   -­‐1.24	  
Ttc12	   ENSRNOG00000008595	   0.1	   1.9	   5.4	   6.7	   4.1	   4.6	   5.0	   5.8	   -­‐1.25	   -­‐1.24	  
Uso1	   ENSRNOG00000002301	   28.5	   37.1	   35.8	   35.4	   43.5	   45.3	   39.3	   36.9	   1.09	   1.24	  
Txndc15	   ENSRNOG00000000133	   23.3	   35.8	   37.5	   41.9	   32.0	   29.0	   35.6	   36.2	   -­‐1.13	   -­‐1.24	  
Fzd6	   ENSRNOG00000004660	   0.3	   2.2	   5.5	   6.0	   4.8	   4.8	   5.7	   6.0	   -­‐1.19	   -­‐1.24	  
Gabarapl2	   ENSRNOG00000019425	   21.1	   16.4	   19.6	   21.5	   15.0	   15.8	   18.4	   19.8	   -­‐1.25	   -­‐1.24	  
Rbm28	   ENSRNOG00000005468	   2.0	   7.4	   8.3	   7.7	   10.3	   10.6	   8.8	   8.7	   1.15	   1.24	  
Ncl	   ENSRNOG00000018273	   22.8	   91.8	   86.9	   78.8	   114.3	   112.0	   95.5	   91.5	   1.18	   1.23	  
Cyp4f6	   ENSRNOG00000034157	   33.9	   26.0	   25.9	   29.7	   21.2	   20.6	   25.2	   25.6	   -­‐1.21	   -­‐1.23	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Trim5	   ENSRNOG00000017191	   13.6	   18.7	   17.2	   17.9	   13.8	   13.5	   17.1	   16.9	   -­‐1.25	   -­‐1.23	  
Men1	   ENSRNOG00000021054	   3.8	   7.1	   8.9	   9.8	   11.1	   11.8	   9.4	   9.7	   1.17	   1.23	  
Rabggtb	   ENSRNOG00000009992	   23.2	   52.4	   36.7	   38.2	   49.1	   47.5	   41.0	   38.8	   1.18	   1.23	  
Nit1	   ENSRNOG00000003881	   59.6	   89.0	   92.8	   92.5	   75.2	   68.9	   86.4	   85.7	   -­‐1.17	   -­‐1.23	  
Tekt1	   ENSRNOG00000014973	   0.0	   1.0	   4.5	   4.9	   3.4	   3.7	   4.0	   4.6	   -­‐1.22	   -­‐1.23	  
Tmem19	   ENSRNOG00000003985	   13.2	   40.3	   32.6	   27.8	   22.4	   20.4	   28.1	   25.4	   -­‐1.27	   -­‐1.23	  
Hps6	   ENSRNOG00000018433	   0.4	   2.5	   3.0	   3.9	   2.6	   2.7	   3.0	   3.4	   -­‐1.18	   -­‐1.23	  
Camsap3	   ENSRNOG00000000986	   1.7	   5.0	   4.3	   4.6	   3.6	   3.6	   4.2	   4.4	   -­‐1.17	   -­‐1.23	  
Arf6	   ENSRNOG00000004791	   14.9	   50.3	   53.9	   56.5	   74.5	   76.6	   60.5	   62.9	   1.21	   1.23	  
Cluh	   ENSRNOG00000002669	   33.7	   29.1	   21.4	   19.2	   26.6	   28.1	   22.4	   23.1	   1.17	   1.23	  
Snapin	   ENSRNOG00000013356	   15.8	   34.4	   37.3	   39.2	   29.6	   27.3	   35.2	   33.9	   -­‐1.21	   -­‐1.23	  
Ndst2	   ENSRNOG00000027171	   3.4	   3.3	   3.7	   4.7	   3.7	   3.5	   4.2	   4.4	   -­‐1.17	   -­‐1.23	  
Ppcdc	   ENSRNOG00000018711	   1.3	   2.4	   1.8	   1.8	   2.6	   2.2	   1.9	   1.8	   1.33	   1.23	  
Cul2	   ENSRNOG00000015292	   9.9	   13.9	   12.5	   12.0	   15.8	   16.2	   13.7	   13.3	   1.14	   1.22	  
Usp43	   ENSRNOG00000003785	   0.0	   0.5	   2.3	   2.5	   2.6	   2.5	   2.1	   2.1	   1.25	   1.22	  
Pigx	   ENSRNOG00000033623	   5.3	   30.3	   37.7	   40.5	   30.3	   30.1	   36.0	   37.2	   -­‐1.21	   -­‐1.22	  
Exoc2	   ENSRNOG00000033643	   2.9	   7.2	   10.1	   11.3	   8.3	   8.2	   10.0	   10.1	   -­‐1.22	   -­‐1.22	  
Faf2	   ENSRNOG00000017607	   9.6	   17.2	   18.2	   16.2	   21.5	   22.8	   18.0	   18.8	   1.18	   1.22	  
Cd81	   ENSRNOG00000020451	   292.1	   992.0	   1166.5	   1179.1	   934.5	   887.5	   1085.9	   1092.3	   -­‐1.18	   -­‐1.22	  
Tp53bp2	   ENSRNOG00000003237	   3.4	   4.2	   6.6	   7.2	   5.8	   5.9	   7.1	   7.2	   -­‐1.23	   -­‐1.22	  
Armc9	   ENSRNOG00000025418	   0.7	   2.9	   4.3	   4.4	   3.8	   3.3	   4.3	   4.1	   -­‐1.16	   -­‐1.22	  
Tle2	   ENSRNOG00000005874	   2.3	   4.4	   5.6	   6.5	   4.7	   4.4	   5.5	   5.5	   -­‐1.20	   -­‐1.22	  
Ppp1r2	   ENSRNOG00000001733	   14.1	   36.0	   88.9	   81.2	   134.2	   120.4	   107.2	   99.7	   1.23	   1.22	  
Timm9	   ENSRNOG00000008222	   9.3	   24.1	   10.7	   12.9	   15.9	   16.1	   11.6	   13.4	   1.35	   1.22	  
Gabpa	   ENSRNOG00000001549	   3.4	   6.4	   8.0	   7.1	   10.1	   9.6	   8.7	   8.0	   1.14	   1.22	  
Rwdd4	   ENSRNOG00000022500	   8.5	   14.2	   14.2	   12.3	   16.8	   16.6	   14.2	   13.8	   1.17	   1.22	  
Smpdl3b	   ENSRNOG00000042326	   0.3	   2.8	   4.6	   4.1	   3.4	   3.2	   4.0	   3.9	   -­‐1.18	   -­‐1.22	  
Tp53	   ENSRNOG00000010756	   8.7	   57.4	   58.1	   55.7	   74.1	   73.1	   64.8	   60.7	   1.13	   1.22	  
Mfap1a	   ENSRNOG00000015984	   3.6	   6.9	   8.3	   7.6	   10.8	   10.9	   8.8	   9.0	   1.20	   1.21	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Ptpra	   ENSRNOG00000021223	   3.2	   8.6	   14.7	   16.0	   13.1	   12.5	   14.3	   15.3	   -­‐1.11	   -­‐1.21	  
Myl12a	   ENSRNOG00000015278	   18.9	   415.5	   663.5	   669.9	   554.9	   506.3	   637.9	   620.0	   -­‐1.17	   -­‐1.21	  
Ift81	   ENSRNOG00000001294	   0.8	   6.1	   7.5	   8.8	   6.3	   6.7	   7.6	   8.2	   -­‐1.23	   -­‐1.21	  
Smg9	   ENSRNOG00000019596	   1.5	   7.4	   5.3	   6.0	   7.5	   7.9	   5.9	   6.6	   1.25	   1.21	  
Zfp275	   ENSRNOG00000018419	   0.1	   1.1	   3.7	   3.5	   3.2	   2.8	   3.8	   3.4	   -­‐1.21	   -­‐1.21	  
Dkc1	   ENSRNOG00000048151	   8.9	   37.6	   28.1	   30.2	   38.0	   37.9	   31.3	   31.6	   1.20	   1.21	  
Me3	   ENSRNOG00000017311	   5.1	   3.6	   4.6	   4.4	   3.7	   3.1	   4.4	   3.8	   -­‐1.21	   -­‐1.21	  
Acadvl	   ENSRNOG00000018114	   84.8	   56.6	   34.1	   36.2	   27.7	   28.1	   32.0	   34.3	   -­‐1.17	   -­‐1.21	  
Rbpms	   ENSRNOG00000013328	   22.2	   147.2	   141.4	   184.6	   123.8	   130.8	   149.8	   159.7	   -­‐1.23	   -­‐1.21	  
RGD1302996	   ENSRNOG00000000812	   5.3	   11.7	   8.1	   7.9	   7.4	   6.4	   8.5	   7.8	   -­‐1.16	   -­‐1.21	  
Pelo	   ENSRNOG00000023127	   5.2	   21.0	   18.8	   19.7	   26.7	   25.3	   21.1	   21.2	   1.25	   1.21	  
Pwp2	   ENSRNOG00000001210	   1.0	   6.3	   6.2	   5.9	   8.6	   7.8	   6.8	   6.5	   1.24	   1.21	  
Ltv1	   ENSRNOG00000015217	   3.9	   14.3	   13.6	   13.2	   16.3	   16.3	   14.3	   13.6	   1.12	   1.21	  
Gtf2f2	   ENSRNOG00000029316	   3.0	   10.4	   5.5	   6.1	   8.3	   8.2	   6.3	   6.9	   1.30	   1.20	  
Hsbp1	   ENSRNOG00000014415	   50.1	   101.7	   101.0	   109.3	   90.0	   80.0	   100.9	   97.2	   -­‐1.14	   -­‐1.20	  
Sp110	   ENSRNOG00000033747	   3.1	   11.8	   12.1	   13.0	   10.1	   9.6	   12.1	   11.7	   -­‐1.21	   -­‐1.20	  
Mpv17l2	   ENSRNOG00000019394	   5.3	   19.8	   12.5	   11.3	   16.5	   14.8	   13.3	   12.5	   1.22	   1.20	  
Pno1	   ENSRNOG00000005524	   4.0	   31.7	   23.2	   22.6	   29.6	   29.5	   25.1	   24.7	   1.16	   1.20	  
Akap8l	   ENSRNOG00000006355	   17.0	   14.5	   13.6	   18.2	   11.9	   13.4	   14.8	   16.2	   -­‐1.26	   -­‐1.20	  
Hmgcr	   ENSRNOG00000016122	   14.5	   17.2	   14.7	   13.5	   19.3	   18.5	   16.8	   15.5	   1.13	   1.20	  
Commd3	   ENSRNOG00000016383	   33.0	   77.1	   90.9	   93.5	   82.1	   73.7	   90.0	   89.3	   -­‐1.11	   -­‐1.20	  
Elk4	   ENSRNOG00000007887	   2.0	   6.6	   8.3	   8.7	   6.4	   6.9	   8.5	   8.4	   -­‐1.35	   -­‐1.20	  
Rnps1	   ENSRNOG00000008703	   6.4	   29.2	   34.6	   35.6	   46.7	   47.2	   39.2	   39.7	   1.17	   1.20	  
Cdkn2aip	   ENSRNOG00000022736	   3.7	   7.5	   11.9	   13.1	   15.5	   16.2	   13.0	   13.6	   1.18	   1.20	  
Mavs	   ENSRNOG00000025295	   6.5	   4.7	   4.5	   5.2	   4.0	   3.9	   4.6	   4.7	   -­‐1.17	   -­‐1.20	  
Hccs	   ENSRNOG00000025910	   4.5	   8.1	   6.4	   6.6	   7.8	   8.2	   6.9	   6.9	   1.12	   1.20	  
Pyurfl1	   ENSRNOG00000006858	   10.1	   23.1	   15.2	   15.8	   12.0	   11.0	   14.3	   13.3	   -­‐1.21	   -­‐1.20	  
Aldh2	   ENSRNOG00000001344	   529.2	   281.1	   151.0	   166.0	   136.2	   128.7	   151.5	   155.5	   -­‐1.13	   -­‐1.20	  
Eml5	   ENSRNOG00000004207	   1.1	   1.2	   1.6	   1.8	   1.4	   1.6	   1.7	   1.9	   -­‐1.24	   -­‐1.20	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LOC364561	   ENSRNOG00000020474	   10.6	   48.8	   44.7	   41.5	   58.8	   50.7	   49.1	   42.8	   1.18	   1.20	  
Zmynd19	   ENSRNOG00000007752	   1.1	   4.3	   5.5	   5.5	   7.8	   7.0	   5.7	   5.9	   1.35	   1.20	  
Tmcc1	   ENSRNOG00000011614	   5.6	   5.1	   7.4	   7.2	   9.7	   10.0	   7.9	   8.4	   1.20	   1.20	  
Abtb2	   ENSRNOG00000008510	   7.8	   8.2	   7.3	   7.2	   8.3	   8.5	   7.2	   7.2	   1.13	   1.19	  
Wdr45b	   ENSRNOG00000036662	   6.1	   23.1	   26.8	   23.1	   30.7	   29.1	   26.9	   24.6	   1.12	   1.19	  
Wdr41	   ENSRNOG00000025462	   2.4	   9.3	   10.2	   11.0	   9.3	   8.6	   10.3	   10.3	   -­‐1.12	   -­‐1.19	  
Ano10	   ENSRNOG00000000219	   9.0	   15.8	   20.6	   22.0	   16.7	   17.6	   19.7	   21.1	   -­‐1.20	   -­‐1.19	  
Lonp2	   ENSRNOG00000015162	   114.9	   43.9	   46.2	   49.7	   40.0	   38.5	   45.0	   46.2	   -­‐1.14	   -­‐1.19	  
Bnip3l	   ENSRNOG00000009820	   11.1	   31.1	   47.6	   52.5	   38.4	   39.4	   46.8	   47.3	   -­‐1.24	   -­‐1.19	  
ND1	   ENSRNOG00000030644	   6897.3	   6680.8	   4622.1	   4927.9	   3915.3	   3613.5	   4879.7	   4336.9	   -­‐1.26	   -­‐1.19	  
Uba2	   ENSRNOG00000021113	   2.0	   5.2	   6.7	   6.6	   9.5	   9.2	   7.7	   7.9	   1.22	   1.19	  
Tnpo3	   ENSRNOG00000021758	   3.6	   12.3	   15.4	   14.3	   19.4	   19.1	   16.5	   16.3	   1.15	   1.19	  
Anapc16	   ENSRNOG00000000576	   3.3	   13.3	   11.3	   13.6	   15.6	   15.4	   11.9	   13.0	   1.29	   1.19	  
Prpf31	   ENSRNOG00000013504	   2.8	   10.6	   9.5	   9.0	   11.7	   11.3	   10.0	   9.6	   1.15	   1.19	  
Ogfod3	   ENSRNOG00000036668	   3.3	   6.7	   10.0	   10.8	   8.9	   8.5	   10.3	   10.2	   -­‐1.18	   -­‐1.19	  
Tfip11	   ENSRNOG00000000663	   3.6	   12.2	   8.9	   8.9	   11.0	   11.6	   9.2	   9.9	   1.18	   1.19	  
Smek1	   ENSRNOG00000027773	   7.1	   9.1	   13.6	   14.4	   18.8	   19.3	   15.4	   16.5	   1.20	   1.19	  
Yy1	   ENSRNOG00000004339	   7.5	   15.5	   18.1	   18.5	   24.8	   24.7	   20.3	   21.1	   1.20	   1.18	  
Dmap1	   ENSRNOG00000019407	   4.1	   14.4	   9.2	   9.8	   7.4	   7.6	   9.0	   9.1	   -­‐1.23	   -­‐1.18	  
Plscr1	   ENSRNOG00000008048	   0.1	   3.0	   14.2	   13.1	   10.2	   9.7	   12.4	   11.5	   -­‐1.24	   -­‐1.18	  
Hp1bp3	   ENSRNOG00000014445	   35.5	   42.5	   71.8	   82.9	   66.0	   64.9	   73.5	   77.3	   -­‐1.13	   -­‐1.18	  
Gba	   ENSRNOG00000049281	   6.5	   18.5	   31.7	   31.8	   27.4	   25.3	   30.5	   30.1	   -­‐1.13	   -­‐1.18	  
Ube2r2	   ENSRNOG00000010727	   22.1	   40.7	   58.0	   64.8	   49.7	   48.5	   61.0	   57.7	   -­‐1.25	   -­‐1.18	  
Zfp259	   ENSRNOG00000018481	   5.9	   29.4	   17.6	   17.4	   22.3	   21.8	   20.1	   18.6	   1.09	   1.18	  
Gata6	   ENSRNOG00000023433	   1.3	   3.2	   7.3	   8.7	   6.8	   7.2	   7.8	   8.6	   -­‐1.18	   -­‐1.18	  
Fam63a	   ENSRNOG00000021131	   7.1	   15.5	   26.5	   26.0	   22.3	   20.9	   26.7	   24.8	   -­‐1.22	   -­‐1.18	  
Tmed7	   ENSRNOG00000003691	   33.6	   28.9	   28.9	   29.0	   33.7	   34.6	   30.1	   29.7	   1.10	   1.18	  
Slc35d2	   ENSRNOG00000027229	   8.2	   26.6	   19.4	   20.2	   16.7	   15.6	   19.3	   18.6	   -­‐1.17	   -­‐1.18	  
Zmiz1	   ENSRNOG00000010488	   1.1	   4.2	   7.1	   7.7	   6.0	   5.9	   7.5	   7.0	   -­‐1.27	   -­‐1.17	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Edem1	   ENSRNOG00000007944	   36.0	   20.2	   25.2	   28.4	   34.2	   35.8	   27.5	   30.8	   1.22	   1.17	  
Ddx18	   ENSRNOG00000025430	   3.4	   14.9	   11.9	   11.6	   15.3	   14.8	   13.7	   12.8	   1.10	   1.17	  
Hebp2	   ENSRNOG00000011409	   0.2	   10.1	   14.5	   14.7	   11.2	   10.9	   13.6	   12.9	   -­‐1.23	   -­‐1.17	  
Traf4	   ENSRNOG00000013169	   5.5	   17.9	   25.7	   26.8	   33.4	   31.3	   29.4	   27.0	   1.12	   1.17	  
Wapal	   ENSRNOG00000039630	   10.1	   14.3	   19.4	   18.7	   24.4	   26.4	   20.7	   22.8	   1.16	   1.17	  
Gatad2a	   ENSRNOG00000022173	   6.8	   18.4	   18.4	   18.0	   23.9	   22.3	   20.8	   19.2	   1.13	   1.17	  
Itm2b	   ENSRNOG00000016271	   268.1	   219.3	   377.2	   390.2	   289.1	   295.4	   346.0	   348.3	   -­‐1.21	   -­‐1.17	  
Zfp180	   ENSRNOG00000029336	   1.4	   3.1	   5.2	   5.9	   7.6	   7.5	   6.1	   6.5	   1.22	   1.17	  
Morc3	   ENSRNOG00000026236	   2.9	   10.0	   11.0	   11.0	   15.2	   14.4	   13.1	   12.4	   1.15	   1.17	  
Calu	   ENSRNOG00000006197	   23.3	   44.7	   95.0	   98.8	   115.8	   116.1	   100.8	   100.5	   1.13	   1.17	  
Plcg1	   ENSRNOG00000016340	   4.8	   12.5	   34.5	   37.5	   32.5	   31.2	   36.3	   36.7	   -­‐1.14	   -­‐1.17	  
Hcfc2	   ENSRNOG00000011072	   1.3	   3.3	   3.3	   3.3	   4.4	   4.0	   3.6	   3.4	   1.20	   1.17	  
Auh	   ENSRNOG00000011684	   27.8	   27.3	   31.5	   29.0	   26.3	   24.0	   29.1	   28.2	   -­‐1.12	   -­‐1.17	  
Cd164	   ENSRNOG00000000304	   356.2	   140.8	   122.0	   145.7	   116.8	   113.4	   128.4	   133.3	   -­‐1.12	   -­‐1.16	  
Dapk2	   ENSRNOG00000017332	   3.8	   27.5	   53.8	   54.2	   48.6	   43.8	   55.6	   51.5	   -­‐1.16	   -­‐1.16	  
Anapc4	   ENSRNOG00000004130	   3.9	   17.5	   18.9	   20.4	   17.6	   16.2	   19.3	   19.0	   -­‐1.11	   -­‐1.16	  
Qsox2	   ENSRNOG00000018574	   0.8	   3.3	   4.1	   4.3	   5.5	   5.8	   4.6	   5.0	   1.16	   1.16	  
Mt-­‐nd4	   ENSRNOG00000029707	   6788.6	   6674.7	   4282.1	   5036.8	   3767.4	   3894.4	   4592.7	   4570.9	   -­‐1.24	   -­‐1.16	  
Kxd1	   ENSRNOG00000019971	   15.2	   26.0	   18.6	   18.2	   22.9	   23.6	   19.6	   20.5	   1.15	   1.16	  
Hnrnpul2	   ENSRNOG00000019507	   11.9	   25.1	   37.3	   33.7	   45.6	   46.2	   40.2	   40.1	   1.12	   1.16	  
Cdk2ap2	   ENSRNOG00000018391	   43.1	   36.8	   25.1	   30.0	   35.2	   32.6	   26.5	   28.3	   1.31	   1.16	  
Ublcp1	   ENSRNOG00000004477	   3.9	   15.1	   15.5	   16.3	   13.3	   13.5	   15.6	   15.8	   -­‐1.18	   -­‐1.16	  
Strap	   ENSRNOG00000007134	   14.1	   48.9	   34.3	   34.0	   43.5	   39.2	   36.6	   34.1	   1.17	   1.16	  
Dnajc11	   ENSRNOG00000008802	   6.8	   19.1	   15.0	   15.2	   19.0	   19.8	   16.4	   17.2	   1.14	   1.16	  
St3gal4	   ENSRNOG00000009850	   2.6	   5.8	   16.1	   15.2	   23.3	   21.6	   19.9	   18.8	   1.15	   1.16	  
Polr1b	   ENSRNOG00000018349	   1.3	   5.2	   3.3	   2.9	   4.3	   3.8	   3.5	   3.3	   1.18	   1.16	  
Morc2	   ENSRNOG00000019624	   1.1	   3.4	   5.9	   6.3	   7.4	   7.7	   6.5	   6.7	   1.11	   1.16	  
Samd4a	   ENSRNOG00000010489	   1.8	   16.9	   12.7	   12.5	   11.1	   10.6	   12.5	   12.4	   -­‐1.14	   -­‐1.16	  
Ccdc53	   ENSRNOG00000005102	   16.0	   29.4	   24.4	   27.6	   19.7	   20.8	   22.4	   24.3	   -­‐1.15	   -­‐1.16	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Gyg1	   ENSRNOG00000011146	   3.1	   19.6	   24.9	   26.6	   21.3	   21.2	   24.7	   24.8	   -­‐1.18	   -­‐1.16	  
Pde12	   ENSRNOG00000013264	   1.9	   6.9	   5.4	   5.2	   7.4	   7.1	   6.1	   6.2	   1.19	   1.16	  
Pkn3	   ENSRNOG00000025892	   1.7	   7.7	   8.8	   8.4	   11.2	   11.0	   9.7	   9.7	   1.13	   1.15	  
Cnp	   ENSRNOG00000017496	   2.2	   24.5	   26.9	   28.3	   24.0	   23.3	   26.0	   27.2	   -­‐1.10	   -­‐1.15	  
Tbc1d9b	   ENSRNOG00000003050	   4.0	   12.4	   13.2	   12.9	   12.0	   10.9	   13.3	   12.6	   -­‐1.12	   -­‐1.15	  
Rpia	   ENSRNOG00000005576	   1.3	   5.3	   7.2	   7.6	   10.3	   9.6	   8.8	   8.4	   1.15	   1.15	  
Fundc1	   ENSRNOG00000003470	   3.6	   8.3	   9.7	   9.9	   7.7	   7.5	   9.2	   8.7	   -­‐1.21	   -­‐1.15	  
Kif1c	   ENSRNOG00000031364	   13.9	   68.9	   101.8	   108.4	   96.0	   91.8	   108.9	   106.7	   -­‐1.15	   -­‐1.15	  
Inpp5k	   ENSRNOG00000004041	   3.1	   9.9	   11.4	   13.8	   10.6	   10.4	   11.8	   12.1	   -­‐1.14	   -­‐1.15	  
Hnrnpk	   ENSRNOG00000019113	   58.2	   119.2	   169.7	   159.0	   200.4	   202.8	   181.1	   177.9	   1.09	   1.15	  
Eif4e	   ENSRNOG00000013183	   8.7	   25.7	   27.3	   27.0	   32.0	   33.3	   28.7	   29.2	   1.10	   1.15	  
Baz1b	   ENSRNOG00000001453	   3.2	   4.8	   9.1	   8.8	   12.9	   11.5	   10.5	   10.1	   1.21	   1.15	  
Mak16	   ENSRNOG00000010783	   2.2	   8.9	   10.6	   10.5	   14.0	   14.0	   12.4	   12.3	   1.11	   1.15	  
Med6	   ENSRNOG00000006976	   4.7	   15.9	   14.8	   15.5	   17.9	   18.6	   14.9	   16.4	   1.18	   1.15	  
Gmcl1	   ENSRNOG00000017838	   4.1	   7.1	   10.9	   11.5	   9.5	   9.1	   10.8	   10.6	   -­‐1.16	   -­‐1.15	  
Pld2	   ENSRNOG00000019604	   0.1	   5.3	   7.2	   7.7	   6.7	   6.2	   7.7	   7.2	   -­‐1.16	   -­‐1.15	  
Dnajc22	   ENSRNOG00000015837	   42.2	   39.1	   24.7	   25.2	   29.3	   28.5	   26.0	   25.1	   1.11	   1.15	  
Bcl3	   ENSRNOG00000043416	   4.3	   18.9	   13.9	   14.7	   21.5	   19.4	   17.1	   17.1	   1.24	   1.15	  
Tmem168	   ENSRNOG00000006690	   7.0	   12.5	   11.5	   11.6	   13.7	   14.6	   12.0	   12.8	   1.13	   1.15	  
Zfp637	   ENSRNOG00000023065	   4.1	   20.2	   19.1	   19.1	   14.6	   14.7	   17.6	   17.0	   -­‐1.23	   -­‐1.14	  
Galk2	   ENSRNOG00000009289	   5.4	   12.0	   18.0	   17.6	   15.5	   15.1	   17.3	   17.5	   -­‐1.13	   -­‐1.14	  
Ilf3	   ENSRNOG00000022741	   2.7	   8.5	   12.4	   12.6	   15.9	   16.1	   13.6	   14.2	   1.15	   1.14	  
Enoph1	   ENSRNOG00000002262	   3.2	   13.3	   14.3	   14.9	   17.5	   17.2	   15.4	   15.2	   1.12	   1.14	  
Trappc8	   ENSRNOG00000022202	   6.2	   6.4	   8.0	   8.0	   9.6	   10.1	   8.0	   8.9	   1.17	   1.14	  
Pkn1	   ENSRNOG00000004131	   3.4	   12.4	   15.3	   14.5	   12.9	   11.7	   14.5	   13.4	   -­‐1.14	   -­‐1.14	  
Acsl1	   ENSRNOG00000010633	   528.6	   33.4	   47.2	   36.3	   33.9	   30.8	   39.2	   35.4	   -­‐1.17	   -­‐1.14	  
Nup54	   ENSRNOG00000002247	   2.5	   9.1	   10.1	   10.4	   13.3	   12.6	   11.1	   11.1	   1.18	   1.14	  
Rab11fip1	   ENSRNOG00000045531	   0.7	   5.9	   6.4	   5.9	   7.2	   6.9	   6.3	   6.2	   1.11	   1.14	  
Mt-­‐nd5	   ENSRNOG00000029971	   1855.6	   2029.4	   1557.7	   1728.2	   1490.3	   1420.7	   1686.5	   1628.3	   -­‐1.15	   -­‐1.14	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Eif4a3	   ENSRNOG00000045791	   14.0	   41.5	   46.4	   45.9	   56.3	   56.2	   48.9	   50.0	   1.13	   1.13	  
Syncrip	   ENSRNOG00000000204	   6.8	   18.8	   24.6	   22.3	   30.4	   28.0	   26.4	   24.9	   1.13	   1.13	  
Eps15l1	   ENSRNOG00000013502	   1.9	   6.3	   10.7	   11.2	   9.8	   9.8	   11.2	   11.2	   -­‐1.16	   -­‐1.13	  
Grpel2	   ENSRNOG00000042682	   2.6	   4.2	   7.0	   6.7	   9.4	   9.2	   7.9	   8.2	   1.17	   1.13	  
Ankh	   ENSRNOG00000010960	   22.2	   15.2	   23.1	   21.9	   18.1	   18.2	   21.3	   20.8	   -­‐1.20	   -­‐1.13	  
Ryk	   ENSRNOG00000008593	   6.8	   22.1	   28.6	   29.5	   26.7	   26.3	   28.8	   30.0	   -­‐1.10	   -­‐1.13	  
Sdr39u1	   ENSRNOG00000020544	   12.0	   12.6	   11.3	   14.0	   10.7	   10.8	   12.1	   12.3	   -­‐1.15	   -­‐1.13	  
Adprhl2	   ENSRNOG00000010849	   5.0	   24.4	   22.3	   24.0	   28.8	   28.6	   23.6	   25.6	   1.20	   1.13	  
Fkbp1a	   ENSRNOG00000008822	   41.6	   240.1	   283.6	   283.7	   255.6	   256.3	   280.8	   291.4	   -­‐1.12	   -­‐1.13	  
Gramd1a	   ENSRNOG00000021106	   2.0	   4.9	   10.5	   11.2	   10.2	   9.7	   11.4	   11.0	   -­‐1.13	   -­‐1.12	  
Smarcd1	   ENSRNOG00000034268	   0.7	   3.7	   6.1	   7.0	   5.4	   5.5	   6.6	   6.2	   -­‐1.24	   -­‐1.12	  
Stau1	   ENSRNOG00000007781	   16.0	   22.3	   23.0	   25.4	   21.5	   21.4	   23.3	   24.2	   -­‐1.10	   -­‐1.12	  
Ufm1	   ENSRNOG00000038176	   12.4	   20.7	   13.4	   14.1	   15.7	   15.8	   13.8	   14.2	   1.12	   1.12	  
LOC100365902	   ENSRNOG00000025383	   12.6	   22.5	   32.7	   33.1	   29.6	   27.8	   32.9	   31.4	   -­‐1.13	   -­‐1.12	  
Pex1	   ENSRNOG00000025991	   9.1	   5.7	   6.6	   6.9	   5.9	   5.8	   6.4	   6.6	   -­‐1.10	   -­‐1.12	  
Cpox	   ENSRNOG00000001654	   20.4	   24.8	   17.7	   16.7	   20.3	   19.7	   18.3	   17.8	   1.09	   1.12	  
Lrpprc	   ENSRNOG00000005877	   19.5	   22.6	   19.5	   17.0	   23.4	   21.5	   20.7	   19.4	   1.11	   1.12	  
Psmd5	   ENSRNOG00000018809	   11.9	   44.4	   25.2	   27.7	   34.0	   32.6	   28.2	   29.5	   1.19	   1.11	  
Tmem127	   ENSRNOG00000022727	   3.8	   8.8	   13.3	   14.3	   11.5	   11.9	   13.3	   13.4	   -­‐1.18	   -­‐1.11	  
Ftsj3	   ENSRNOG00000009857	   2.8	   25.9	   16.2	   16.2	   20.8	   19.5	   18.4	   17.6	   1.11	   1.11	  
Fbxo11	   ENSRNOG00000016396	   2.5	   7.1	   12.0	   13.5	   10.6	   10.9	   12.9	   12.3	   -­‐1.23	   -­‐1.11	  
Cfl2	   ENSRNOG00000045892	   12.5	   55.4	   81.3	   76.2	   69.3	   66.0	   79.1	   74.1	   -­‐1.16	   -­‐1.11	  
Armc1	   ENSRNOG00000013253	   8.7	   7.4	   6.9	   8.0	   9.4	   8.9	   7.9	   8.1	   1.18	   1.11	  
Mgat2	   ENSRNOG00000004234	   9.3	   14.6	   14.8	   16.4	   19.6	   18.6	   16.1	   16.9	   1.20	   1.11	  
Rchy1	   ENSRNOG00000002546	   6.4	   14.2	   13.7	   13.5	   15.7	   14.4	   13.2	   13.0	   1.17	   1.11	  
Stxbp3	   ENSRNOG00000020392	   7.2	   14.0	   16.6	   17.4	   14.7	   15.3	   16.6	   17.0	   -­‐1.15	   -­‐1.10	  
Gnai3	   ENSRNOG00000019465	   28.5	   77.2	   63.9	   65.8	   75.1	   77.4	   68.7	   70.7	   1.08	   1.10	  
RGD1566359	   ENSRNOG00000047934	   3.8	   11.8	   17.8	   18.0	   16.3	   16.5	   18.3	   18.4	   -­‐1.15	   -­‐1.10	  
Dennd5a	   ENSRNOG00000012206	   3.0	   15.5	   27.3	   29.0	   25.1	   25.0	   28.0	   27.8	   -­‐1.13	   -­‐1.10	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Msantd4	   ENSRNOG00000022245	   6.7	   12.1	   11.9	   14.1	   11.0	   11.6	   12.1	   12.9	   -­‐1.11	   -­‐1.10	  
Sav1	   ENSRNOG00000005264	   2.7	   8.0	   10.4	   11.6	   10.0	   10.7	   11.2	   11.9	   -­‐1.13	   -­‐1.10	  
Ncstn	   ENSRNOG00000005355	   13.2	   21.1	   29.4	   32.4	   28.1	   29.0	   30.4	   32.2	   -­‐1.10	   -­‐1.10	  
Brd7	   ENSRNOG00000014419	   12.0	   26.0	   29.2	   29.0	   35.2	   34.6	   31.9	   31.7	   1.09	   1.10	  
Zdhhc16	   ENSRNOG00000046530	   3.8	   13.3	   14.8	   16.6	   13.5	   13.7	   14.6	   15.2	   -­‐1.10	   -­‐1.10	  
Kifap3	   ENSRNOG00000002544	   2.4	   11.1	   15.0	   16.8	   13.1	   13.6	   14.9	   15.0	   -­‐1.15	   -­‐1.10	  
Micu2	   ENSRNOG00000011168	   10.0	   28.5	   30.0	   31.0	   27.9	   27.1	   29.8	   29.8	   -­‐1.08	   -­‐1.09	  
Os9	   ENSRNOG00000025570	   53.5	   49.0	   70.5	   67.1	   60.3	   58.4	   67.6	   63.4	   -­‐1.14	   -­‐1.08	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 When genes that are differentially expressed in any of the uninfected time-
mediated comparisons were removed, this left a small subset of 16 genes that 
specifically change as a result of HBV expression, but not due to time spent in 
culture (Fig. 20B [yellow and blue overlap], C-D [yellow triangles]). These genes, 
referred to as the "HBV-only" subset, are described in Figure 21. Despite their 
HBV-mediated regulation in this study, none of the 16 DEG in the HBV-only 
subset have been previously shown to be directly regulated by HBV, although 
some of the DEG are within pathways that are regulated by HBV. For example, 
Mdm4 is involved in apoptosis and p53 regulation, both of which have previously 
been associated with HBV replication (reviewed in [101]). Of additional interest 
was the identification of three BPI family B (BPIFB) proteins. These proteins are 
involved in lipid binding and have very low endogenous expression in PRHs, but 
expression increases dramatically in HBV-expressing PRHs. 
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Figure 20. Overall analysis of HBV-mediated changes in gene expression. 
A. Venn diagram of DEG from AdGFP 48 hr to AdHBV 48 hr (blue), AdGFP 72 hr 
to AdHBV 72 hr (yellow), AdGFP 48 hr to AdGFP 72 hr (green) and AdHBV 48 hr 
to AdHBV 72 hr (red) comparisons. B. Venn diagram of DEG from AdGFP 48 hr 
to AdHBV 48 hr (blue), AdGFP 72 hr to AdHBV 72 hr (yellow), and any DEG from 
all Uninfected/time-mediated comparison (green). C-D. HBV-mediated gene 
expression changes were plotted for 48 hr samples (C) and 72 hr samples (D) as 
the log10 RPKM value for genes in AdGFP samples versus the log2 fold change 
compared to AdGFP for genes in the indicated comparison. Yellow diamonds 
indicate DEG in the "HBV-only" subset, red squares represent DEG in the "HBV-
specific" subset, and blue circles represent all DEG in the AdGFP to AdHBV 
comparison at the indicated time point. 
Figure 21. Description of HBV-only subset of differentially expressed genes. Gene name, Ensembl ID, and 
associated protein name are given for genes within the HBV-only subset of genes. Fold changes comparing expression in 
AdGFP to AdHBV at the indicated time points is included, along with a heatmap depicting expression variation (by Z-
score) across all samples. 
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HBV effect on time-mediated changes 
While identifying genes that exhibit expression changes solely due to the 
presence of HBV is of particular interest, simply removing genes that exhibit 
time-dependent expression changes is likely too strict of an exclusion factor (the 
“HBV-only” and “HBV-specific” subsets above). This is because analyzing HBV-
mediated changes in the context of time-dependent changes can also yield 
important information about the cellular impact of HBV replication, which 
becomes apparent when analyzing the 48 hr to 72 hr comparisons across 
treatment types.  
When comparing uninfected cells at 48 hr and 72 hr, 6,698, or 32% of all 
expressed genes, are significantly differentially expressed (Table 2, row 6). The 
same 48 hr to 72 hr comparison in AdGFP-infected cells results in 4% more 
(6,973 total) DEG, which could be partially explained due to sample-to-sample 
variation (Table 2, row 9). In addition, the presence of adenovirus in this system 
could potentially induce some changes in gene expression. Adenovirus can 
activate the innate immune response, along with other cellular pathways, through 
the binding of cell surface receptors (reviewed in [478]), although the minimal 
expression of adenoviral transcripts in our system (Fig. 17) suggests adenovirus 
is not likely having a significant direct effect on the cells.  
In contrast, when examining the AdHBV-infected 48 hr to 72 hr 
comparison (Table 2, row 10), ~16% more genes (7,447 total DEG) were 
differentially expressed than in uninfected cells, and 11% more than in AdGFP-
infected cells. When examining overlap between these three subsets of DEG, 
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Figure 22. HBV-mediated impact on time-mediated differential gene 
expression. A-H. Individual gene expression was plotted as RPKM value over 
time for Uninfected PRHs, AdGFP-infected PRHs, and AdHBV-infected PRHs.
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82% of DEG in uninfected cells between 48 hr and 72 hr were also differentially 
expressed in AdGFP-infected PRHs between 48 hr and 72 hr; however, only 
72% of DEG were shared between uninfected and AdHBV-infected cells in the 
same time comparison. This means that despite the fact that more genes were 
differentially expressed in AdHBV-infected cells, fewer DEG were in common 
with uninfected cells. Overall, these comparisons show that although changes in 
gene expression occur over time in culture, the presence of HBV clearly affects 
the expression of genes that also exhibit time-dependent expression changes.  
To further illustrate the complexity involved in determining the potential 
importance of genes with time-mediated changes in expression in the context of 
HBV infection, we directly examined the expression of a number of cell cycle 
regulatory genes. These genes, including Cyclin A2 (Ccna2), p21 (Cdkn1a), p27 
(Cdkn1b), Cdk1, and Cyclin E1, are each differentially expressed in a time-
mediated fashion in uninfected cells (Fig. 22). This suggests that the process of 
isolating and plating the cells is likely moving the cells out of G0 and into the 
active cell cycle, with a number of genes either steadily increasing or peaking at 
48 hr after plating. If the cells are undergoing cellular changes that are allowing 
them to adapt to culture conditions, as suggested by the large shift in gene 
expression in uninfected cells, altered expression of genes closely involved in 
regulating the cell cycle is expected. When the infected PRHs are considered, 
similar patterns of expression are maintained; however, the level of alteration to 
expression is often more dramatic in the presence of replicating HBV. For 
example, while Ccna2 drops 6.7-fold (from an RPKM of 21.8 to 3.3) between 48 
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hr and 72 hr in AdGFP infected cells, the drop is nearly 15-fold (from an RPKM of 
31.2 to 2) in AdHBV infected cells (Fig. 22A). In uninfected cells, Ccna2 is 
expressed at an RPKM of about 1.5 before increasing up to 17.6 at 48 hr and 
returning down to 3.4 at 72 hr, demonstrating that while there is a distinct time-
mediated pattern of expression for this gene, the presence of HBV has a 
significant impact on gene expression as well. Such HBV-mediated differences 
would be ignored if time-dependent factors serve as exclusion criteria for 
potentially HBV-mediated changes in gene expression. 
Confirmation of differential gene expression 
As validation, an independent RNA-seq experiment was conducted to 
verify the observed HBV-mediated changes to the primary hepatocyte 
transcriptome. This experiment served as a biological replicate to rule out effects 
specific to a single rat or a single preparation of AdHBV or AdGFP (Fig. 23, Table 
7). Although, overall, there were fewer HBV-mediated effects on gene expression 
in the second dataset, a high degree of overlap existed between the two 
datasets. Specifically, of the 547 HBV-mediated DEG at 48 hr in the second 
dataset, 80% (435) were also differentially expressed in the primary dataset in 
the same comparison. Similarly, of the 2,122 DEG at 72 hr in the second dataset, 
70% (1,476) were also differentially expressed in the same comparison in the 
primary dataset (Fig. 24).  
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Figure 23. Secondary RNA-seq dataset overview. A. Euclidean sample 
distance was mapped allowing unbiased ordering of samples based on sample 
similarity. B. Plot of distribution of average RPKM values per sample. 
Table 7. Overview of RNA-sequencing for secondary dataset. 
Sample Total Reads Mapped % Mapped 
Uniquely 
Mapped 
% Unique 
Mapped 
% 
Unmapped 
Multi-mapping 
Reads 
% Multiple 
Mapping 
Total Mappings 
of Reads 
AdGFP 
48 hr 1 62,035,925 54,699,531 88.17% 45,279,986 72.99% 11.83% 9,419,545 15.18% 75,019,296 
AdGFP 
48 hr 2 65,451,761 60,356,560 92.22% 53,126,437 81.17% 7.78% 7,230,123 11.05% 74,599,751 
AdGFP 
48 hr 3 72,267,486 66,252,133 91.68% 58,169,751 80.49% 8.32% 8,082,382 11.18% 81,543,851 
AdGFP 
72 hr 1 73,097,534 68,327,976 93.48% 60,585,755 82.88% 6.52% 7,742,221 10.59% 83,247,054 
AdGFP 
72 hr 2 66,572,995 62,081,699 93.25% 54,839,530 82.38% 6.75% 7,242,169 10.88% 76,977,086 
AdGFP 
72 hr 3 66,903,351 61,813,748 92.39% 54,577,976 81.58% 7.61% 7,235,772 10.82% 76,944,856 
AdHBV 
48 hr 1 54,228,235 50,317,733 92.79% 43,575,294 80.36% 7.21% 6,742,439 12.43% 64,463,333 
AdHBV 
48 hr 2 66,242,876 61,179,224 92.36% 53,795,112 81.21% 7.64% 7,384,112 11.15% 75,013,066 
AdHBV 
48 hr 3 59,761,079 54,826,230 91.74% 47,973,672 80.28% 8.26% 6,852,558 11.47% 68,091,603 
AdHBV 
72 hr 1 68,226,176 62,726,736 91.94% 55,527,851 81.39% 8.06% 7,198,885 10.55% 76,985,743 
AdHBV 
72 hr 2 68,525,390 63,206,866 92.24% 55,804,636 81.44% 7.76% 7,402,230 10.80% 78,067,158 
AdHBV 
72 hr 3 69,793,432 64,649,015 92.63% 56,680,020 81.21% 7.37% 7,968,995 11.42% 82,054,442 
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While the secondary dataset contained only AdGFP- or AdHBV-infected 
PRHs, without uninfected PRHs, a substantial overlap was seen between time-
dependent comparisons in the primary and secondary datasets. When analyzing 
AdGFP-infected or AdHBV-infected cells at 48 hr and 72 hr, 67% of DEG 
identified in the second dataset were also differentially expressed in the first. This 
supports the observation that a specific subset of genes had altered expression 
in a time-dependent manner in addition to any HBV-mediated effects on the 
primary hepatocyte transcriptome. While, overall, there exists a very high degree 
of overlap between these two datasets, much of the variability between these 
sets can likely be attributed to the different cDNA preparation kits used to create 
the respective cDNA libraries prior to sequencing (See Materials and Methods). 
The method used for cDNA library preparation has previously been shown to 
influence downstream results [479], although the two kits used for these datasets 
are primarily based on similar concepts, allowing an overall high level of 
agreement between the two datasets. 
The overlap between these two datasets is similar to the amount of 
overlap seen when analyzing the primary dataset with multiple differential 
expression analysis pipelines. For example, 76% of DEG between AdGFP- and 
AdHBV-infected cells at 48 hr in the primary dataset were also identified as DEG 
when using edgeR instead of DESeq2 (Figure 25, Table 8). In fact, 55% of DEG 
in the 48 hr comparison were identified as differentially expressed in all four 
pipelines used (Figure 25). Importantly, of the 16 genes identified as being 
regulated specifically by HBV in the primary dataset, 13/16 were DEG in the 
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BWA pipeline, 15/16 were DEG in the edgeR pipeline, and 12/16 were DEG in 
the Tuxedo pipeline. Overall, the overlap between the primary and secondary 
dataset and the identification of DEG by multiple pathways support the finding 
that HBV is having a significant impact on hepatocyte gene expression. 
Figure 24. Confirmation of differential gene expression by independent 
RNA-seq. A-D. Venn diagrams indicating DEG overlap between primary (light) 
and secondary (dark) datasets for AdHBV to AdGFP at 48 hr (A) and 72 hr (B), 
AdGFP 48 hr to 72 hr, and AdHBV 48 hr to 72 hr (D). Percent overlap indicated 
represents number of DEG identified in secondary dataset that are also 
differentially expressed in the primary dataset. 
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Figure 25. Confirmation of differential gene expression by multiple analysis 
pipelines. A-B. Venn diagram indicating overlap of differentially expressed genes 
identified using the STAR -> DESeq2 pathway, STAR -> edgeR pipeline, BWA -> 
DESeq2, or Tuxedo suite. Comparisons are for DEG identified between AdGFP-
infected or AdHBV-infected PRHs at 48 hr (A) or 72 hr (B). 
A.# AdHBV#48hr#to#AdGFP#48hr#
B.# AdHBV#48hr#to#AdGFP#72hr#
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Table 8. Comparison of differential gene expression analysis pipelines. 
STARè 
DESeq2 STAR è  EdgeR BWA è  DESeq2 
TopHat è  
Cufflinks 
DEG 
DEG ≥ 
2-fold 
change 
DEG 
DEG ≥ 
2-fold 
change 
DEG 
DEG ≥ 
2-fold 
change 
DEG 
DEG ≥ 
2-fold 
change 
HBV 48 hr to 
GFP 48 hr 3323 115 2816 192 3255 133 2914 127 
HBV 72 hr to 
GFP 72 hr 5070 512 4867 713 5159 571 4371 439 
GFP 48 hr to 
GFP 72 hr 6973 1814 6904 2024 7122 1908 5575 1274 
HBV 48 hr to 
HBV 72 hr 7447 1899 7240 2018 7519 1855 6067 1473 
Pathway analysis 
To analyze cellular pathways impacted by HBV, we utilized the 
iPathwayGuide analysis tool, which identifies differentially regulated pathways, 
biological functions, and cellular processes using an "Impact Analysis". This 
analysis scores pathway impact based on overrepresentation of DEG as well as 
the impact of differential expression of a gene across all of the annotated 
interactions of the gene [460]. A number of cellular pathways or biological 
functions previously associated with HBV replication were identified as being 
altered in the presence of HBV (Table 9). As expected based on the differential 
expression analysis described above, cell cycle and related cellular processes 
were some of the most impacted cellular processes. This result is of particular 
interest because of the well-established role of cell cycle regulation in HBV 
replication. While some cell cycle-related processes were altered at both time 
points, the impact of HBV on the cell cycle was most obvious at the earlier 
infection time-point (48 hr). On the other hand, metabolic processes were also 
significantly impacted by HBV, but more so at the later infection time point (72 
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hr), when pathways and processes including PI3K/Akt signaling, and lipid and 
amino acid metabolism were significantly perturbed. HBV-mediated disruption of 
metabolic pathways has been previously shown by RNA-seq analyses in multiple 
model systems [244, 480]. 
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Table 9. HBV-mediated pathway perturbation 
Pathway	   p-­‐value	  at	  48	  hr	   p-­‐value	  at	  72h	  
ECM-­‐receptor	  interaction	   0.068	   <	  0.001	  
Central	  carbon	  metabolism	  in	  cancer	   0.167	   <	  0.001	  
Carbon	  metabolism	   0.143	   <	  0.001	  
Nitrogen	  metabolism	   0.434	   0.001	  
Butanoate	  metabolism	   0.538	   0.002	  
Metabolic	  pathways	   0.654	   0.002	  
Glycolysis	  /	  Gluconeogenesis	   NA	   0.002	  
PI3K-­‐Akt	  signaling	  pathway	   0.038	   0.002	  
Biosynthesis	  of	  amino	  acids	   0.013	   0.002	  
Glycine,	  serine	  and	  threonine	  metabolism	   0.010	   0.004	  
Taurine	  and	  hypotaurine	  metabolism	   NA	   0.004	  
Bile	  secretion	   0.104	   0.004	  
Focal	  adhesion	   0.021	   0.004	  
Galactose	  metabolism	   NA	   0.005	  
Aminoacyl-­‐tRNA	  biosynthesis	   0.244	   0.006	  
Arginine	  and	  proline	  metabolism	   0.563	   0.006	  
Hematopoietic	  cell	  lineage	   0.022	   0.007	  
Fructose	  and	  mannose	  metabolism	   0.666	   0.007	  
Amoebiasis	   0.691	   0.009	  
Glycosphingolipid	  biosynthesis	   0.306	   0.009	  
Glycosphingolipid	  biosynthesis	   0.410	   0.009	  
Glycosphingolipid	  biosynthesis	   0.410	   0.009	  
Drug	  metabolism	   0.539	   0.010	  
Calcium	  signaling	  pathway	   0.127	   0.010	  
Neuroactive	  ligand-­‐receptor	  interaction	   0.168	   0.012	  
Tryptophan	  metabolism	   NA	   0.013	  
Small	  cell	  lung	  cancer	   0.086	   0.017	  
PPAR	  signaling	  pathway	   0.415	   0.019	  
Rap1	  signaling	  pathway	   0.853	   0.024	  
Insulin	  secretion	   0.490	   0.026	  
Glycosphingolipid	  biosynthesis	   0.306	   0.026	  
Glycosphingolipid	  biosynthesis	   0.410	   0.026	  
Glycosphingolipid	  biosynthesis	   0.410	   0.026	  
Maturity	  onset	  diabetes	  of	  the	  young	   0.341	   0.031	  
Cytokine-­‐cytokine	  receptor	  interaction	   0.570	   0.033	  
Retinol	  metabolism	   0.123	   0.038	  
Alanine,	  aspartate	  and	  glutamate	  metabolism	   0.083	   0.040	  
Inflammatory	  mediator	  regulation	  of	  TRP	  channels	   0.942	   0.041	  
Cholinergic	  synapse	   0.140	   0.042	  
Pathways	  in	  cancer	   0.033	   0.043	  
Glycosphingolipid	  biosynthesis	   0.306	   0.043	  
185 
Glycosphingolipid	  biosynthesis	   0.410	   0.043	  
Glycosphingolipid	  biosynthesis	   0.410	   0.043	  
Butirosin	  and	  neomycin	  biosynthesis	   NA	   0.045	  
Cyanoamino	  acid	  metabolism	   0.150	   0.045	  
Valine,	  leucine	  and	  isoleucine	  biosynthesis	   0.150	   0.045	  
Glutathione	  metabolism	   0.244	   0.046	  
Vascular	  smooth	  muscle	  contraction	   0.179	   0.048	  
Protein	  digestion	  and	  absorption	   0.004	   0.053	  
Dilated	  cardiomyopathy	   0.044	   0.111	  
Hypertrophic	  cardiomyopathy	  (HCM)	   0.030	   0.153	  
Arrhythmogenic	  right	  ventricular	  cardiomyopathy	  (ARVC)	   0.036	   0.281	  
MicroRNAs	  in	  cancer	   <	  0.001	   0.339	  
Fanconi	  anemia	  pathway	   0.010	   0.460	  
Bladder	  cancer	   0.028	   0.520	  
p53	  signaling	  pathway	   0.007	   0.738	  
*NA represents pathways that had no differentially expressed genes in this comparison
*Blue highlighted pathways are significant in both comparisons
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Chapter 6. Results: Analysis of HBV-mediated metabolomic changes 
187 
HBV has been referred to as a "metabolovirus" due to its close 
relationship with the metabolic pathways of the liver[229]. In an attempt to 
determine the early metabolic changes induced by HBV we performed 
metabolomic profiling of PRHs infected with AdGFP, AdGFP-HBV, or AdGFP-
HBx. Eight replicates per data point were derived from 2 individual rat livers, with 
PRHs infected with recombinant adenoviruses 24 hr after plating of cells. PRHs 
were collected 48 hr and 72 hr after plating (24 hr and 48 hr after infection) for 
analysis of a panel of 369 known biochemicals (Fig. 26).  
The effective use of the PRH model has previously been shown, with 
detection of HBV replication as early as 24 hr after infection (described above 
and in [2, 29, 30]), and reproducibility of results in primary human hepatocytes 
[82, 167]. For these studies, low levels of GFP expression were visible at 48 hr, 
with a dramatic increase in GFP expression 72 hr, showing an infection efficiency 
of ~90% (Fig. 27). These infection kinetics were similar across all samples, and 
in both rats (data not shown). 
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Figure 26. Experimental flowchart for metabolomic profiling. 
Rat 1 Rat 2 
AdGFP AdHBV AdHBx 24hr after 
plating 
48hr after 
plating 
72hr after 
plating 
Collect Cells 
Collect Cells 
Metabolomic Analysis 
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Figure 27. Recombinant adenovirus infection of primary rat hepatocytes. 
GFP expression was monitored in PRHs to confirm equal infection efficiency 
across samples. Images are representative of all samples across treatment-type. 
AdGFP 
Uninfected 
AdHBV 
AdHBx 
48hr 72hr Time Point 
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Overview of Metabolomic Profiling Study 
A principle component analysis of the dataset showed a hierarchy of 
variables influencing the clustering of the data, such that the two replicate rats 
represented the primary variable, with individual time points as the secondary 
component, and treatment type (AdGFP, AdGFP-HBV, AdGFP-HBx) as the 
tertiary component (Fig. 28). This distribution is not unexpected, as samples 
were isolated from outbred rats and rat-to-rat variability is to be expected. In 
addition, differences between hepatocytes based on time spent in culture has 
previously been shown [470, 481], and correlates well with our PRH 
transcriptome data demonstrating that time in culture causes changes in gene 
expression (described in Chapter 5). It is important, therefore, to consider that 
the experimental system used for these studies presents a confounding factor in 
data interpretation. Previous studies, along with our transcriptome data, however, 
have demonstrated the utility of this system and its biological relevance [29, 30, 
82, 167].  
In confirmation of the PCA analysis, when comparing the same treatment 
type samples at 48 hr and 72 hr, significant numbers of metabolites are changed. 
For example, in AdGFP-expressing PRHs 152 biochemicals were significantly 
changed, with a p-value ≤ 0.05. In addition, another 19 metabolites were 
approaching significance, with a p-value between 0.05 and 0.10. Of these 171 
biochemicals, 119 were decreased while 52 were increased. For HBV-expressing 
PRHs, 174 metabolites were significantly altered, with 31 approaching 
significance. 126 of these were decreased, while 79 were increased. 
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Interestingly, HBx-expressing PRHs had a similar number of altered metabolites 
(167 significantly changed, 27 approaching significance), but the pattern of 
regulation was drastically different. Unlike control and HBV-expressing PRHs 
where the majority of altered metabolites were decreased, 136 metabolites were 
increased, while only 58 were decreased (Table 10).  
Figure 28. 3D principle component analysis of the metabolomic dataset. 
48h 
48h 
48h 
72h 
72h 
72h 
 Table 10. Time-mediated changes to hepatocyte metabolome. 
 
Table 11. Treatment-mediated changes to hepatocyte metabolome. 
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Similar to the results of the transcriptome analysis, while additional 
confounding factors exist (i.e. rat, time), significant differences are still identifiable 
between control and HBV- or HBx-expressing PRHs. Specifically, at 48 hr 47 
metabolites were significantly different between HBV-expressing and control 
PRHs with 15 approaching significance. 46 of these were higher in HBV-
expressing PRHs, while 16 were higher in control PRHs. Similarly, HBx-
expressing PRHs had 28 metabolites significantly altered compared to control, 
with another 23 nearly significant. While HBV-expression increased the majority 
of the altered metabolites, HBx decreased 38 metabolites while increasing only 
13. At 72 hr, HBV significantly altered 139 metabolites, with an extra 43 nearing
significance. Of these, 118 were increased and 64 were decreased between HBV 
and control PRHs. For HBx-expressing PRHs, 149 metabolites had significant 
changes, plus an additional 35 that were nearly significant. 153 were increased in 
HBx-expressing PRHs, while only 31 were decreased in HBx-expressing PRHs 
(Table 11).  Interestingly, of the 47 metabolites altered by HBV at 48 hr, 31 were 
also altered by HBV at 72 hr.   
Although it could be inferred from the comparisons to control PRHs, it was 
interesting to compare metabolite changes between HBV- and HBx-expressing 
PRHs. At 48 hr , 41 metabolites, with an additional 29 nearly significant, were 
altered in this comparison. Interestingly, only 3 of these 70 metabolites were 
increased in HBx-expressing cells. This directional regulation is not as dramatic 
at 72 hr, when there were 131 metabolites significantly altered and 29 nearing 
significance. Of these 160 metabolites, 115 were higher in HBx-expressing cells.  
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In a broader investigation of altered metabolite expression, the potential 
overall scale of HBV- or HBx-mediated regulation becomes apparent. In the 
dataset there are 9 relevant comparisons for each of the 369 biochemicals 
(AdGFP 48 hr vs AdGFP 72 hr, AdHBV 48 hr vs AdHBV 72 hr, AdHBx 48 hr vs 
AdHBx 72 hr, AdHBV 48 hr vs AdGFP 48 hr, AdHBx 48 hr vs AdGFP 48 hr, 
AdHBx 48 hr vs AdHBV 48 hr, AdHBV 72 hr vs AdGFP 72 hr, AdHBx 72 hr vs 
AdGFP 72 hr, and AdHBx 72 hr vs AdHBV 72 hr), resulting in a total 3,321 total 
comparisons. Within these comparisons across both time and treatment type, 
only 242 (~7%) metabolites had a ≥ 2-fold change up or down, despite the fact 
that 1,028 (31%) were statistically significantly altered. This could be the result of 
the short timeframe of the studies, or reflect broader implications of the moderate 
changes induced by HBV. In fact, when this distribution is broken down further, 
145 of these ≥ 2-fold changes (60%) are within the time-mediated comparisons, 
despite these comparisons making up only a third of the total dataset. HBV-
mediated changes account for 29 of the ≥ 2-fold changes (12%), and HBx-
mediated changes account for 34 of the ≥1.5-fold changes (14%), with HBV- to 
HBx-expressing cells making up the remaining comparisons. This means, as 
suggested by the PCA plot (Fig. 28), that HBV- and HBx-mediated changes are 
identifiable, but occur on a smaller scale than those seen in time-mediated 
comparisons.  
Together, these results demonstrate that within the analysis variables in 
the dataset (i.e. time, treatment type), significant changes to the metabolomic 
profile are occurring. These results also suggest a potentially interesting 
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differential regulation of metabolites between HBV and HBx. For example, when 
comparing within treatment groups over time, AdGFP- and AdGFP-HBV-infected 
PRHs have similar patterns of time-mediated changes, with 70% and 61% of 
metabolites decreased between 48 hr and 72 hr. AdGFP-HBx-infected cells, on 
the other hand have a profile that is nearly the opposite of the other treatment 
types, with 30% of metabolites decreased, and 70% increased. This difference 
between HBV- and HBx-expressing cells could be the result of specific HBx-
mediated effects due to the potentially over-expressed levels of HBx, or they 
could represent an earlier time point of changes that may also be seen in HBV at 
a later time point once levels of HBx increase to the levels expressed in the 
AdGFP-HBx infection. This would require further investigation to address, 
however, particularly through the use of an HBx-deficient version of the HBV 
genome. 
Pathway analysis of altered metabolites 
Because metabolism is the result of a cascade of biochemical reactions, 
analysis of individual metabolites only offers limited information. Instead, pathway 
analysis of metabolites can generate a clearer picture of the impact of HBV on 
hepatocyte physiology through disruption of specific metabolic pathways. Within 
the metabolome analysis, metabolites were grouped by super pathway and 
subpathway based on Kyoto Encyclopedia of Genes and Genomes (KEGG) 
identifiers. These groupings consisted of 8 super pathways (amino acid, peptide, 
carbohydrate, energy, lipid, nucleotide, cofactors and vitamins, and xenobiotics), 
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with between 2 (peptide and energy) and 28 (lipid) subpathways. Each 
subpathway was made up of between 1 and 31 metabolites, with the large 
majority (85%) containing less than 10. While this means that the dataset offers 
information on a large number of metabolic pathways, it also implies that 
changes to a single metabolite could potentially lead to drastically different 
interpretations of pathway regulation depending on the KEGG designation of the 
metabolite. Because of this, a level of caution should be used when interpreting 
these metabolic changes in the context of their KEGG pathways. 
When interpreting the data in the context of KEGG pathways, obvious 
patterns emerge. For example, the lipid super pathway, which makes up 38% of 
all metabolites in the analysis, had obvious HBV- and HBx-mediated alterations 
across multiple subpathways. At 48 hr, 26 significantly altered metabolites were 
increased in HBV-expressing PRHs, while 4 were decreased; at 72 hr 68 were 
increased and 6 were decreased. Specifically, of the 14 metabolites in the long 
chain fatty acid subpathway, only 3 were not significantly altered by HBV at 48 hr 
, and all three of these were altered at 72 hr. Interestingly, HBx-expressing PRHs 
had only one metabolite in the long chain fatty acid subpathway, myristate, which 
was significantly altered at 48 hr. By 72 hr all but 2 of the 14 metabolites were 
significantly altered. Similarly, the polyunsaturated fat subpathway, which 
contains 12 metabolites, had 9 metabolites significantly altered in HBV-
expressing cells at 48 hr and 7 at 72 hr, with all altered metabolites increased. 
Interestingly, HBx demonstrated delayed metabolite regulation compared to 
HBV-expressing cells, with 0 significant alterations at 48 hr, but 9 out of 12 
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altered at 72 hr. A similar pattern of delayed kinetics in HBx-expressing PRHs 
was seen in the long chain fatty acid subpathway. Together, these results imply 
that HBV- and HBx-mediated alterations to the metabolites in each of these 
pathways results in an increased pool of free fatty acids, potentially through 
increased uptake or synthesis of these metabolites.  
Other subpathways within the lipid super pathway were also altered, 
including the largest subpathway in the dataset, phospholipid metabolism. 
Interestingly, within this subpathway only minimal regulation was seen at 48 hr. 
HBV-expressing PRHs had only 2 out of 31 metabolites increased, while HBx-
expressing cells had 3 altered metabolites, though they were all decreased. At 72 
hr however, HBV-expressing PRHs had 11 significantly increased and 2 
significantly decreased metabolites. For HBx, biochemical alteration was even 
more dramatic, with 23 of 31 metabolites involved in phospholipid metabolism 
increased at 72 hr. This regulation of phospholipid metabolism could imply 
increased membrane biosynthesis, however, these lipids also play important 
roles in other pathways.  For example, phosphatidylserine in plays an important 
role in apoptosis, and phosphatidylinositol-generated second messengers are 
crucial in the PI3K/Akt pathway and calcium signaling [482]. 
Another important subpathway involved in lipid signaling is the 
sphingolipid pathway. This subpathway is altered in both HBV- and HBx-
expressing cells and contains metabolites, including the sphingomyelins, which 
are an important component of lipid membranes [482]. Similar to phospholipid 
metabolism, this pathway seems to be altered more at 72 hr, with only limited 
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alteration at 48 hr. The similar regulation of these two pathways could represent 
their similar roles in lipid membrane formation, or activation of similar signaling 
pathways that involve both lipid classes, such as apoptosis [482].  The recently 
described requirement for cellular lipids in viral envelope formation and infection 
of hepatocytes [483, 484] underscores the importance of understanding how 
these HBV-mediated alterations to lipid pathways may contribute to HBV 
replication. 
While the lipid super pathway contains the most subpathways and 
metabolites, and therefore the most opportunity for analysis, other pathways also 
showed interesting treatment-mediated regulation. In particular, the carbohydrate 
super pathway contained multiple subpathways with HBV- or HBx-mediated 
metabolite regulation. For example, HBx-expressing cells showed an increase in 
6 out of 11 glycolysis intermediates at 72 hr, including glucose, glucose-6-
phosphate, and frucose-6-phosphate (Fig. 29). HBx-expressing cells also 
demonstrated increased intermediates of the pentose phosphate pathway (PPP) 
at 72 hr, and both HBV-expressing and HBx-expressing cells exhibited increased 
glycogen metabolism at both 48 hr and 72 hr (Fig. 30).  
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FIgure 29. HBV- and HBx-mediated alteration of glycolysis and 
gluconeogenesis. Comparison of levels of metabolites associated with 
glycolysis/gluconeogenesis in the metabolomic profile of AdHBV- or AdHBx-
infected PRHs. 
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Figure 30. HBV- and HBx-mediated alteration of glycogen metabolism. 
Comparison of levels of metabolites associated with glycogen metabolism in the 
metabolomic profile of AdHBV- or AdHBx-infected PRHs. 
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 Perhaps as interesting as the altered regulation of these subpathways in 
the carbohydrate super pathway is the general lack of regulation of the 
metabolites associated with the TCA cycle in the energy superfamily. Of the 6 
TCA cycle-classified metabolites, none exhibited HBV-mediated regulation at 48 
hr, and only citrate and succinate were increased at 72 hr. HBx-expressing PRHs 
had one metabolite (citrate) decreased at 48 hr, but this metabolite was then 
increased at 72 hr. HBx-expressing PRHs did exhibit increased metabolites 
associated with oxidative phosphorylation at 72 hr, but this subpathway consisted 
of only 2 metabolites (one of which is phosphate). Together with the data from 
the carbohydrate superpathway, these results suggest that HBV- and HBx-
expressing cells may be altering the energy state of the hepatocyte, and 
potentially shifting cells towards increased glycolysis [482].  
 
Integration of Metabolomic and Transcriptomic data 
 Although this metabolomic analysis allows an informative view of a large 
panel of metabolites, the complicated nature of cellular metabolic processes 
means that further interpretation of this dataset would be required before strong 
conclusions can be drawn. In particular, analyzing the levels of enzymes 
associated with the generation of these factors could give an idea of how 
pathways identified as altered within the metabolome study are being regulated. 
Because of this, we utilized the previously described transcriptome data (Chapter 
5) to attempt to correlate changes in the levels of gene expression to changes in 
the levels of associated metabolites. 
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The initial step in associating these two datasets was to look for pathways 
regulated by HBV in both analyses. Because the gene ontology pathway analysis 
also utilizes KEGG identifiers to organize genes into pathways, it should be 
possible to identify common pathways and correlate the two. For example, one of 
the pathways with the highest perturbation in the transcriptome analysis at 72 hr 
was the glycolysis/gluconeogenesis pathway. At 48 hr, not only was this pathway 
not identified as statistically significantly altered, it wasn't even identified as 
altered at all (Table 9). Similarly, the metabolome dataset only identified 
alterations to the glycolysis/gluconeogenesis subpathway at 72 hr, with minimal 
alterations at 48 hr. While the broad analysis suggests a correlation, the data 
also correlate within this pathway. For example, the third step of glycolysis 
involves the conversion of fructose-6-phosphate to fructose 1,6-bisphosphate by 
the enzyme phosphofructokinase (PFK). Both of these metabolites are increased 
in HBx-expressing cells at 72 hr and trending towards a significant increase in 
HBV-expressing cells, and the gene encoding the liver-specific subunit of 
phosphofructokinase is increased in HBV-expressing cells at 72 hr in the 
transcriptome analysis. 
Similarly, the metabolome data also suggested increased use of the PPP 
by HBx-expressing cells at 72 hr. The oxidative phase of the PPP is the 
conversion of glucose-6-phosphate to ribose 5-phosphate. Both of these 
metabolites are increased by HBx-expressing cells at 72 hr. The initial enzyme in 
this cascade, glucose-6-phosphate dehydrogenase, is also upregulated at 72 hr 
in the transcriptome data. While not significant, there is a trend towards 
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perturbation of the PPP in the transcriptome dataset as well, with a p-value at 72 
hr of 0.06. 
Another pathway identified as perturbed in the transcriptome analysis was 
glutathione metabolism, which was significantly altered at 72 hr . Multiple points 
in the glutathione metabolic pathway were directly altered due to HBV-mediated 
dysregulation of genes, including glucose-6-phosphate dehydrogenase and 
multiple gamma-glutamyltransferases. Similarly, the metabolome results 
suggested alteration of the glutathione metabolism subpathway at 72 hr, with 8 of 
the associated metabolites altered in HBV-expressing PRHs and 6 altered in 
HBx-expressing PRHs. This alteration of glutathione metabolism implied 
increased oxidative stress in HBV- and HBx-expressing PRHs, which has also 
previously been shown in HBV-tg mice [485].  
Analysis of the lipid super family shows similar correlations between the 
metabolome and the transcriptome analyses. Specifically, the PI3K/Akt pathway 
was one of only 6 pathways perturbed at both time points in the transcriptome 
analysis, which correlates with the alteration at 72 hr of the phospholipid 
metabolism subpathway in the metabolome analysis. Another example of lipid 
regulation is HBV-mediated increase in myristate, the substrate for protein 
myristoylation, which correlates well with increased expression of N-
myristoyltransferase, the enzyme responsible for transferring the myristoyl group 
to the glycine residues of targeted proteins. This potential mediation of 
myristoylation by HBV is interesting because of the requirement for myristoylation 
of L-HBsAg in viral binding to NTCP during infection [45, 104].  
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 The observed increase in the pool of free fatty acids in HBV- and HBx-
expressing PRHs could be the result of multiple pathways. For example, it could 
be caused by decreased β-oxidation, which is supported by a significant 
decrease in enzymes associated with β-oxidation in the transcriptome analysis. 
An example of this is the HBV-mediated downregulation at 72 hr of the genes 
encoding the subunits of enoyl-CoA hydratase, the enzyme responsible for 
catalyzing the second step of β-oxidation. The increased pool of free fatty acids 
could also be the result of increased lipogenesis, which is supported by the 
significant increase in sterol regulatory element binding protein 1 (SREBP1) in 
HBV-expressing PRHs in the transcriptome analysis. This transcription factor is a 
main regulator of lipogenesis and fatty acid uptake, and is transcriptionally 
activated by HBx [486]. Fatty acid synthase, and its fatty acid product palmitate, 
are also increased by HBV in the transcriptome and metabolome, respectively. 
Another possible cause for the increased fatty acid pool is increased lipolysis, 
which correlates with increased HBV-mediated expression of G0S2, a 
multifunctional protein involved in regulating the breakdown of fat [476]. 
 Together, the metabolome and transcriptome datasets synergistically 
support the hypothesis that HBV mediates metabolic changes in a hepatocyte, 
likely to optimize the cellular environment for its own replication. The vital role of 
the liver in metabolic pathways means that understanding the role that HBV plays 
in modulating these pathways could be an important step towards understanding 
HBV-associated disease. By analyzing the impact of HBV on a metabolome-wide 
perspective, we are able to generate an understanding of the complex network of 
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biochemical changes induced in an HBV-infected cell, and how these pathways 
communicate to ultimately result in successful viral replication. 
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Chapter 7. Results: Analysis of the interplay between HBV and miRNAs 
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Pathway analysis: miRNAs in cancer 
An interesting result of the iPathwayGuide pathway analysis for the 
hepatocyte transcriptome (Chapter 5) was the identification of "miRNAs in 
cancer" as being altered in HBV-expressing PRHs. This is particularly interesting 
because multiple groups have recently begun to determine the role that miRNAs 
may have in the HBV life cycle and HBV-associated disease, including HBV-
associated HCC (reviewed in [1, 487, 488]). Within the results of these published 
studies, a small subset of miRNAs have been identified more often than others 
as having HBV-mediated changes in expression. One such miRNA is miR-125a, 
an miRNA that was also identified in our iPathwayGuide analysis as a miRNA for 
which a number of its targets exhibited HBV-mediated differential expression. 
Multiple studies have shown up-regulation of miR-125a in HBV-expressing cell 
lines and HBV-infected patient samples [355], and miR-125a has also been 
proposed to inhibit HBV replication either through direct targeting of the HBV 
RNAs or targeting of cellular mRNAs required for HBV replication [410, 411]. The 
iPathwayGuide analysis also showed HBV-mediated regulation of multiple 
members of the let-7 family of tumor suppressor miRNAs. In the normal liver, four 
of the top nine total miRNAs expressed are members of the let-7 family, and 
expression is significantly decreased in undifferentiated cells and cancers, 
including HCC [290]. In addition, expression of the let-7 family exhibits HBV-
mediated regulation [325, 326, 328, 358], in agreement with the effects seen in 
our iPathwayGuide analysis. 
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Quantification of miRNA expression 
In addition to RNA-seq analysis, total RNA from the secondary RNA-seq 
dataset (described in Chapter 5) was used to perform a qPCR analysis of 
expression for a set of 84 liver-enriched miRNAs. As expected, miR-122 had the 
highest average expression across all samples, along with high expression of 
other miRNAs, including multiple let-7 family members and miR-21. Differential 
expression analysis between AdGFP and AdGFP-HBV-infected cells identified 
only minimal HBV-mediated regulation of miRNA expression occurring in our 
system (Fig. 31). Specifically, of the 84 miRNAs examined, only miR-224-5p had 
a ≥ 2-fold change in expression when comparing AdGFP and AdGFP-HBV 
infected cells at 48 hr. Four additional miRNAs had statistically significant (but < 
2-fold) HBV-mediated differential expression at this time point (miR-148b-3p, 
miR-221-3p, miR-222-3p, and miR-378a-3p). These miRNAs correlate well with 
the miRNAs identified by the pathway analysis; all but miR-224-5p were 
considered significantly altered miRNAs in the iPathwayGuide analysis at 72 hr. 
In fact, the pathway analysis showed that miR-378a had the most altered 
targeting of all miRNAs at 72 hr.  
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Figure 31. qPCR analysis of miRNA expression. A-B. Expression of a panel of 
liver-enriched miRNAs was analyzed by qPCR array and plotted to visualize 
differential expression at 48 hr (A) and 72 hr (B) between AdGFP-infected and 
AdGFP-HBV-infected PRHs. Outer diagonal lines indicate a 2-fold change. 
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Interestingly, each of the miRNAs that were altered in the qPCR array has 
an established association with HBV replication or HBV-associated disease. For 
example, miR-224 and miR-148a (which shares a seed sequence with and likely 
targets many of the same mRNAs as miR-148b [489]) are both part of a miRNA 
regulatory network through which HBx regulates levels of PI3K, mTOR, and 
autophagy [365, 368]. Along with regulation by HBx, increased expression of 
miR-224 has been identified as a potential biomarker for the early development 
of HBV-associated HCC [319, 490]. Furthermore, both miR-221 [319, 491] and 
miR-222 [492] undergo HBV-mediated regulation of expression.  
It is important to note that in identifying "miRNAs in cancer" as a 
significantly altered cellular pathway, the iPathway analysis specifically analyzed 
differential expression of miRNA target genes, and not expression of the miRNA 
itself. This implies that the iPathway analysis more specifically assessed the 
function of miRNAs, instead of relying on analysis of miRNA expression levels. 
As technology has improved and allowed methods that characterize profiles of 
multiple RNAs being targeted by multiple miRNAs instead of identification of 
single miRNA-target interactions at a time, it has become important to consider 
the targeting profile of miRNAs, and not just their overall expression level. While 
we demonstrated only minimal HBV-mediated changes to miRNA expression, the 
pathway analysis suggested that HBV could be significantly altering the function 
of specific miRNAs without altering their expression level. This interpretation is 
supported by the identification in the pathway analysis of differential expression 
of target genes associated with miRNAs, such as miR-125a, whose expression 
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level did not change in our qPCR array but has an established link to HBV in the 
literature and our pathway analysis. Previous studies investigating the impact of 
HBV on the profile of miRNA expression using next-generation sequencing on 
HBV-infected liver samples reported only minimal HBV-mediated changes to 
miRNA expression levels [171, 290]. This is contrary to the significant level of 
HBV-mediated changes reported using various cell culture models and 
immortalized cell lines [325, 327, 406] (reviewed in [1]), and further supports the 
use of cultured primary hepatocytes, and our model system, as a more 
biologically relevant model than immortalized cell lines. 
Investigation of Functional miRNAs by CLIP 
In an attempt to identify HBV-mediated changes to the profile of mRNAs 
undergoing miRNA-mediated regulation, we applied newly described techniques 
that utilize next-generation sequencing to identify all of the miRNAs and their 
bound targets in the cell. These techniques, HITS-CLIP and PAR-CLIP, are 
derivations of the CLIP protocol, and take advantage of the ability to cross-link 
RNA binding proteins to their target RNAs, followed by immunoprecipitation of a 
specific protein of interest. By immunoprecipitating the Argonaut proteins, the 
family of RNA-binding proteins that are the primary protein component of RISC, 
these protocols can be used to identify both the miRNAs and target mRNAs 
associated with RISC and therefore involved in miRNA-mediated regulation. 
The CLIP-based protocols are a cascade of steps, with each successive 
step dependent on completion of the previous step. Because of this, optimization 
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of the protocol is presented here in a stepwise fashion. First, we confirmed our 
ability to detect Ago from PRHs using a pan-Ago antibody, which has been 
shown to recognize all 4 human Ago proteins [493]. In addition to detection of 
Ago at the expected size (~95kD), the antibody also recognized radixin (~70kD), 
a cytoskeletal protein previously shown to be recognized by this antibody (Fig. 
32). Importantly, recognition of radixin did not interfere with immunoprecipitation, 
and Ago expression levels were significant enough to detect after 
immunoprecipitation. This was shown by the presence of a strong band at ~95kD 
in the eluate lane after immunoprecipitation by anti-Ago coated beads, while 
radixin remained in the supernatant and was not immunoprecipitated (Fig. 33A). 
These results were also seen across other cell types used in the optimization of 
these protocols, including the Ad293 (Fig. 33B) and Huh7 (Fig 33C) cell lines. 
These cell lines were sometimes used during optimization steps in place of PRHs 
due to availability of the required cell numbers in the later steps of the protocol. 
Also, probing the eluate after immunoprecipitation with only secondary antibody 
showed that detected bands were not a non-specific result of secondary antibody 
binding (Fig. 33D). 
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Figure 32. Western blot analysis of Ago expression. Primary rat hepatocyte 
total cell lysate was analyzed for expression of Argonaut proteins by western blot 
using a pan-Ago specific antibody. 
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Figure 33. Immunoprecipitation of Ago. Efficiency of immunoprecipitation 
using anti-Ago-coated magnetic beads was analyzed in PRHs (A), Ad293 cells 
(B), and Huh7 cells (C). Eluate lanes represent sample released from beads after 
immunoprecipitation, and supernatant represents the portion of proteins 
remaining in the lysate after immunoprecipitation. Proteins were 
immunoprecipitated with a pan-Ago antibody, and visualized by western blot 
using the same pan-Ago antibody. D. The specificity of the western blot results 
was shown by probing the blot with only anti-mouse secondary antibody. 
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After confirming expression and detection of Ago in our cell systems, we 
next confirmed effective cross-linking of RNA to proteins using 254nm UV light. 
Cross-linking was apparent based on the shift in expected protein size when total 
RNA:Ago2 complexes were analyzed by western blot (Fig. 34). This shift 
represents protein cross-linked to full length target mRNAs that are of varying 
length, causing a smear upwards from the non-cross-linked Ago at ~95kD, and 
increased in a dose-dependent manner at varying doses of irradiation. In addition 
to exposure to 254nm UV light, PRHs were treated with 4-thiouridine (4-SU) and 
exposed to varying doses of 365nm UV light. Unlike PRHs exposed to 254nm 
light, irradiation with 365nm UV light did not result in cross-linking of Ago:RNA 
complexes (Fig. 34). The lack of successful cross-linking of complexes with 
365nm UV light could be due to multiple causes, including limited uptake of 4-SU 
by PRHs, lack of incorporation of 4-SU into newly synthesized RNAs, or lack of 
RNA turnover in PRHs, resulting in minimal amounts of 4-SU-labeled RNAs. To 
confirm that 4-SU was able to enter into PRHs, we treated PRHs with tritiated 
uridine and measured incorporation into RNA over time. Within the first hour after 
treatment, we were able to see decreased uridine in the culture medium, and 
increased uridine in isolated RNA, indicating successful uptake and incorporation 
of the uridine (Fig. 35). While this trend continued over the complete time course, 
implying that PRHs are able to take up and utilize exogenous uridine, the percent 
incorporation of 4-SU peaked at only 0.05%. Because the isolation of Ago:RNA 
complexes in the PAR-CLIP protocol depends on 4-SU incorporation, this low 
level of 4-SU incorporation adds an additional variable and layer of complexity to 
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the protocol. With this in mind, and because of the considerable overlap between 
post-cross-linking steps, much of the subsequent optimization was done with a 
focus on the HITS-CLIP protocol, which does not require incorporation of 
exogenous 4-SU. 
Figure 34. UV cross-linking of PRHs. PRHs were treated with the indicated 
amount of 4-thiouridine (4-SU) overnight. Cells were then exposed to the 
indicated doses of 254nm or 365nm UV light. After cross-linking, total cell lysate 
was collected and analyzed by western blot for Ago expression using a pan-Ago 
antibody. 
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Figure 35. [3H]-uridine uptake and incorporation. 24 hr after plating PRHs, 3H-
uridine was added to culture medium. Medium and total RNA were collected at 
the indicated time points after treatment and radioactivity was measured.  
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Following successful 254nm cross-linking, complexes were treated with 
RNase to partially cleave and shorten targeted mRNA. As different CLIP 
protocols utilize different RNases, comparisons were done between RNase A 
and RNase T1, the number of RNase treatments, and the RNase concentration 
(data not shown). A single RNase T1 treatment allowed clear visualization of a 
concentrated band, representing Ago bound to small RNA fragments (Fig. 36A). 
After digestion, Ago:RNA complexes were immunoprecipitated using 
antibody-coated magnetic beads. Multiple bead types were compared in the 
optimization of these steps, including comparisons of Sepharose or magnetic 
beads and comparisons of protein A-conjugated vs. protein G-conjugated beads, 
before ultimately deciding upon protein G-conjugated magnetic beads (data not 
shown). Similarly, antibody concentrations were optimized to maximize Ago 
immunoprecipitation while minimizing contamination by radixin. 
Immunoprecipitated Ago:RNA complexes were dephosphorylated, followed by 
end-labeling with γ-32P. This labeling allowed visualization of immunoprecipitated 
complexes after separation by polyacrylamide gel electrophoresis. Importantly, 
the inclusion of a non-cross-linked sample confirmed the effective cross-linking of 
the Ago:RNA complex, as without cross-linking there was no end-labeled RNA 
(Fig. 36A). In addition, analysis of the gel after transfer showed effective transfer 
of digested Ago:RNA complexes (Fig. 36B) and western blot analysis showed 
equal expression of Ago proteins in all samples, including a non-cross-linked 
sample, further supporting the specificity of labeling (Fig. 36C). Radio-labeled 
Ago:RNA complexes were electrotransferred to nitrocellulose and bands/smear 
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at the expected size were excised for RNA isolation. Together, each of these 
results demonstrated that the CLIP procedure was successful up to the point of 
visualization of the immunoprecipitated complex. The presence of a concentrated 
band on the film, with a smear for partially digested RNA, which was only present 
in cells that had been cross-linked confirmed that RNA was present in these 
samples. The prior confirmation of successful Ago immunoprecipitation, 
combined with the presence of the radiolabeled RNA at the expected size 
confirmed that we were able to successfully immunoprecipitate Ago-associated 
RNA using the CLIP protocol. 
A number of subsequent steps were taken towards completion of the CLIP 
protocol; however, we were unable to confirm the successful precipitation of RNA 
from the immunoprecipitated complexes. These confirmation steps involved 
isolating the RNA according to published protocols [461], followed by 
quantification by nanodrop, analysis by Agilent Bioanalyzer 2100 using a small 
RNA assay (Jefferson Cancer Center Genomics Laboratory), and direct 
visualization of isolated RNA by TBE/Urea gel (Fig. 37). Each of these methods 
either failed to show a difference in RNA content between the excised radio-
labeled band of the blot and a random, negative control excised area of the blot, 
or could not reproducibly generate an RNA fragment of the expected size. In 
addition, alternatives to RNA labeling and isolation, including ligation of a radio-
labeled RNA linker, followed by RT-PCR to amplify any potential samples failed 
to show RNA products at the expected size (data not shown). These negative 
results could be due to multiple potential hurdles in using the model to study the 
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Figure 36. CLIP analysis of Ago:RNA complexes with or without RNase 
treatment. PRHs were cross-linked with 254nm UV light as indicated and treated 
with 1U/µl RNAse T1. After digestion, Ago:RNA complexes were 
immunoprecipitated, RNA was end-labeled with 32P, and samples were run on 
10% NuPAGE gel before transfer to nitrocellulose membrane. Both the 
membrane (A) and the gel (B) were visualized by X-ray film after transfer. C. In 
addition, a small portion of sample was run on a separate gel for analysis by 
western blot using the anti-pan-Ago2 antibody.  
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pool of miRNAs. Specifically, as it has been well established that in the cell lines 
used for these studies a very large number of cells is required to generate 
enough material for downstream analysis. It is possible that, due to the nature of 
hepatocytes in culture, even larger numbers of cells are needed to isolate 
enough RNA to generate a cDNA library. Also, considerable variation was seen 
between replications of the same experimental protocols when using the PRH 
model, making it difficult to reproduce successful results. Because of these 
issues, it became clear that utilizing an analysis of the complete transcriptome 
(as described in Chapter 5) to determine the HBV-mediated global regulation of 
the hepatocyte transcriptome was a more feasible approach to address the 
question of HBV-mediated alteration of hepatocyte gene expression which could 
then ultimately be correlated with miRNA function through additional downstream 
analyses. 
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Figure 37. Visualization of Ago-associated RNA. A. Ago-associated RNA was 
isolated from section of excised nitrocellulose. Lane titles indicate cellular input 
amount for respective samples, with 10 cm or 15 cm referring to the size of the 
culture dish used for hepatocyte maintenance.  B. Radio-labeled RNA was 
precipitated and analyzed by TBE/Urea gel with radio-labled decade RNA 
marker. C. Darker exposure of B. 
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Chapter 8. Discussion and Future Directions 
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 HBV is a non-cytopathic virus that establishes a long-term, chronic 
infection that can last for decades. For many chronically infected individuals, the 
endpoint of disease is the development of HBV-associated HCC. While the exact 
mechanisms leading to the development of HBV-associated HCC remain 
incompletely understood, research has focused on three main areas: chronic 
inflammation-mediated hepatocyte destruction with concomitant regeneration, 
the deleterious effects of HBV DNA integration into the host genome, and the 
impact of viral proteins, such as HBx [158, 494-496]. On a cellular level, HBV 
replication depends on the establishment of a complex network of host-virus 
interactions that involve disruption of many cellular pathways and factors, 
potentially altering hepatocyte physiology. This long-term disruption to 
hepatocyte physiology could ultimately be a contributing factor in the 
development of HBV-associated HCC. Typically, studies that investigate these 
host-virus interactions focus on a single factor or pathway and determine a 
relationship to HBV replication or disease. In addition, because of the lack of an 
effective model system that mimics a natural HBV infection, these studies are 
often done in immortalized and transformed cell lines, sometimes leading to 
conflicting results.  
 In the studies described here, we have utilized broad, "-omics"-based 
techniques to characterize the complex host-virus interactions during viral 
replication on a cell-wide scale. Using an ex vivo primary rat hepatocyte model, 
we have investigated HBV-mediated changes to both the hepatocyte 
transcriptome and metabolome to determine how HBV replication impacts overall 
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hepatocyte physiology, beyond the investigation of single pathways or cellular 
factors. Using this model, we are able to simultaneously identify multiple genes 
and cellular pathways that are altered in HBV-expressing hepatocytes, including 
a list of genes that are specifically differentially expressed only in HBV-
expressing cells. In addition, for a number of metabolic pathways we were able to 
demonstrate coordinated HBV-mediated regulation of both metabolic enzymes 
with their respective metabolites, confirming HBV-mediated alteration of these 
pathways. Also, these studies allowed us to support the use of the cultured 
primary rat hepatocyte model as a biologically relevant model for liver-based 
studies by showing that, although gene expression changed due to time in 
culture, cultured hepatocytes still maintain a similar overall gene expression 
profile to freshly isolated hepatocytes. Finally, we were also able to demonstrate 
that the use of recombinant adenovirus as a delivery vehicle for the HBV genome 
has only minimal, if any, impact on hepatocyte physiology. Cumulatively, our 
results support the hypothesis that HBV mediates a complex network of host-
virus interactions, likely to meet its replication requirements. This includes 
alteration of cell cycle regulation, energy metabolism, lipid metabolism, miRNA-
mediated gene regulation, and many other cellular pathways whose long-term 
alteration could contribute to the development of HBV-associated pathogenesis. 
 Many HBV-related studies attempt to identify mechanisms of HBV-
associated HCC development by determining HBV-mediated changes to the host 
cell that give the cell a more cancer-like phenotype. These studies, however, 
often do not take the time-frame of HCC development into consideration; if HBV 
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causes dramatic tumorigenic changes immediately after infection, HCC likely 
would take weeks or maybe years to develop, not of decades. Instead, HBV-
mediated changes to any one factor or pathway are likely not dramatic, and the 
carcinogenic potential of HBV may be due to the accumulation of subtle changes 
that occur as the virus optimizes the cellular environment for viral replication and 
long-term survival. We support this hypothesis here through multiple analyses. 
Our transcriptome analysis showed that at 24 hr after infection, only 3% of 
significantly differentially expressed genes had a ≥ 2-fold HBV-mediated change; 
at 48 hr after infection this was 10%. In the metabolome analysis, metabolite 
regulation was more dramatic, but still only 16% of HBV-mediated metabolite 
changes were ≥ 2-fold. On the other hand, a more drastic cellular insult, such as 
isolation of hepatocytes and adaptation to culture may be expected to cause 
more dramatic cellular changes. This is supported by the observation that 57% of 
statistically significant differentially expressed genes between 0 hr and 24 hr in 
uninfected cells have ≥ 2-fold change. In the metabolome analysis, 29% of the 
statistically significant time-mediated changes were ≥ 2-fold. The observation that 
HBV induces subtle, likely cumulative, changes to the cell underscores the 
importance of working in a model system which closely mimics the normal 
hepatocyte physiology. This is an important aspect of our studies, as they are 
specifically designed to identify early, upstream HBV-mediated changes to a 
primary hepatocyte.  
 In analyzing these broad, transcriptime-wide, and metabolome-wide 
datasets, it became immediately obvious that both the initial isolation and plating 
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of hepatocytes and the amount of time spent in culture have a distinct impact on 
hepatocyte physiology. In the transcriptome analysis, the number of differentially 
expressed genes was highest when comparing freshly isolated cells to cells at 
later time points, but this is not unexpected and has been reported previously for 
cultured primary hepatocytes [470]. As with many organs, the in vivo 
environment of the liver has a number of distinct characteristics that make it 
difficult to replicate in a cell culture system. In particular, the liver is a collection of 
multiple cell types, and while hepatocytes make up the large majority of cells in 
the liver, our culture model lacks the additional cell types that have previously 
been shown to help maintain primary hepatocyte viability and differentiation 
[497]. In addition, only around 1 in every 20,000 hepatocytes is undergoing 
replication at any given time in a normal liver [217]; however, previous studies 
have shown activation of pathways resembling liver regeneration, including entry 
into the G1 phase of the cell cycle, following liver perfusion and hepatocyte 
isolation [227, 481, 498]. In fact, hepatocytes transit from G0 into G1 during 
isolation and are able to progress through mid-late G1 without supplementation of 
any additional growth factors [481]. While only minimal proliferation occurs after 
plating of primary hepatocytes, our data support the potential activation of some 
of these replicative pathways. Evidence of this can be seen by the up-regulation 
of cell cycle-related and DNA replication-related genes in our uninfected cultured 
PRHs over time. Interestingly, this level of replication activation may be very 
relevant for studies of a chronically HBV infected liver. This is because a number 
of studies have suggested chronic inflammation of the liver occurs during chronic 
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HBV infection, resulting in immune-mediated hepatocyte destruction and 
concomitant hepatocyte regeneration (reviewed in [131]). In fact, during a 
transient WHV infection in woodchucks, at least 1 full liver turnover occurs during 
recovery [499]. While additional studies would be needed to determine the 
similarities between the activation of regenerative pathways in these two 
systems, studies of the impact of HBV on hepatocyte physiology in a similar 
regenerative context to an in vivo system would increase the biological relevance 
of this model system. 
 On the other hand, despite the time-mediated changes, primary 
hepatocytes remain a much more physiologically relevant model than 
immortalized and transformed cell lines. In particular, transformed cell lines, 
which are often used for liver-based studies, have drastically different 
phenotypes than primary hepatocytes or in vivo samples. By definition, these cell 
lines retain many characteristics of the tumorigenic environment from which they 
were originally isolated, particularly the ability to replicate indefinitely. For 
example, while a recent RNA-seq analysis of HBV-mediated gene expression 
changes in the Huh7 cell line did identify metabolic pathways as being altered by 
HBV, only minimal identification of cell cycle-related differential gene expression 
was reported [244]. This may be due to the altered baseline of cell cycle 
regulation occurring in these transformed cells, limiting the ability to detect 
alteration to genes whose expression is already drastically altered. Another 
example is the recent description of the HBV-mediated metabolic response using 
a comparison of HepG2 and HepG2.2.15 cells [500]. While this study identified a 
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dramatically different metabolomic profile in HepG2.2.15 cells than HepG2 cells, 
the continual passage of these cell lines since their original creation makes it 
difficult to interpret the results. Specifically, the increased utilization of both 
glycolysis and the TCA cycle, promotion of the pentose phosphate pathway, and 
requirement for increased hexosamine biosynthesis identified in this study could 
all be the result of cellular adaptation to continuous HBV replication in these 
cells. Such changes are more easily identified in a primary hepatocyte model, as 
time-mediated changes which separate cultured primary hepatocytes from 
freshly isolated cells can be directly identified and serve as a baseline for 
expression changes, instead of the endogenously altered baseline present in cell 
lines. In fact, multiple studies have demonstrated the significant phenotypic 
differences between primary hepatocytes and cell lines [470, 501], which was 
also recently supported by a transcriptome analysis of the HepG2 
hepatoblastoma cell line. This study compared HepG2 cells to primary liver 
tissue and confirmed that the majority of up-regulated genes were associated 
with cancer and cellular proliferation pathways, prompting the authors to warn 
against the use of HepG2 cells in liver cancer-related studies of the 
transcriptome [166]. In our transcriptome analysis, while we do identify time-
mediated changes in our PRH model, the large numbers of time-mediated 
changes in gene expression are likely biased by genes with a low expression 
level or small fold change (Fig. 19). Specifically 47% of all genes with ≥ 2-fold 
change between 0 hr and 24 hr also had an RPKM value of ≤ 1. In fact, the 
overall similarity of freshly isolated and cultured hepatocytes is supported by a 
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high correlation when the complete gene expression profile is compared between 
0 hr samples and later time points, which agrees with previously published 
reports of similar expression profile comparisons [470]. Based on these previous 
studies, and on the data reported here, the use of cultured primary hepatocytes 
is the most biologically relevant cell culture-based model for identifying alteration 
of cellular pathways, including those altered in the context of HBV infection.  
 A potential concern about our studies was the use of recombinant 
adenovirus as a delivery vehicle for the HBV genome. Because of the inclusion 
of uninfected PRHs in the transcriptome analysis, we were able to analyze two 
important aspects of the use of the recombinant adenovirus-based system: the 
impact of an adenovirus infection on the PRH transcriptome and the level of 
expression of adenoviral transcripts. First, the results of the differential gene 
expression analysis implied that adenovirus infection had only a minimal effect 
on the PRH transcriptome. Infection with AdGFP resulted in only 4% more DEG 
between 48 hr and 72 hr than in uninfected PRHs at the same time comparison. 
The similarity between AdGFP and uninfected cells was even more obvious 
when infected cells were compared directly to uninfected cells. Specifically, at 48 
hr only 3% of genes were differentially expressed between AdGFP and 
uninfected cells, while 25% of genes were differentially expressed between 
AdHBV-infected and uninfected PRHs. Beyond the effect on differential gene 
expression, alignment of reads to the pAdEasy sequence showed expression of 
only a single adenoviral transcript, pIX, which is immediately downstream of the 
insertion site of the GFP/HBV DNA. In fact, only ~5% of all reads aligning to 
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pAdEasy-1 aligned outside of this region, so expression of adenoviral transcripts, 
which could be a concern when using these vectors, is minimal. These results 
allow us to attribute the majority of AdHBV-mediated effects to the presence of 
HBV, as adenovirus seems to be having minimal, if any, impact on the cells. 
 The transcriptome analysis identified many genes and cellular pathways 
that exhibit HBV-mediated changes in expression. A number of these, such as 
cell cycle regulators Cyclin A, Cdk2, and Cyclin D [30, 502], metabolic factors 
such as Glut2 [244], immune mediators such as PD-L1 [503], and PI3K/Akt 
signaling [82] have previously been reported to be affected by HBV. For many 
others, the association with HBV replication is novel, highlighting the utility of 
using a transcriptome-wide approach to identify cellular changes on a broader 
scale. Interestingly, of the list of 16 "HBV-only" genes altered in an HBV-
dependent, time-independent fashion, none have previously been shown to be 
affected by HBV. One of these genes, Mdm4, is a crucial gene for the regulation 
of p53, and although Mdm4 itself has not been directly associated with HBV 
replication or HBx expression, p53 has been shown by multiple groups to interact 
with HBx [504-507]. While the ultimate outcome of this interaction remains 
incompletely understood, it appears to be cell-type specific, with HBx-p53 
interaction inhibiting apoptosis in some cell lines, while the interaction is 
functionally irrelevant in other contexts (reviewed in [101]). The identification of 
HBV-mediated regulation of Mdm4 activity, potentially leading to HBV-mediated 
inhibition of the p53 transcriptional activation domain [508], could be an important 
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step in understanding this important relationship between HBV and p53, and will 
require further investigation. 
 Because of the established role of cellular lipids in the HBV life cycle, the 
alteration of lipid-related pathways in both the transcriptome and metabolome 
analyses is one of the interesting aspects of this research. Previous work has 
shown that cellular lipids are required for viral envelopment [483], and additional 
studies have shown that decreased cellular cholesterol alters the HBV envelope 
protein, inhibiting envelopment [484]. In addition, studies of cellular gene 
expression following NTCP binding by HBV have shown significant alteration of 
bile acid and cholesterol metabolism [212]. Our studies support this relationship 
between HBV and cellular lipids. Interestingly, three of the 16 "HBV-only" genes 
are members of the BPI family [509, 510], which are typically associated with 
lung tissue and saliva and play a role in lipid binding and transfer and the innate 
immune response [511]. In the transcriptome analysis, these three genes 
exhibited an interesting pattern of very low endogenous expression, which was 
increased at least 4.5-fold at both time points for all three genes in the presence 
of HBV. In addition to these BPI-family proteins, other lipid-related genes were 
also significantly altered in the transcriptome analysis. Alteration of these genes 
led to identification of HBV-mediated perturbation of multiple lipid-related 
pathways including PI3K/Akt signaling, for which phospholipid metabolism is a 
central factor, bile secretion, 9 glycoshingolipid biosynthetic pathways, and PPAR 
signaling, which represents one of the main family of transcription factors 
responsible for regulating lipid metabolism [512]. As expected based on the 
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pathway analysis, expression of a number of enzymes involved in lipid metabolic 
processes was altered by HBV, including both catalytic and regulatory subunits 
of the PI3K enzymes. Individual genes not directly associated with a KEGG 
pathway, but with known lipid-related functions were also identified. One example 
is G0s2, which encodes a multifunctional protein with described roles in 
apoptosis, regulation of oxidative phosphorylation, cell cycle regulation, and as a 
regulator of lipolysis, and exhibited HBV-mediated regulation at both time points.  
  Similar to the transcriptome analysis, lipid metabolic pathways 
represented a large portion of the HBV-altered metabolic pathways in our 
metabolome analysis. By 48 hr post infection, over 50% of all metabolites in the 
lipid super-pathway (the largest super-pathway in the analysis), across all sub-
pathways, were altered. In support of altered PI3K/Akt signaling in the 
transcriptome analysis, phospholipid metabolism was one of the most 
significantly altered pathways within the metabolome analysis. Similarly, lipid 
pathways involved in cell membrane remodeling were altered in both analyses, 
potentially representing HBV-mediated regulation of these pathways as a 
mechanism to prepare for, or as a result of, viral capsid envelopment.  
 Other metabolic pathways were also altered in both the transcriptome and 
metabolome study. Importantly, one of these pathways was the 
glycolysis/gluconeogenesis pathway, with alterations in both analyses suggesting 
that HBV may shift the energetic profile of hepatocytes towards increased usage 
of glycolysis. The important role of the liver in maintenance of energy 
homeostasis makes understanding the impact of HBV on the energetic pathways 
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important to understanding HBV-associated disease. Interestingly, this HBV-
mediated shift towards glycolysis has recently been suggested by others, though 
in less relevant experimental systems that require careful interpretation of results 
[250, 500].  
 Another altered pathway potentially related to HBV-associated 
pathogenesis was the identification of "miRNAs in cancer" in the transcriptome 
analysis. Identification of this pathway represents an interesting application of the 
rapidly expanding field of HBV-miRNA studies. By specifically investigating the 
levels of known miRNA targets, this pathway analysis was able to suggest that 
HBV may be altering the function of a subset of miRNAs. This was in contrast to 
our results suggesting only minimal regulation of absolute expression levels of 
mature miRNAs in our HBV-expressing PRHs. Together, these results suggest 
that HBV may be altering the function of a subset of miRNAs, but in a primary 
hepatocyte in which the miRNA expression profile is heavily dominated by miR-
122, HBV does not significantly alter the expression of these miRNAs. While this 
is in contrast to the significant body of literature suggesting HBV-mediated 
regulation of miRNA expression levels in cell lines, the miRNA profile in these 
cells is already drastically different than that of a primary hepatocyte and 
therefore may be more susceptible to HBV-mediated regulation. In particular, 
HepG2 cells express very low levels of miR-122, so their pool of mature miRNAs 
is going to be altered just based on the lack of the miRNA making up the largest 
part of the primary hepatocyte miRNA pool. Recent studies have also suggested 
that the cellular environment can influence the profile of functional miRNAs 
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without impacting the overall levels of miRNAs [429, 430], which is again 
supported by the results described here and in other studies [171, 290]. We 
showed minimal changes in miRNA expression, though transcriptome analysis of 
annotated miRNA targets suggested altered function of multiple miRNAs which 
have been previously associated with HBV and HBV-associated HCC. Although 
we were unable to directly investigate the pool of functional miRNAs using CLIP 
due to technical limitations, the results of the pathway analysis support our 
hypothesis that HBV alters the profile of miRNAs actively involved in miRNA-
mediated regulation. Future research utilizing newer technologies that directly 
assess the profile of functional miRNAs in relevant cell models, instead of 
profiling the overall expression level of miRNAs, could help to determine the role 
that miRNAs play in HBV replication and HBV-associated pathogenesis. 
 Although our experimental model is limited, both by the use of 
recombinant adenovirus and primary rat hepatocytes and not primary human 
hepatocytes, to specifically studying the cellular changes associated with viral 
replication and viral protein expression, our results maintain a high level of 
biological relevance.  While one aspect of the application of this newly generated 
"-omics"-based dataset is in the identification of novel factors and pathways 
associated with HBV, the use of this dataset to confirm previously identified 
changes, but on a broader, simultaneous level, allows us to have a high level of 
confidence in the relevance of novel changes that are identified.  For example, 
the identification of WHV-mediated up-regulation of PD-1 in a transcriptomic 
analysis of the differences between the immune response in acute and chronic 
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WHV infection[513, 514], is supported by significant up-regulation of PD-1 in our 
analysis.  Also, many of the identified changes in cell cycle-related genes have 
previously been shown to be required for HBV replication in both primary rat and 
primary human hepatocytes [30, 167], again, underscoring the relevance of 
differentially expressed genes in our dataset.  On a broader level, multiple 
pathways identified in our pathway analyses have been shown to be required to 
HBV replication, including HBV-mediated alteration of PI3K/Akt signaling [82].   
 Together, in both identifying novel, HBV-mediated changes to hepatocyte 
physiology and confirming previously identified changes, these studies have 
allowed us to begin to generate a clearer understanding of the complexity of an 
HBV infection. Unlike typical studies investigating single factors or pathways, the 
broad approach of these analyses has allowed the simultaneous identification of 
multiple HBV-mediated effects. By demonstrating HBV-mediated regulation of 
genes involved with cell cycle control, we are able to support the hypothesis that 
HBV pushes hepatocytes from G0 into G1 to optimize the cellular environment for 
replication of its genome. Similarly, alteration of a number of genes involved in 
cell cycle regulation, genes associated with cancer development and 
progression, and multiple metabolic genes, which were also supported by 
alteration of their associated metabolites, demonstrate the impact of an HBV 
infection on hepatocytes. While in the short term these pathways are likely 
important for viral replication, the long-term HBV-mediated alterations of these 
central cellular pathways likely contribute to the development of HBV-associated 
disease and could represent targets for the development of novel therapeutics.   
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Future Directions 
 Future studies derived from this work could be described in two main 
directions. The first direction is the interpretation and application of these 
datasets to get a more specific understanding of identified HBV-mediated 
changes to hepatocyte physiology. The second direction is the enhancement of 
the datasets to utilize additional technology and techniques that will increase the 
scope and relevance of the data even further.  
 The datasets described here represent a comprehensive analysis of HBV-
mediated changes to the hepatocyte transcriptome and metabolome. Many of the 
HBV-mediated effects identified in these analyses support observations from 
previous studies, including alteration of PI3K/Akt signaling and cell cycle 
regulation, both of which have been published previously by our lab [29, 30, 82, 
167]. Beyond this, however, a number of observations with little-to-no known 
association with HBV replication or HBV protein expression have also been 
identified. These observations include broad, pathway-type observations, such 
as the potential shift in HBV-expressing PRHs towards increased glycolysis, 
which has only recently been described elsewhere [250, 500], and the HBV-
mediated alteration of multiple lipid pathways involved in membrane biosynthesis 
and increases in the pool of free fatty acids. Each of these pathways could be 
having a distinct effect on the HBV life cycle, and ultimately HBV-associated 
disease, and warrant significant further investigation.  
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 Further research into the HBV-mediated increase in the pool of free fatty 
acids could lead to a better understanding of the relationship between chronic 
HBV infection and development of hepatic steatosis, as this relationship currently 
remains controversial. While some groups have reported increased hepatic 
steatosis in chronically infected HBV patients, others have reported no 
correlation, or even a potentially protective role of HBV against development of 
hepatic steatosis [486, 515-517]. Recent evidence suggests an important role for 
free fatty acids in HBV replication, as fatty acid synthase was highly over-
expressed in HBV-tg mice, and inhibition of fatty acid synthase blocked HBV 
replication [518]. This corresponds with HBV-mediated increased expression of 
fatty acid synthase and palmitate in our analyses. Interestingly, HBx-mediated 
increased levels of palmitate in the metabolome analysis could suggest a central 
role for HBx in regulating this pathway. By comparing levels of fatty acid 
synthase in PRHs expressing either HBV or a copy of the HBV genome unable to 
produce HBx, we can get a clearer picture of the role of HBx in regulating this 
pathway. A similar approach could be applied to genes associated with other 
pathways involved in the pool of free fatty acids, including those involved in β-
oxidation and lipolysis. 
 HBV-mediated alterations to the energy state of the hepatocyte is another 
aspect of these studies which could generate important information about the 
development of HBV-associated disease. By shifting the hepatocyte towards 
increased glycolysis, HBV could, in combination with other cancer-related 
pathways such as altered cell cycle regulation, be creating a more oncogenic 
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environment. The absence of altered TCA cycle regulation in the presence of 
increased glycolysis in HBV-expressing hepatocytes may imply a delicate 
balance of energetic requirements in an HBV-infected hepatocyte. More specific 
studies of the energetic shift in HBV-expressing hepatocytes would be required 
to more fully understand the relationship between these two pathways and their 
influence on HBV replication. For example, a number of assays are available to 
assess glycolytic activity in cells, including those to measure glucose uptake, 
lactate production, and each of the steps in between. Together these assays 
would generate a more complete picture of the level of activation of glycolysis in 
HBV-expressing cells.  
 Also, it would be very informative to investigate the role of HBV-mediated 
alteration of lipid pathways in formation of the viral envelope.  As yet, the lipid 
content of an infectious Dane particle has not yet been fully characterized; 
determining if HBV-mediated alteration of any of these lipid pathways is 
influencing the formation of the viral envelope could provide a novel avenue for 
pursuing alternative therapeutic options.  This approach is supported by recent 
evidence demonstrating a requirement for cellular lipids, specifically cellular 
cholesterol, in both the successful formation of the viral envelope [484] and 
infection of hepatocytes [483]. 
 In addition to investigating the role of cellular pathways, a number of 
individual genes warrant further studies. For example, the protein G0S2 has roles 
in apoptosis, cell cycle regulation, oxidative phosphorylation, and lipolysis, and 
showed a very high level of HBV-mediated alteration. Knockdown and over-
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expression-based studies could help to confirm the role G0S2 in HBV-replication, 
and inhibition of individual G0S2-involved pathways could help to identify which, 
if any, of these roles may be contributing to the G0S2-mediated effects on HBV 
replication. For example, if over-expression of G0S2 enhanced HBV replication, 
but inhibition of Bcl-2, which is the role of G0S2 in apoptosis, did not, the 
apoptotic function of G0S2 could likely be discounted as a mechanism for G0S2-
mediated regulation of HBV replication. 
 Both GLUT1, which is responsible for the basal level of glucose uptake in 
cells, and GLUT2, a bidirectional transporter that serves as the primary 
transporter of glucose between the liver and blood, likely play important roles in a 
potential shift towards glycolysis in HBV-expressing hepatocytes. Interestingly, 
our transcriptome analysis showed an HBV-mediated increase in GLUT1 levels, 
and decreased GLUT2 levels, potentially indicating HBV-expressing PRHs were 
increasing glucose uptake (GLUT1) while simultaneously decreasing the 
transporter to export glucose (GLUT2). Additional research into the role of each 
of these transporters in HBV replication could have important implications in the 
overall understanding of how the virus impacts the energy pathways of the cell. 
Investigating the energy state of HBV-expressing hepatocytes, particularly 
examining glucose uptake and glycolysis, in the presence of individually altered 
transporters will help to determine whether simultaneous regulation of these 
transporters is required for effective HBV replication.  
 Similar to the genes described above, each of the 16 genes listed on the 
"HBV-only" list, as well as many of genes on the larger list of 403 genes altered 
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by HBV at both time points (but without excluding time-mediated changes) are 
potentially interesting targets of further investigation. By examining HBV 
replication in the context of over-expression or knockdown of individual genes, 
we can begin to get an idea of the role these genes may be playing in HBV 
replication and HBV-associated disease. These types of studies serve as both 
extension and confirmation of the results described here and demonstrate how 
these broad, "-omics"-based studies can act as a springboard for future research.  
 Beyond extending the information gathered in the transcriptome and 
metabolome datasets, another future direction for this work would be to use this 
as a base from which to build an even larger, and more accurate dataset to 
represent the HBV-mediated changes to hepatocyte physiology. Technological 
advances allowing the generation of "-omics" data have greatly increased the 
large-scale generation of data. In addition to the studies described here, which 
utilize transcriptomic and metabolomic analyses, application of these types of 
broad techniques could help to generate a more complete understanding of the 
changes in hepatocyte physiology induced by an HBV infection. Such goals 
could be achieved through the combination of transcriptome-wide and proteomic 
studies to better understand the role gene regulation is playing in the HBV-
mediated changes to the hepatocyte proteome. This relationship between gene 
regulation and protein regulation has become increasingly important in light of 
recent findings suggesting that specific cellular conditions, specifically pathogen 
exposure, can impact the relative importance of mRNA abundance and protein 
production in the cell [519]. These findings seem to correlate, at least 
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phenotypically, with the results suggested by our PRHs transcriptome analysis. 
For example, while significant changes to cell cycle-related genes were seen in 
our analysis, there were no noticeable changes to the levels of cellular 
proliferation. On the other hand, HBV-mediated alteration of the genes encoding 
multiple metabolic enzymes correlated well with HBV-induced changes in the 
corresponding metabolites. Further investigation could determine the role, if any, 
HBV is playing in directly influencing the relationship between mRNA abundance 
and protein production. 
 While our studies attempt to address the early initiating events that result 
in the cellular changes associated with replicating HBV, some caveats do exist. 
For example, while the use of primary cells instead of cell lines increases the 
relevance of these results, using purified hepatocytes does mean that additional 
cell types of the liver are not present. Although hepatocytes make up 80% of the 
cellular mass of the liver [294], and cultured primary hepatocytes are a well-
accepted model of liver biology, future in vivo studies investigating the early time-
points of an HBV infection may help to further strengthen our understanding of 
HBV-mediated transcriptome changes. Similarly, the use of recombinant 
adenovirus to deliver the HBV genome bypasses the infection-related steps of 
the HBV life cycle. The use of transgenic animals expressing the recently-
described HBV receptor, sodium taurocholate cotransporting peptide 
(NTCP/SLC10A1), may be the next step in addressing HBV-mediated 
transcriptome-wide changes in gene expression that follow direct infection of 
hepatocytes, though these systems currently are unable to support HBV 
243 
	  
replication and will require additional development. Another alternative could be 
the use of humanized mice to study direct infections, with a recently described 
mouse model with both a humanized immune system and liver able to support 
direct infection with HBV and establish persistent disease [207]. While these 
potential future directions offer the opportunity to enhance the current dataset, 
the studies described here are an important step in understanding the HBV-
mediated impact on hepatocyte physiology, and additional studies using the 
transcriptome and metabolome datasets will help to identify specific factors that 
may be playing a central role in the development of HBV-associated 
pathogenesis and serve as potential targets for the development of novel 
therapeutics. 
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APPENDIX A 
 
 
 
LIST OF ABBREVIATIONS 
 
PRH(s) - primary rat hepatocyte(s) 
HBV - hepatitis B virus 
HBx - hepatitis B virus X protein 
HCC - hepatocellular carcinoma 
cccDNA - covalently closed circular DNA 
NTCP - sodium taurocholate cotransporting peptide 
ORF - open reading frame 
miRNA - microRNA 
RISC - RNA-induced silencing complex 
HNF - Hepatocyte nuclear factor 
GFP - green fluorescent protein 
AdGFP - recombinant adenovirus expressing hrGFP 
AdHBV - recombinant adenovirus expressing hrGFP and a greater than unit 
 length copy of the HBV genome 
AdHBx - recombinant adenovirus expressing GFP and HBx 
RPKM - reads per kilobase length of transcript per megabase of reads 
DEG - statistically significant differentially expressed gene 
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PBS - phosphate buffere saline 
PMPG - 1X PBS, 2% empigen 
4-SU - 4-thiouridine 
 
 
